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Abstract 
Late-onset Alzheimer’s disease (LOAD) is the most common form of dementia, 
with an incidence of up to 50% in western populations over the age of 85 and a high 
heritability (up to 80%). The identification of risk factors for the development of 
LOAD is imperative for improving our understanding of this disease and for 
identifying therapeutic targets for treatment or prevention. Currently, the major 
known risk factors for the development of LOAD are age and the ApoE 4 genotype.  
Previous studies have implicated plasma levels of the amyloid beta (Aß) peptide as a 
LOAD-associated quantitative trait and identification of loci influencing this trait 
could provide new insights into LOAD. In this thesis, plasma levels of the Aß 
peptides Aß40 and Aß42 have been measured in two isolated populations and 
genome-wide linkage and association analyses were performed. The genome-wide 
association analyses identified a number of promising quantitative trait loci; 
highlighting both novel and previously reported LOAD genes for further study, 
whilst also providing an excellent resource for genetic convergence studies with 
other LOAD related traits. 
Several studies have reported an association between levels of oxidative stress and 
levels of Aß  such that increasing levels of Aß appear to increase markers for 
oxidative stress and vice versa. The role of oxidative stress in LOAD and aging was 
therefore also investigated through analysis of mitochondrial mutational burden and 
DNA damage respectively, using DNA isolated from both blood and the brain and 
by carrying out a candidate gene association study of loci involved in mitochondrial 
function in LOAD cases and controls. Approaches to the investigation of 
mitochondrial genetics for the study of LOAD are comprehensively reviewed, 
adapted and tested and the results indicate a need for additional research in this 
aspect of the disease.  
This thesis therefore presents a focus on two aspects of genetic research into LOAD, 
a complex disease with multiple environmental and genetic influences which aims to 
advance our understanding of the disease and bring us closer to treatment and 
prevention strategies. 
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Chapter 1. Introduction 
1.1 Overview  
Alzheimer’s disease (AD) was first described by Dr Alois Alzheimer in 1906 when 
he reported the clinical symptoms of a 51 year old female psychiatric patient 
(Auguste. D.) [4]. His post-mortem neuropathological examination of the patient’s 
brain resulted in the first description of extracellular plaques and intracellular 
neurofibrillary tangles. Given the age of the patient, it is likely that she suffered 
from what is now referred to as early-onset Alzheimer’s disease. Dr Alzheimer’s 
findings in this first patient were presented at the 37th Meeting of the Southwest 
German Psychiatrists in Nov 1906 and published as a short report in 1907 [4, 5]. In 
1910, Dr Alzheimer’s colleague and mentor, Dr Emil Kraepelin, named the disease 
after him and a more extensive report was published in 1911, which also included 
the clinical and pathological description of a second patient, a 56 year old man 
(Johann.F.) [6, 7].  
For many years it was believed that the disease described by Alzheimer was a rare 
form of pre-senile dementia. This changed in 1970 when Tomlinson, Blessed and 
Roth [8] showed that a substantial percentage of elderly patients with dementia have 
large numbers of plaques and tangles that are not distinct from those occurring in the 
presenile dementia described by Alois Alzheimer. Following this seminal 
observation, Alzheimer’s disease has emerged as an important affliction of the 
elderly that is clearly separate from normal aging. It is relatively rare before the age 
of 65 years but, in industrialized countries, is present in ~10% of elderly subjects 
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over the age of 65 and up to 50% of people over the age of 85, where it is the most 
common form of dementia.  
Alzheimer’s disease is characterized by progressive memory loss, personality 
changes and eventual loss of motor functions, resulting in death. The range of life 
expectancy for patients following onset of symptoms is from 3 to 10 years. With the 
rapid growth of the elderly population, AD places an ever-increasing burden on 
health care systems and caregivers [9, 10] 
 
1.2 Diagnosis of AD 
Neurologists diagnose Alzheimer’s disease based upon a clinical examination and 
detailed patient and family history in combination with patient performance on 
cognitive tests. Several tests have been developed for measuring the cognitive 
function of suspected AD patients. The most commonly used test is the mini-mental 
state examination (MMSE), although other more rigorous tests are also used. 
Specific criteria have been set forth by the NINCDS-ADRDA (National Institute of 
Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and 
Related Disorders Association) [11] and the DSM-IV (Diagnostic and Statistical 
Manual of Mental Disorders) work group in order to ensure standardized diagnosis 
of Alzheimer’s disease. Most neurologists adhere to these guidelines, which 
clinically separate patients into those with a diagnosis of “probable AD”, where only 
evidence for AD is present, and “possible AD”, where there is some evidence for 
other pathology that could cause dementia (e.g. cerebrovascular disease).   
Chapter 1. 
- 18 - 
Although considerable progress has been made in accurately diagnosing AD during 
life, the only way to make a definite diagnosis in a demented patient is by 
demonstrating large numbers of senile plaques and neurofibrillary tangles in the 
brain at autopsy.  Several papers recommending pathological guidelines for making 
a definite diagnosis of AD have been published, the most frequently used are the 
CERAD criteria for quantification of plaques, Braak staging for quantification of 
NFT’s and the NIA-Reagan guidelines [12-14]. Despite the development of 
pathological guidelines for a definite diagnosis of AD, diagnosis is often 
complicated because pathological lesions associated with other dementias are 
present in addition to plaques and tangles. This not infrequently results in a post-
mortem diagnosis of mixed dementia with AD [15]. 
Aside from clinical tests for the diagnosis of AD, Dr Ron Peterson at the Mayo 
Clinic developed criteria for determining incipient dementia termed Mild Cognitive 
Impairment (MCI) [16-18]. Within five years, approximately 50% of subjects 
diagnosed with MCI develop Alzheimer’s disease. The diagnosis of MCI is, 
therefore, useful for identifying patients who will develop AD early in the course of 
disease, when therapy may be more effective. 
In addition to the clinical methods that neurologists use for diagnosing MCI and 
probable or possible AD, researchers are continually working to develop more 
reliable and sophisticated methods for diagnosing AD at an early stage using 
neuroimaging and biochemical approaches. One good example is Pittsburgh 
compound B (PiB), a fluorescent analog of thioflavin T that binds to amyloid in 
senile plaques. PiB, can be used effectively in positron emission tomography scans 
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to image plaques during life [19-21] and is now being employed in many clinical 
studies of AD. Additional neuroimaging markers, biomarkers present in CSF or 
plasma and identification of genetic risk factors are all potential clinical tools that 
may be useful in the future for predicting risk of this disease.  
 
1.3 Neuropathology 
There are two classical neuropathological features that lead to a definite diagnosis of 
AD at autopsy. These are extracellular amyloid plaques (sometimes referred to as 
senile or neuritic plaques) and intracellular neurofibrillary tangles (NFT’s) (Figure 
1.1). In addition, there is substantial neuronal loss in AD that results in atrophy of 










Figure 1.1 Neuritic plaques and neurofibrillary tangles in Alzheimer’s disease 
brain. A) Modified Bielschowsky silver staining identifies dense neuritic plaques. 
Neuritic plaques are typically circular and 10-50 microns in diameter. B) High 
power view of two neurofibrillary tangles stained with a Bielschowsky silver stain. 
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1.3.1 Neurofibrillary tangles and tau 
In his initial report, Alzheimer used the Bielschowsky silver staining method to 
observe a then novel intracellular lesion. It is now known that the neurofibrillary 
tangles first described by Alzheimer are comprised of paired helical and some 
straight filaments in which the main component is the tau protein [22-26]. This 
pathology occurs in most cases of AD but it is not exclusive to AD. ‘Tau 
neurofibrillary tangles’ also occur in other neurodegenerative diseases collectively 
termed ‘tauopathies’, although the nature and distribution of these tangles varies 
depending on the disease.  
The tau protein is a microtubule binding protein that stabilizes and promotes 
microtubule assembly. Tau is produced by the MAPT gene located on chromosome 
17 and has six major isoforms expressed in the brain. In AD, tau aggregates within 
the cell, forming paired helical filaments when it is hyperphosphorylated, resulting 
in reduced microtubule stabilization, impaired axonal transport and intracellular 
tangles. [22, 27-29].  
Neurofibrillary tangles can be identified using silver staining techniques similar to 
that used by Alzheimer, or more recently with immunohistochemistry techniques, 
using antibodies that recognize phosphorylated tau protein. The density and 
distribution of these tangles throughout the brain can be assigned to various 
categories called Braak stages, proposed and designated by Braak and Braak in 1991 
[9]. This classification is used for post-mortem diagnosis of AD where a Braak stage 
of 4 or greater, combined with the presence of many dense amyloid plaques, 
indicates a diagnosis of AD. 
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In 1998, mutations at the MAPT locus were shown to cause one of the 
neurodegenerative diseases that fall under the classification of tauopathies, FTD17-
P, so that it became clear that a loss of normal tau function (via mutation) can result 
in neurodegenerative disease [30]. In the case of AD there have, so far,  not been 
any mutations identified at the MAPT locus that directly cause AD. However there 
have been at least 45 independent published AD case control association studies 
reported for SNPs at the MAPT locus with 15 of them reporting a positive 
association with AD (data from AlzGene [31] August 2010). 
Whilst it is likely that a loss of normal function of the tau protein, via 
hyperphosphorylation, contributes to the pathogeneses of AD, it is currently not 
clear what causes this. It is likely that a number of complex pathways result in the 
hyperphosphorylation of tau in the manner associated with AD. 
Under normal conditions, tau is a soluble protein which can be measured in samples 
of CSF. Researchers are exploring CSF tau measures as a clinical tool for disease 
risk prediction and in genetic association studies. 
 
1.3.2 Amyloid Plaques 
Senile plaques, which are most commonly associated with AD, are complex 
extracellular lesions. Each plaque consists of an amyloid core surrounded by altered 
neurites. The altered neurites, which contain paired helical filaments like those that 
comprise neurofibrillary tangles, can be identified with silver stains. Enveloping the 
cluster of altered neurites are astrocytes, with processes that project toward the 
amyloid core. Activated microglia are closely associated with most of the amyloid 
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core, indicating a possible role for inflammation in this disease [32]. This type of 
plaque, with a dense core, can be referred to as ‘dense plaques’. In most cases of 
AD, amyloid is deposited not only in these plaques but also in the walls of blood 
vessels in the brain, a disorder referred to as cerebral amyloid angiopathy (CAA). 
Amyloid, by definition is highly insoluble extracellular protein in the form of 5-10 
nm wide, relatively straight fibrils. The protein in amyloid fibrils has a crossed beta 
sheet conformation which binds aromatic dyes like Congo Red. Amyloid is 
deposited in various organs in many different diseases since there are many different 
proteins that can spontaneously assemble into insoluble amyloid fibrils in the 
extracellular space. In the mid 80s, the amyloid in AD brain and meningeal vessels 
was isolated, solubilised, and sequenced [33-35]. This amyloid was found to be 
composed of a then novel, ~4 kDa peptide, now referred to variously as the amyloid 
ß protein, amyloid ß peptide, amyloid ß, Aß, or A4.  
When anti-Aß antibodies were used to immunostain AD brains, it became evident 
that, in addition to dense, cored plaques there was a second class of plaques referred 
to as diffuse plaques. The main constituent of diffuse plaques is also the amyloid ß 
protein, however these are frequently identified in both AD subjects and in the 
brains of elderly subjects without cognitive impairment. Diffuse Aß plaques can be 
found in areas of the brain not typically associated with AD such as the cerebellum 
and are not usually associated with abnormal neurites or reactive microglia and 
consequently may represent a pre-symptomatic form of A deposition [36, 37].   
Evidence from several studies suggests that relatively small Aß oligomers act as 
seeds which nucleate assembly of the large insoluble amyloid fibrils observed in 
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senile plaques. [38, 39]. Many proteins are associated with the fibrillar amyloid in 
senile plaques (Table 1.1). It is widely believed that these proteins adhere non-
specifically and have little pathogenic significance, but could have implications for 
plaque formation and stability.  
Surprisingly, the presence and density of senile plaques do not correlate well with 
severity of clinical symptoms [40-42]; this is in contrast with the other major AD 








Cytokines, chemokines, complement proteins, complement 
inhibitor, myeloperoxidase and immunoglobulins. 
Metal Ions Fe, Cu, Zn, Cr, Ni, Mn, Pb, Al and Si. 
Amyloidogenic 
related molecules 
Non-A component of AD amyloid (NAC),  , low density 




1-antichymotrypsin, 1-trypsin, lysosomal proteinases, 
ubiquitin and -2-macroglobulin. 
Antioxidant defense 
proteins 
Ferritin ceruloplasmin, Super OxideDismutase-1 & 2( SOD-
1 & -2), heme oxygenenase (HO-1) and catalase.  
Cholinesterase’s Acetylcholinesterase and butyrylcholinesterase. 
Other proteins 
Multifunctional clusterin (ApoJ, SP-40,40) apolipoprotein E 
(ApoE) 
 
Table 1.1. Proteins and other molecules that have been reported to be 
associated with amyloid plaques in addition to the A peptide. Adapted from 




- 24 - 
1.3.3 Atrophy of the brain  
In AD, progressive neuronal and synaptic loss results in brain atrophy. This atrophy, 
which can be observed ante-mortem using in vivo imaging techniques such as 
magnetic resonance imaging (MRI) and upon post-mortem examination of the brain 
is also a characteristic feature of AD. Brain atrophy is observed in many forms of 
dementia. in each of which the type and location of cell death involved correlates 
with the clinical features of the disease [43, 45]. The temporal lobe, frontal lobe, and 
hippocampus are the areas most involved with cortical loss in Alzheimer’s disease. 
Major association areas are also involved with notable cortical atrophy. Relatively 
spared areas include the primary motor and sensory cortex as well as the visual 
cortex. With atrophy of the brain parenchyma, there is notable enlargement of the 
cerebral ventricles. There is good evidence that neuroimaging techniques can 
identify atrophy of affected brain areas before the appearance of clinical symptoms 
indicating neuroimaging as a viable tool in the study and diagnosis of 
neurodegenerative diseases such as AD [46]. 
 
1.4 Amyloid-beta protein (A) 
In 1987, the gene that encodes A was cloned and mapped to a locus on 
chromosome 21 [47-49]. In this gene (APP), Aß is encoded as an internal peptide 
within a much larger protein, the Aß precursor protein (APP). The APP is a 
transmembrane glycoprotein with a large luminal domain and a short cytoplasmic 
domain. The A peptide sequence starts in the luminal domain and ends within the 
transmembrane domain. The APP gene produces three alternatively spliced 
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isoforms, but in each of them, Aß extends from just outside the membrane (amino 
end) to a position about half way through the single membrane-spanning domain 
(carboxyl end) [49, 50]. Interestingly, one of these isoforms (APP695) differs from 
the others in that it is largely neuron specific and lacks a Kunitz-type inhibitor 
domain that is common to the other two isoforms [51, 52]. The precise functions of 
these isoforms have not yet been elucidated. In mammals, there are two homologous 
proteins, called APP-like proteins (APLP1 and APLP2), although critically these 
lack the A peptide domain.  
When the APP gene was first cloned, it was known that patients with trisomy 21 
(Down’s syndrome) always develop AD pathology (senile plaques and 
neurofibrillary tangles) if they live past the age of 40 [53, 54]. This suggested that 
there is a gene, or perhaps a combination of genes, on chromosome 21, that can 
cause AD when over-expressed. When the APP gene was mapped to chromosome 
21, it was evident that it might be the gene that causes AD in patients with trisomy 
21.  
In 1992, Dr. Younkin’s laboratory and several others discovered essentially 
simultaneously that normal processing of the APP results in secretion of Aß [55-58]. 
Most secreted Aß has forty amino acids (Aß40) but a small percentage has two extra 
amino acids at its carboxyl end (Aß42) [59, 60]. Cells of all types produce APP and 
secrete both Aß40 and Aß42, which are readily detected in human plasma and 
cerebrospinal fluid [61, 62]. The cells in brain produce particularly large amounts, 
however, and the concentration of Aß in CSF is 50-times greater than in plasma . 
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This may explain why there is selective amyloid deposition and plaque formation in 
the brain as opposed to peripheral organs. 
The normal physiological role, if any, of the amyloid ß protein is still currently not 
understood. A is produced following enzymatic processing of the amyloid 
precursor protein (APP), known as amyloidogenic processing (see section 1.8, 
Figure 1.4). It initially exists as a monomer but under certain conditions A can 
form oligomers that can aggregate into insoluble amyloid fibrils that are classically 
associated with AD [63, 64]. 
 
1.4.1 Neurotoxicity of A
It is likely that A exerts toxicity via multiple molecular mechanisms, an improved 
understanding of which can have important implications for the development of 
therapeutics for treating AD. The Aß42 peptide is particularly important in AD. In 
vitro, synthetic Aß42 spontaneously assembles into amyloid fibrils far more rapidly 
than Aß40 [63-65], so Aß42 is far more amyloidogenic than Aß40. In one third of 
AD brains, Aß ending at the 42 position is virtually the only form of Aß deposited 
and in another third it is by far the major form of Aß [66]. In the remaining third of 
AD brains, a large amount of Aß ending at position 40 is deposited in addition to 
Aß42. The amount of Aß42 deposited varies considerably from brain to brain, but 
appears to be independent of how much Aß40 is deposited. Thus, a large amount of 
Aß42 is deposited in all AD brains, whereas substantial amount of Aß40 is deposited 
in only one-third of AD cases [66]. Initially it was believed that aggregated amyloid 
deposits were the most neurotoxic species of A. However more recent data 
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implicates both intra-cellular and extra-cellular A oligomers as the most neurotoxic 
form of the peptide. In 1999, recently reviewed by Walsh D.M. and Selkoe D.J. 
[67], several research groups published data indicating improved correlation 
between soluble A oligomers and disease course, implicating this as the neurotoxic 
species of aggregated A[68-70]. Over the past decade there has been increasing 
evidence suggesting that soluble A oligomers are indeed the pathogenic form of the 
peptide [67, 71, 72]. A thorough understanding of the neurotoxic effects of A will 
have important implications for therapeutic targeting. 
 
1.5 Genetics risk factors for Early Onset Familial AD (EOFAD) 
Many families were identified in which AD occurred at an early age (35-60 years) 
with fully penetrant, autosomal dominant inheritance. Termed early onset familial 
AD (EOFAD), the AD produced through this simple Mendelian pattern of 
inheritance constituted a small fraction (<1%) of all AD, but analysis of the EOFAD 
families proved to be highly informative.  
 
1.5.1 APP 
Several families were identified in which EOFAD was produced by mutations in the 
APP gene. Many of the first mutations identified all occurred at the same location, 
namely, several amino acids from the carboxyl end of Aß [73-76]. The next APP 
mutations discovered included a double missense mutation (Swedish)  affecting the 
two amino acids just before the amino terminus of Aß [77], as well as several 
additional mutations shown in Table 1.2. It is notable that several independent 
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mutations were found at the same residue of the APP protein, for example four 
different mutations cause the Val residue at position 717 in the APP protein to be 
altered. Furthermore, mutations in APP that cause AD tend to cluster in exons 16 
and 17 of the transcript, which encode the A peptide domain.  
In addition to the mutations listed in Table 1.2, two studies also identified recessive 
mutations in the APP gene segregating in EOFAD families [78, 79]. Recently, 
duplication of the APP locus has been identified as causing EOAD with associated 
CAA [80, 81].  
 
1.5.2 PSEN1 and PSEN2 
Following the identification of mutations at the APP locus on chromosome 21, 
researchers quickly realized that EOFAD was a heterogeneous disease since not all 
families could be explained by mutations in the APP gene. Mapping of additional 
loci that cause this disease was pursued and linkage to chromosome 14 was 
identified in some families [82-84]. In 1995, mutations at the PSEN1 locus (Chr 
14q24.3) were identified in EOFAD families with an aggressive form of the disease 
identified by a markedly earlier onset of clinical symptoms [85]. Over the past 15 
years, many hundreds of variants have been identified at this locus in EOFAD 
pedigrees. These variants are distributed throughout the gene and do not appear to 
accumulate in any one domain of the protein. Due to the fact that so many variants 
have been described in this gene these have not documented here, but a 
comprehensive overview can be found at the AD & FTD mutation database: 
http://www.molgen.ua.ac.be/ADMutations [86].  
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Whilst mutations at the PSEN1 locus were being investigated, a third EOFAD locus 
was also identified that was highly homologous to PSEN1 [87, 88]. This is now 
known as the PSEN2 gene and is located on chromosome 1q31-q42. 
In contrast to PSEN1, variation at the PSEN2 gene in EOFAD pedigrees is rarely 
observed, so that to date there are only 14 pathogenic mutations that have been 
found in this gene [86]. It is worth noting that the expression of PSEN2 is lower than 
that of PSEN1 in the brain and it is thought that Psen1 is the major presenilin that 
forms the -secretase in the brain [89-91]. This might explain why fewer mutations 
at the PSEN2 locus cause EOFAD when compared with PSEN1. 
 
Careful study of the genetic changes that cause AD, by the Younkin laboratory and 
others, showed that virtually all of these changes in APP, PSEN1 and PSEN2 
increase Aß42. However, trisomy 21 increases both Aß42 and Aß40 and the double 
mutation in the APP gene described previously, which occurs in a large Swedish 
family, also increases both Aß42 and Aß40. These elevations in Aß40 and Aß42 
have been demonstrated in cells transfected with mutant PSEN1, PSEN2 and APP 
genes, the brains of transgenic mice expressing EOFAD mutations, and plasma from 
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Mutation Alternate name Exon/Domain References Year 
Met 670 Leu,   
Lys 671 Asn 
Swedish double Exon 16, N-term [77] 1992 
Asp 678 Asn Tottori Exon 16, N-term [98] 2004 
Glu 682 Lys Leuven Exon 16, N-term [99] 2008 
Ala 692 Gly Flemish Exon 17, N-term [100] 1992 
Glu 693 Lys Italian Exon 17, N-term [101] 1999 
Glu 693 Gln Dutch Exon 17, N-term [102-104] 1990 
Glu 693 Gly Arctic Exon 17, N-term [105] 1992 
Asp 694 Asn Iowa Exon 17, N-term [106] 2001 
Ala 713 Thr na Exon 17, TM-1 [107-110] 2002 
Thr 714 Ala Iranian Exon 17, TM-1 [111-113] 2002 
Thr 714 Ile Austrian Exon 17, TM-1 [114, 115] 2000 
Val 715 Met French Exon 17, TM-1 [116, 117] 1999 
Val 715 Ala German Exon 17, TM-1 [118, 119] 2001 
Ile 716 Phe Florida Exon 17, TM-1 [120] 1997 
Ile 716 Phe na Exon 17, TM-1 [121] 2008 
Ile 716 Thr na Exon 17, TM-1 [122] 2002 




Val 717 Phe na Exon 17, TM-1 [129, 130] 1991 
Val 717 Leu na Exon 17, TM-1 [75] 2000 
Val 717 Gly na Exon 17, TM-1 [73] 1991 
Leu 723 Pro Australian Exon 17, TM-1 [131] 1998 
Lys 724 Asn Belgian Exon 17, C-term [132] 2006 
 
Table 1.2 Pathogenic APP mutations segregating in families with EOFAD. 
Certain mutations are widely known by the geographical location of the primary 
family in which they were identified, noted here under ‘alternate name’. The year of 
the first publication for each mutation is also indicated under ‘year’. Adapted from: 
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1.6 Amyloid Cascade Hypothesis 
One might argue that trisomy 21 and EOFAD mutations all foster Aß aggregation 
and plaque formation, but that these changes do not cause the neurofibrillary tangles, 
synapse loss, neuronal loss or dementia seen in AD. This line of thinking suggests 
that it is additional changes caused by these genetic variants, but not by elevated 
Aß42, that actually cause dementia. This seems highly unlikely, however, because 
an enormous body of evidence has accumulated indicating that aggregated Aß, most 
likely some form of soluble Aß oligomer, is highly toxic to neurons both in vitro and 
in vivo [67-70, 72]. In addition, there is good evidence that Aß accelerates the 
process of tangle formation in mice expressing the tau mutation (P301L) that causes 
fronto-temporal parkinsonism with dementia. This enhancement is particularly 
prominent in hippocampal pyramidal neurons which are widely believed to be most 
susceptible to tangle formation in AD [133].  
Together, with the genetic evidence from the study of EOFAD, these observations 
indicate that increased production of A can cause AD and it was from these 
findings that the amyloid cascade hypothesis for Alzheimer’s disease was born [134-
137]. The hypothesis postulates that the major triggering event in the disease is 
deposition of A and that additional pathological and clinical changes occur as a 
result of A deposition. This hypothesis is still held in high regard today, although it 
is widely believed that it is not insoluble amyloid fibrils but soluble A oligomers 
that are the pathogenic form of A in AD [67, 71].   
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As illustrated in Figure 1.2 there are two major pathways which can lead to an 
increase in A in the brain: increased A production or decreased A clearance. 
This forms the basis of the amyloid cascade hypothesis. 
As the evidence for the amyloid cascade hypothesis developed, many 
pharmaceutical and biotechnology companies began preclinical work to develop 
novel strategies to treat AD using Aß as the therapeutic target, and many academic 
laboratories began to study the trafficking and processing of APP and to investigate 
the mechanisms involved in removal of Aß. This effort generated an enormous 
amount of additional information that is summarized in the sections that follow. 
 
1.7 APP trafficking 
The APP protein has been identified at the plasma membrane implicating trafficking 
through the secretory pathway, but it has also been identified at the membranes of 
endosomes, lysosomes and mitochondria [138-140]. APP that reaches the plasma 
membrane through the secretory pathway is quickly internalized by recognition of a 
“YENPTY” internalization motif in APP. Following endocytosis of APP, much of it 
is believed to be delivered to lysosomes for degradation but a small component is 
recycled to the plasma membrane, as illustrated in Figure 1.3. This is believed to be 
a major pathway for A secretion [141]. The cellular localization of APP has 
implications for proteolytic processing of the protein, which in turn has implications 
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Figure 1.2. Interpretation of the 
amyloid cascade hypothesis. 
This figure is a simplified 
interpretation of the amyloid cascade 
hypothesis, as multiple pathways 
may influence the cellular processes 
that in turn influence A production 
and degradation. Studies of EOFAD 
however show that a direct effect of 
altered APP processing fits this 
hypothesis and it is therefore likely 
that the sporadic form of the disease 
also fits albeit a result of less direct 
processes.  
A: Known mutations in APP, PS1 
and PS2 that cause altered APP 
processing which result in either an 
increase in the total amount of A 
produced or a relative increase in the 
more amyloidogenic form A42. 
B: Amyloid-beta degradation is less 
well defined, although multiple lines 
of evidence implicate several 
degradation pathways as being 
involved in AD pathogenesis. A 
number of amyloid-beta degrading 
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For example, synaptic transmission is believed to lead to an increase in endocytosis 
of APP and consequently increased amyloidogenic processing (which is more 
prevalent in endosomes), resulting in increased levels of secreted A [142-144].  
Furthermore, the processing of APP appears to be sensitive to cellular cholesterol 
concentrations, since evidence from several studies suggests that an increased 
cholesterol content in membrane microdomains referred to as ‘lipid rafts’ fosters co-
localization of APP and the secretases that release the A peptide domain, resulting 
in an increased A production [144, 145].  
Multiple molecular mechanisms can influence the trafficking and proteolytic 
processing of APP, so a continued effort to understand these mechanisms may lead 
to improved therapeutic strategies. 
 
1.8 APP processing 
Three enzymes or enzyme complexes are known to cleave the APP protein, which 
are known as ,  and  secretases. APP processing can follow an amyloidogenic 
pathway: cleavage by ß-secretase followed by γ-secretase. Or it can follow a non-
amyloidogenic pathway: cleavage by α-secretase followed by γ-secretase. The 
amyloidogenic pathway results in the production of the Aß peptide (Figure 1.4) plus 
soluble APP-beta (sAPP-) and the APP intracellular domain (AICD). The non-
amyloidogenic pathway results in the production of soluble APP-alpha (sAPP-, a 






















Figure 1.3. APP trafficking. 1. Anticipated site of both alpha and beta 
secretase activity. 2. Anticipated site of gamma secretase activity. 3. Expected 
gamma and beta secretase activity. 4. Evidence suggests that at least some APP 
is directed to mitochondrial membranes and may be cleaved here or continue 
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Similar to the A peptide, P3 can vary in the C-terminal residues at the site of the 
gamma secretase cleavage, although the impact this may have on this peptide is 
poorly understood. Likewise, AICD will also have variability at its N-terminus due 
to heterogeneity at the -secretase cleavage site, however subsequent processing at a 
second site (-site) results in a 50 residue peptide, in which the variable length 
fragment is removed. Cleavage of APP, by either  or secretase, results in the 
production of one of two forms of a long secreted APP N-terminal fragment (sAPP 
and ), which differ at the carboxyl-terminal, with the alpha form containing the 
first 16 residues of the A peptide. The putative roles identified for the products of 
APP processing, other than A, are summarized in Table 1.3.  
 
Studies of these proteins have identified various possible neuroprotective and 
neurotoxic effects, indicating that these may act as modifiers of Alzheimer’s disease 
etiology. However, the presence of the A peptide as the major constituent of the 
classic AD lesion, its propensity to aggregate and the wealth of evidence supporting 
its neurotoxic effects all indicate that A is the main pathogenic peptide produced 





































Figure 1.4 APP Processing: The APP is a transmembrane protein relevant to 
Alzheimer’s disease, since proteolytic processing of APP results in the production 
of Aß protein, the major constituent of amyloid plaques. APP can be processed by 
ß-secretase followed by γ-secretase generating Aß (amyloidogenic pathway). 
Alternatively, it can be processed in a non-amyloidogenic pathway, with cleavage 
by α-secretase followed by γ-secretase. Mutations in the APP and PSEN1/2 genes, 
which encode the catalytic subunit of γ-secretase, are associated with the early-
onset familial Azheimer’s disease. The Figure is modified from Hardy J. with blue 
circles representing residues 41 and 42. Red circles represent pathogenic APP 





























Enzymes Function related to the brain 
sAPP alpha  
Studies using rats indicate that sAPP increases long term 
potentiation (LTP), and improves spatial memory [145], a finding 
that is inversely linked to some of the deficits observed in AD 
subjects. Others have shown positive effects, in vitro, of sAPP 
on NMDA receptor associated neurite growth, synaptic plasticity 
and LTP [147-149], indicating that sAPP may have 
neuroprotective properties.  
sAPP beta  
Both secreted forms of the APP ectodomain can trigger an 
inflammatory response in the brain through activation of 
microglia via a glutamate pathway that might also interact with 
ApoE [150, 151]. However, unlike sAPP, studies of sAPP 
have not identified any neuroprotective properties for this protein 
resulting in an imbalance in neurotoxic effects of sAPP that 
could consequently contribute to neuronal dysfunction and 
disease. Furthermore, Li et al. recently implicated a role for 
sAPP in transcriptional regulation of transthyretin and klotho 
proteins, which have been associated with the formation of -




P3 is equivalent to A 17-40/42 [155]. It has not been as 
extensively studied as full-length A and its normal function is 
not well understood. P3 has been identified as the major 
constituent of extracellular deposits observed in the cerebellum 
of Down’s Syndrome patients, called pre-amyloid lesions and it 
has also been found in AD neuritic plaques [156]. Studies have 
also implicated a role for P3 in neuronal apoptosis [157]. P3 
probably represents a peptide with similar properties to A that 
has either reduced neurotoxicty or toxicity that is not well 
understood. 
AICD gamma 
The APP Intracellular domain (AICD) is generated by both APP 
processing pathways (Figure 1.4.). Following initial  secretase 
activity, the AICD is further cleaved at an  cleavage site which 
results in the 50 residue AICD peptide. The AICD has been 
frequently linked to regulation of gene expression via association 
with various other factors such as Fe65 and Tip60. GSK3, 
which has frequently been linked to tau hyper-phosphorylation, is 
among the genes believed to be regulated by the AICD  [158]. 
Goodger Z.V. et al. have reported that the AICD generated via 
the amyloidogenic pathway has a greater preference for nuclear 
localization, and consequently regulation of gene expression, 
than that produced by the non-amyloidogenic pathway, perhaps 
due to the sub-cellular localization of the amyloidogenic pathway 
events [159]. 
Table 1.3. Summary of some of the putative roles identified for products of APP 
processing, other than A.  
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1.8.1 Alpha secretase 
As shown in Figure 1.4. alpha secretase cleaves APP between residues 16 and 17 of 
the A peptide, resulting in the shedding of the APP ectodomain (sAPP) and 
consequently precludes the production of full length A. Recent studies indicate that 
members of the ADAM (a disintegrin and metalloprotease) family of proteases are 
responsible for -secretase activity. This family of multi-domain, membrane bound 
proteases have been associated with the action of ectodomain shedding for a number 
of transmembrane proteins in addition to APP, although exactly which members of 
this family have this activity on APP in the brain remains to be elucidated. Several 
reports have identified the action of ADAM 9, 10, 17 and 19 as the most likely APP 
-secretase candidates [160-163] whilst ADAM 9, 10 and 12 have been the target of 
AD genetic association studies, with varying results [164-168]. Furthermore the 
activity of ADAM proteases on APP has been identified at both the plasma 
membrane and the trans-golgi network [169]. This indicates multiple sub-cellular 
locations for -secretase activity, which are consequently likely to be sensitive to 
multiple regulatory pathways. Collectively, the evidence to date suggests that whilst 
the APP alpha-secretase may be one or more members of the ADAM family, more 
research is needed to better understand how these functions might influence 
Alzheimer’s disease. 
 
1.8.2 Beta secretase. 
Beta-secretase cleaves the APP protein resulting in the production of a 99 residue C-
terminal fragment (CTF99) which is later cleaved by -secretase to produce 
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A(Figure 1.4). In 1999, four research groups identified BACE-1, a membrane 
bound aspartyl protease, as having beta-secretase activity [85-88]. More recently, 
the same was shown for BACE-2 [89] and members of the cathepsin family of 
proteases [72, 90] although it appears that these proteases do not have the same level 
of beta secretase activity in the brain as BACE-1 and so probably do not have the 
same impact on the amyloidogenic processing of APP [72, 91]. APP is not the only 
substrate of BACE-1, since additional substrates include the APP like proteins 
(APLP-1 and 2), LRP and neuregulin [170]. Similar to the  and  secretases, it is 
probable that BACE-1 acts upon these other substrates in sub-cellular compartments 
which may not entirely overlap with that of APP. BACE-1 performs optimally at 
low pH and is consequently most frequently found in  acidic sub-cellular 
compartments such as endosomes [171], although evidence suggests that there is 
some activity at the plasma membrane and also in the Golgi. Cleavage of APP by -
secretase in intracellular compartments such as the Golgi is enhanced with the 
Swedish APP double mutation (APPswe), which is known to cause EOFAD (Table 
1.2) [93, 172].  
Studies of SNPs at the BACE-1 locus for association with LOAD have revealed 
heterogeneous results [31], which is a common finding for LOAD candidate genes . 
Additional evidence implicating BACE-1 as the -secretase comes from studies of 
BACE-1 knock-out mice, which exhibit an essentially complete depletion of 
neuronal A secretion, providing further evidence that BACE-1 is critical for 
amyloidogenic APP processing [173].  
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The overwhelming majority of research indicates that BACE-1 is the most likely 
source of -secretase activity. Additional enzymes may be able to cleave APP at the 
-secretase cleavage site but it is unlikely that they are active in vivo.  
 
1.8.3 Gamma secretase. 
The gamma-secretase that cleaves APP is an aspartyl protease and, as illustrated in 
Figure 1.5, is a complex of four transmembrane proteins; Nicastrin, (NCT), 
Presenilin enhancer 2 (PEN2), anterior pharynx defective 1 (APH-1) and Presenilin 
1 or 2 [89]. The presenilins are believed to be responsible for forming the catalytic 
domain and, in the brain, PS1 has been found to be the predominant presenilin [90, 
91]. The remaining three cofactor proteins are thought to be involved in formation 
and stability of the complex, although some reports also indicate a role in substrate 
recognition [174, 175]. Current evidence indicates that -secretase cleaves APP 
within the membrane, where two aspartate residues, located within transmembrane 
domains 6 and 7 of presenilin, are critical to the hydrolysis of the target peptide 
bond [90]. This action is heterogeneous, since the particular bond that is hydrolyzed 
can vary, resulting in different terminal residues of the resultant peptides. Mutations 
in APP, PSEN1 and PSEN2 that have been implicated in EOFAD cause preferential 
hydrolysis at particular sites resulting in a selective increase in A42 production. 
[73-75, 85, 87, 88].  
The mature -secretase complex has been found in many sub-cellular compartments 
and is also found at the plasma membrane [140, 176, 177]. However, with respect to 
APP, the -secretase preferentially exerts its activity on the APP C terminal 
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fragment: APP-CTF (following cleavage by alpha or beta secretase) and is 
consequently most active against APP in compartments enriched in the APP-CTF. 
The components of the -secretase are also known to have enzymatic activity against 
other type-1 membrane proteins, in addition to APP. The most significant and well 
known alternative -secretase substrate is Notch [178, 179]. For this reason, attempts 
at using the -secretase as a therapeutic target have so far failed. Notch is a 
signalling peptide involved in several cellular processes and consequently altered 
Notch processing can result in an embryonic lethal phenotype in mouse studies and 
unfavourable side-effects in drug trials [180-182]. A recent study identified loss-of-
function mutations in PSEN1 that cause a dominant form of the skin disease acne 
inversa (AI). It is likely that these mutations result in altered notch processing, the 
major target of the -secretase in skin cells [183]. Interestingly, Wang et al [183] 
indicate that AD and AI may be mutually exclusive suggesting that mutations of 
PSEN1 and 2 that cause AD likely represent gain-of-function mutations affecting 
APP cleavage, thus altering the amount of Aß produced. 
Recent developments have identified selective -secretase mechanisms that 
influence APP processing without affecting Notch. These include selective targeting 
of Aph-1 isoforms and more recently a  novel -secretase activating protein (GSAP)  
[184, 185]. This provides promise for future research on the specific therapeutic 
targeting of -secretase effects on APP. 
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Figure 1.5. Postulated membrane location of  secretase β secretases, and the multi-subunit  secretase.  and β secretases  are 
believed to be membrane bound via a transmembrane domain (T) and to have a catalytic domain (C) as shown by the red domains. The 
catalytic domain of -secretase is believed to include two aspartate residues in transmembrane domains 6 and 7 of presenililin, as shown 
by the red circles. Two common models for presenilin are of 8 or 9 transmembrane domain proteins, although these models are not easily 
resolved, so the ninth transmembrane domain is shown here with an asterix. Modifed from De Strooper B. et al. [170].
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1.9 A degradation and clearance.  
Understanding the molecular mechanisms involved in the production of the A 
peptide is of critical importance in understanding the pathogenesis of AD. This is 
highlighted by the fact that most cases of EOFAD are caused by mutations that 
influence the production of A. However the majority of AD cases have a more 
complex aetiology and cannot be directly linked to abnormal A production. The 
more common form of AD is not pathologically distinct from EOFAD, so a major 
hypothesis is that LOAD is caused by an imbalance of A concentrations in the 
brain, which results from alternative molecular mechanisms from EOFAD (see 
Section 1.6).  
The main pathways that have been targeted by researchers in the search for 
alternative mechanisms that influence Adeposition, are A degradation and 
clearance from the brain. Soluble, monomeric A can cross the blood brain barrier 
(BBB) through interactions with two receptors: receptor for advanced glycation end 
products (RAGE, influx) and low-density lipoprotein receptor related protein-1 
(LRP-1, efflux) for review see Deane et al. and Citron, M. [186, 187]. Inhibition of 
RAGE and up-regulation of LRP-1 are potential therapeutic strategies that are being 
explored to decrease uptake and increase removal of A from the brain into the 
peripheral circulation, where it is largely bound to other proteins so cannot form 
toxic aggregates. The long term effects of continued A increases in the blood is 
unknown however.  
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In addition to receptor mediated transport across the BBB, brain A levels can also 
be altered by the action of A peptidases and several enzymes that are known to 
degrade A These include, but are not limited too, neprilysin (MME), insulin 
degrading enzyme (IDE), angiotensin converting enzyme (ACE), plasmin (PLG), 
endothelin converting enzymes (ECE-1 and ECE-2) and matrix metallopeptidases 
(MMP-2, MMP-3 and MMP-9) [188-193]. These enzymes and factors that regulate 
the expression and activity of these enzymes have been the target of both genetic 
and biochemical research, in an effort to identify molecular mechanisms that can be 
exploited therapeutically. Whilst each of the above peptidases have evidence 
implicating them as able to degrade A, their impact on AD pathogenesis is less 
clear. Furthermore, whilst neprilysin is probably the most established A peptidase, 
genetic evidence for association with AD is more compelling for the genes encoding 
ACE and IDE. The association of SNPs in genes encoding one of these enzymes 
(IDE), with plasma A levels and AD is explored further in Chapter 3. 
One final area of research focused on A clearance from the brain is that of innate 
immunity. As mentioned previously, neuritic (or dense) amyloid plaques are 
associated with microglial activation, indicating that an inflammatory response is a 
component of the disease. Recent studies suggest that phagocytosis of A by 
macrophages may be defective in AD patients [194, 195]. Studies carried out in 
mice also show that administration of A antibodies stimulate clearance of A by 
activation of micoglia [196]. This work is based upon research published in 1999 
and 2000 demonstrating that vaccination of AD mouse models with A1-42 resulted 
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in reduced deposition of A [197] and improvement in memory phenotypes [198]. A 
similar vaccination protocol as a therapeutic treatment for AD reached clinical trials 
in 2002 [199, 200]. Unfortunately the trials were cancelled due to unexpected 
toxicity caused by a neuroinflammatory response (meningo-encephalitis) in some 
patients. The field continues to pursue this avenue of research in order to develop a 
treatment for AD [201, 202]. 
 
 
1.10 Measurement of A in human samples 
A can be measured in samples of CSF and plasma and has also been measured in 
homogenates of human brain [66]. The availability of plasma is much greater than 
that of CSF so, more work has been carried out using this source. In plasma, 
contrary to what is found in plaques, A42 is not the most abundant form of the 
peptide. In published studies measuring plasma Aβ40 and Aβ42, plasma 
concentrations of Aβ40 range from 2 to 10 times as high as those for Aβ42 [95, 
203].  
In previous studies of EOFAD families, it was found that all of the genetic changes 
that cause AD alter APP processing in a way that is evident in plasma [95]. In 2001, 
Ertekin-Taner et al. demonstrated that in a study of 15 typical LOAD pedigrees, 
plasma A40 and A42 showed highly significant heritability (p<0.0001) of 41% 
and 56% respectively [204]. In additional studies by the Younkin laboratory, plasma 
A concentrations in extended LOAD pedigrees were also used to identify a QTL 
on chromosome 10 [62] and subsequent association with SNP’s at several genes 
proximal to the linkage peak [205-207]. 
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Several studies have been published over the past 14 years demonstrating the utility 
of plasma A measures in genetic and epidemiological studies of AD. Many of these 
studies made use of a sandwich ELISA system developed by N .Suzuki in the 
Younkin lab [94]. 
In this thesis, the same sandwich ELISA system has been used to measure plasma 
A in population isolates in order to identify genetic loci that influence this trait. 
This is a novel approach, since the study subjects have not been selected based on a 
priori knowledge of cognitive deficits or individuals with high plasma A levels. 
 
1.11 Genetic factors that influence LOAD 
Most cases of early onset AD segregate in families and are caused by mutations in 
three genes (APP, PSEN1 and PSEN2) that show an autosomal dominant pattern of 
inheritance. However, the more common late-onset AD (LOAD) disorder does not 
exhibit an autosomal dominant pattern of inheritance but is highly heritable with an 
estimated heritability of 58-79%, based upon twin studies [208]. Thus, 
understanding genetic factors that influence AD is clearly pertinent to understanding 
the disease, predicting disease risk and development of targeted therapeutic 
strategies. 
Several studies have investigated the APP, PSEN1 and PSEN2 loci for single 
nucleotide polymorphisms (SNPs) that might influence LOAD, with largely 
negative findings [31, 209]. However some evidence suggests a possible role for 
SNPs at these loci that may influence gene expression [210-213] or interaction with 
another locus such as APOE [214, 215]. 
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Following on from the success of linkage studies in EOFAD pedigrees, several 
groups undertook a similar approach using LOAD pedigrees and in 1991 linkage to 
chromosome 19 was observed [216]. In 1993, apolipoprotein E (APOE) on 
chromosome 19 was determined to be a risk locus for LOAD based upon co-incident 
studies that identified association of APOE alleles with LOAD [217, 218] and the 
finding that ApoE and A are binding partners [219-221].  
Whilst APOE genotype is now a well established risk factor for LOAD, it does not 
explain all of the genetic variance of LOAD. APOE risk alleles are neither necessary 
nor sufficient for development of LOAD, consequently additional LOAD linkage 
studies were undertaken in an effort to identify further genetic risk loci. These 
linkage studies were followed by candidate gene studies, often analysing variation in 
genes under the identified linkage peaks.  
Bertram et al. created a  database called Alzgene in order to provide convenient 
access to results from the large numbers of LOAD genetic association studies [31]. 
The primary purposes of AlzGene are to record the results of published AD 
association studies and to perform meta-analyses. 
At the time of writing there are data from 2916 polymorphisms collected from 1380 
studies of 666 genes in the AlzGene database. These numbers illustrate the 
substantial effort by researchers over the past 15-20 years in an attempt to identify 
LOAD susceptibility loci. Despite this effort, APOE remains the “top gene” on a list 
of genes with nominally significant meta analysis p-values, ranked based upon 
HUGENet criteria and compiled by AlzGene [222, 223]. 
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Figure 1.6 Ideogram representations of 6 human chromosomes with genes known to influence AD. Genes identified that are 
known to cause EOFAD are shown in red and genes identified that are known to influence risk for LOAD are shown in blue. 
Ideograms are adapted from the Alzgene website [31]. Chr = chromosome.  
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Furthermore, APOE remained, until recently (and may still be considered by some), 
the only gene to be irrefutably accepted as a LOAD susceptibility gene, due in large 
part to inconsistent replication of other genes and variants in additional populations. 
The effect size of APOE is also much larger than any subsequently identified loci, 
although some studies initially report inflated odds ratios, a phenomenon referred to 
as ‘the winner’s curse’ [224]. It is likely that if additional ‘common’ LOAD loci 
with an effect size equal to or larger than APOE do exist, they would have been 
identified already. Consequently the remaining genetic risk for LOAD is now 
believed to be due to multiple gene variants with modest effect size or rare gene 
variants with moderate to large effect sizes, since the latter are not efficiently 
screened by genetic association studies using common variants  [225] 
 
1.11.1 APOE 
APOE is located on chromosome 19q13.2,  flanked by two genes: TOMM40 3’ and 
APOC1 5’. A two SNP Haplotype (rs7412 and rs429358) tags three common APOE 
alleles, namely APOE E2, E3 and E4 [226].  The APOE E4 allele confers increased 
risk for disease with an OR of ~4.0 for the E4  versus the E3 allele or an OR ~ 15.0 
for E4/E4 homozygotes versus E3/E3homozygotes (Alzgene meta analysis[31]). 
The APOE E2allele is believed to confer protection from AD but with a weaker 
effect than APOE E4 [227]. In addition to the effects of the APOE locus on disease 
risk, it has also been reported that the allele can influence the age of onset of the 
disease, where E4 carriers have an earlier age at onset of the disease when compared 
with non-carriers [217].  
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Several studies have been published recently postulating that genes lying proximal 
to APOE may contribute to or account for the genetic association at the APOE 
region or independently modify risk for LOAD [228]. Whilst this remains 
controversial, it is possible that disease modifying variants in multiple closely linked 
genes might influence the disease, that might help to explain the genetic 
heterogeneity observed at other LOAD loci. 
APOE encodes the apolipoprotein E, which is the main cholesterol chaperone in the 
brain. It has been hypothesized that one way in which the APOE protein might 
influence risk for AD is through altered cholesterol trafficking. Cholesterol is a key 
component of lipid rafts and as mentioned in Section 1.6, cholesterol concentration 
in lipid rafts may influence APP trafficking/processing and consequently risk for 
AD. It is thought that the APOE 4 protein isoform, encoded by the E4 allele, binds 
cholesterol less efficiently than the E3 and E2 isoforms and that the resulting effects 
on cholesterol trafficking may impact disease [229]. The relationship between 
cholesterol, ApoE and neurodegeneration is, however, likely to be complex and may 
be modified by many other genetic and environmental factors (see recent reviews 
[230, 231]. 
 
1.11.2 Novel LOAD loci identified by GWAS 
Significant progress has been made in identifying LOAD susceptibility genes over 
the past two to three years with the advent of genome-wide association studies 
(GWAS). Studies with a sample size of >100 are summarized in Table 1.4. GWAS 
can be highly informative since they interrogate the whole genome with high density 
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coverage, and they provide an unbiased approach to screen for SNPs in novel trait-
associated genes. The majority of LOAD GWAS published to date (Table 1.4) 
genotyped between 300,000 and 500,000 SNPs using microarray technology. To 
illustrate how quickly this technology has evolved, the most recent platforms are 
offering microarrays that genotype over 1 million SNPs and there are plans for 
platforms offering 5 million SNP genotypes (www.illumina.com, November 2010). 
GWAS also present challenges, however, in the form of multiple testing. 
Corrections for multiple tests must be performed which result in a low p-value 
threshold (approx 1.7E-07 for 300,000 tests) to pass significance at an  of <0.05. 
Many of the early LOAD GWAS studies were unable to identify loci that passed the 
stringent criteria for multiple test corrections with the exception of SNPs on 
chromosome 19 proximal to the APOE locus (Table 1.4). Genes that were 
implicated in these earlier studies were not replicated consistently, similar to the 
results observed for candidate gene studies, likely due lack of statistical power in 
either the initial or subsequent follow-up studies. [232-234]. However as sample 
sizes increased more promising results (and smaller p-values) emerged.  
Many of the most recent studies are the product of large collaborative efforts 
between multiple research groups, for example the Genetic and Environmental risk 
in Alzheimer’s disease 1 consortium (GERAD1) and the European Alzheimer’s 
Disease Initiative stage 1 (EADI1) consortium which published LOAD GWAS data 
in 2009. 
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GWAS Authors Reference Design Population(s) No SNPs 
No AD GWAS 
(Follow-up) 
No CON GWAS 
(Follow-up) 
Highlighted genes * 
Grupe et al 2007  [235] 
Case-
control 
USA & UK  17,343  380 (1428)  396 (1666) APOE 
Coon et al 2007, 






 502,627  446 (415)  290 (260) APOE, GAB2 
Li et al 2008 [237] 
Case-
control 
Canada & UK  469,438  753 (418)  736 (249) APOE 
Abraham et al 2008 [238] 
Case-
control 
UK  561,494  1082 (n.a)  1239(1400) APOE 
Bertram et al 2008 [239] 
Family 
based 
USA  484,522  941 (1797)  404 (838) 
APOE, ATXN1, CD33, 
GWA_14q31 
Beecham et al 2009 [240] 
Case-
control 
USA (d)  532,000  492 (238)  498 (220) APOE, FAM113B 





USA (b)  313,504  844 (1547)  1255 (1209) APOE, PCDH11X 





Europe (c)  ~540,000  2032 (3978)  5328 (3297) APOE, CLU, CR1 





USA & Europe 
(b,c) 
 ~610,000  3941 (2023)  7848 (2340) APOE, CLU, PICALM 
Seshadri et al 2010 [228] 
Case-
control 




 3006 (6505)  22,604 (13,532) 
APOE, BIN1, CLU, 
EXOC3L2, PICALM 
Naj et al 2010 [244] 
Case-
control 
USA & Europe 
(a, d) 
 483,399  931 (1338)  1104 (2003) APOE, MTHFD1L 





 658,610  549 (n.a)  544 (n.a) - 
Table 1.4. LOAD GWAS studies.Table modified from  Bertram et al [246]. Summary of published GWAS studies (with an n>100) 
where the phenotype tested is clinical or pathological diagnosis of LOAD. *Genes highlighted by the indicated study to have achieved 
study-wide/genome-wide significant association: the criteria used to define ‘genome-wide’ significance within a study is not standardized 
and may vary between studies. Overlap in subjects used between studies is indicated under the populations field (a,b,c or d). # Seshadri et 
al report imputed SNP data. 
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In 2009 the largest LOAD GWAS, at the time of publication, were presented. 
Carrasquillo et al identified genome-wide significant association for a SNP within 
the PCDH11X gene on ChrXq21.3 [241] in a two-stage study totalling 2391 LOAD 
cases and 2464 elderly controls (Table 1.4). This was the first LOAD GWAS to 
unequivocally identify genome-wide significant association, independent from 
APOE, in an un-stratified dataset according to the strictest correction for multiple 
tests (Bonferroni). The data obtained from this GWAS are used later in this thesis to 
perform convergent phenotype analysis (Chapter 3) and as part of a candidate gene 
study (Chapter 4).  
Later in 2009 Harold et al and Lambert et al [242, 243] independently published two 
large GWAS which combined data from several research labs (the Harold et al study 
includes the data from the Carrasquillo et al GWAS). The two studies identified 
genome-wide significant association at the APOE locus and an additional three loci, 
remarkably one of which was common to both reports. Two SNPs were identified by 
Harold et al: rs11136000 on chromosome 8p21-p12 within an intron of the CLU 
gene (OR = 0.86, p = 8.5E-10) and rs3851179 on chromosome 11q14 ~90kb 5’ of 
PICALM (OR = 0.86, p = 1.3E-09). In the Lambert et al study rs11136000 within 
CLU also significantly associated with LOAD (OR 0.86, p = 7.5E-09) and the 
authors identified association for a second SNP rs6656401 (OR = 1.21, p = 3.7E-09) 
within an intron of the CR1 gene on chromosome 1q32. Over the past year several 
reports of replication of the association observed at these three loci provide evidence 
in support of the SNPs proximal to CLU, PICALM and CR1 in LOAD pathogenicity 
[228, 245, 247-250]. 
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In 2010 three LOAD GWAS have been reported thus far [228, 244, 245]. Seshadri 
et al present data from several combined LOAD GWAS (both novel and previously 
published GWAS) where SNP imputation allowed for the combination of data 
obtained from multiple genotyping platforms and created the largest LOAD GWAS 
to date. The previously reported association at the CLU and PICALM loci were 
confirmed and an additional two novel loci were identified that achieved genome-
wide significant association with LOAD. rs744373 on chromosome 2q14, ~30kb 3’ 
of BIN1  (OR = 1.13, p = 1.59E-11) and rs597668 on chromosome 19q13.32 ~7kb 
5’ of EXOC3L2 (OR = 1.18, p = 6.45E-09). This locus is ~300kb distal of APOE, 
the authors indicate that the association reported for rs597668 is independent of 
APOE.  
The Seshadri et al study overlaps with another LOAD GWAS, also published in 
2010, reported by Naj et al [244]. In this study genome-wide significant association 
was identified for a novel LOAD locus, rs11754661 within the MTHFD11 gene on 
chromosome 6q25.1 (OR = 2.03 , p = 4.7E-08). The authors reported significant 
replication of this finding in an independent case-control series, however this finding 
is so novel that additional replication has not yet been reported. 
In summary, to date, more than 10 GWAS have identified several SNPs with strong 
association with LOAD. Multiple studies have reported loci which achieved study-
wide significance, of which seven (CLU, CR1, PICALM, BIN1, EXOC3L2, 
PCDH11X and MTHFD11) maintain significance after conservative bonferonni 
correction for multiple tests.  
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The first five genes listed in the previous paragraph are also ranked from positions 
2-6 in the AlzGene ‘tophits’ list (at the time of writing). As mentioned previously 
APOE has consistently occupied position 1 on this list which ranks genes on the 
basis of nominally significant meta analysis p-values [31]. The remaining genes or 
loci that make up the ‘top ten’ AlzGene genes are SORL1 [251], a locus on 
Chr14q32.13 [235], TNK1 [235]and IL8 [252]. These genes were initially identified 
as LOAD susceptibility genes through GWAS or candidate gene studies and they 
represent additional LOAD loci which have strong evidence for a role in disease 
aetiology.   
The associations reported here are of modest effect size (OR ~ 0.8 – 1.3) with the 
exception of the most recent GWAS locus (MTHFD11) identified with an OR ~2. 
Although these effect sizes are small they may still, in principal, be useful for 
identifying therapeutic targets and the at risk population. Of particular relevance is 
the emergence of genes involved in common pathways, for example CLU (clusterin) 
also known as APOJ (apolipoprotein J) is, like ApoE, a cholesterol transport protein 
and is the second most abundant of the cholesterol chaperones in the CNS. Several 
other genes involved in cholesterol metabolism have been implicated in LOAD 
[230]. The implications of variation in these genes on LOAD pathogenicity is 
discussed in more detail in each of the respective publications and summarized in 
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1.12 Approaches for studying complex genetic diseases. 
Over the past decade advances have been made in technological and methodical 
approaches for interrogating the human genome for markers of human disease. In 
2003 the International Hapmap project was launched in which the aim was to map 
common variation in the human genome which can be used as a tool by researchers 
to identify genes involved in human disease [253]. For example the data collected by 
the Hapmap project was used to identify SNPs that tag common haplotypes in 
certain populations. This data facilitated the development of panels of 300,000 to 
500,000 SNPs  that constitute the main component of genome-wide genotyping 
platforms used for GWAS. More recently an initiative to identify less common 
variation (as low as 0.1%) in the human genome was launched called the 1,000 
Genomes Project. This project involves sequencing the genomes of over 2000 
subjects from many ethnic backgrounds in an effort to identify all genetic variation 
in the human genome with a frequency of 1% or greater and to catalogue identified 
rare variants (frequency as low as 0.1%). Currently the project has sampled 500 
people from each of five ancestral backgrounds (European, West African, East 
Asian, America’s and South Asian) [254]. This is the first large scale study to 
explore new sequencing technology referred to as ‘next-generation sequencing’. The 
ability to sequence the entire genome or exome of study subjects is a powerful new 
method, considered to be the next phase in the exploration of the human genome 
consistent with the overall aim of identifying variation that influences human 
phenotypes and disease. This novel approach has only recently become 
economically feasible and it is still costly for sequencing large numbers of subjects. 
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It is anticipated that over the next 2-3 years as the cost of this sequencing technology 
decreases there will be a vast amount of data available for the exploration of the 
genetic causes of human disease. Given the novelty of this technology the approach 
was not explored in this thesis but will be useful for future studies.  
With respect to AD and other complex diseases such as diabetes, it has become 
apparent that large numbers of cases and controls are necessary for identifying 
association to common variants in novel disease loci using a case-control approach. 
Since large case-control series (many thousands of subjects) are not readily available 
to most researchers, other approaches have been developed to improve the success 
rate, such as studies aiming to identify quantitative trait loci (QTL) or disease 
susceptibility loci. These include the use of endophenotypes, isolated populations 
and phenotypic convergence analysis, all of which are explored in this thesis. 
 
1.12.1 Use of endophenotypes and convergence approaches. 
The molecular mechanisms that lead to a disease outcome in complex genetic 
diseases such as AD, schizophrenia and type 2 diabetes mellitus are, by nature, 
complex and sometimes difficult to explore using a categorical disease outcome 
phenotype. To this end, the use of intermediate disease related phenotypes or 
‘endophenotypes’ can be useful for identifying susceptibility genes. This approach is 
based on the hypothesis that phenotypes or traits that represent certain aspects of a 
disease have a simpler genetic aetiology than the full disease trait. This approach has 
been used to improve our understanding of genetic factors that influence complex 
genetic disorders such as type-2-diabetes [255] and schizophrenia [256, 257]. 
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Likewise several relevant endophenotypes for exploring the genetics of AD have 
also been reported. These include plasma concentrations of A discussed previously 
and CSF levels of tau and A as well as neuroimaging measures, cognitive traits and 
gene expression levels measured from brain tissue samples.  
In this thesis plasma A levels (concentration) are measured and explored as an AD 
endophenotype in genome-wide linkage and association studies in an effort to 
identify novel LOAD candidate genes. Furthermore this data is combined with that 
obtained from parallel studies of gene expression levels and AD disease phenotype 
in a phenotype convergence analysis described in chapter 3. 
 
1.12.2 Utility of isolated populations. 
Complex genetic diseases such as AD are heterogeneous and likely to be influenced 
by multiple genes with small effect sizes, which can make the identification of 
disease susceptibility loci challenging. One approach to reduce genetic and 
environmental heterogeneity in a study is to use isolated populations.  
Population isolates are defined as populations arising from a small number of people 
(founders) that have experienced little admixture for many hundreds, or in some 
cases thousands, of years. In these populations genetic drift has resulted in reduced 
allelic heterogeneity and extended linkage disequilibrium (LD), making them an 
attractive resource for gene mapping of complex diseases and traits [258]. In 
population isolates it is likely that there are fewer genetic factors that influence 
quantitative traits or diseases. The effect size of these loci may be larger than in 
outbred populations and therefore more easily identified and mapped. Based on this 
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hypothesis several research studies have been conducted on isolated populations 
throughout the world to identify susceptibility genes for complex disease and traits. 
This approach proved successful for rare recessive disorders [259], Mendelian 
disorders and more recently for more common complex traits such as type-II-
diabetes, schizophrenia and other diseases and disorders [260-263] 
In this thesis isolated populations sampled from two Croatian islands (Vis and 
Korcula) are used to identify genetic loci that influence plasma A levels in an effort 
to identify novel candidate LOAD loci. These populations have been well 
characterized and exhibit many features associated with population isolates [264-
268]. However these populations also exhibit enough similarity to outbred 
populations of European origin, for example in sharing of common variants 
influencing traits, for QTL to be identified in these studies that are also relevant in 
larger outbred populations [269]. Over 300 anthropometric and biochemical traits 
have been measured  in the study samples, which have also been genotyped for over 
300,000 SNPs, making genome-wide association analysis possible for each of the 
measured traits [270, 271]. The evaluation of serum uric acid concentrations in these 
populations led to the identification a novel locus, SLC2A9, which was shown to be  
a novel urate transporter, influencing genetic susceptibility to gout as well as 
variation in this quantitative trait. This finding was confirmed in additional 
populations illustrating the utility of the approach for identifying relevant and novel 
QTL [272, 273]. 
Whilst the populations sampled from Vis and Korcula, represent excellent study 
populations for mapping QTL, they were not ascertained on the basis of a priori 
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knowledge of cognitive traits, AD diagnosis or levels of segregating plasma A 
levels.   
 
1.13 Mitochondrial role in AD 
Several studies have outlined how mitochondrial dysfunction can impact neuronal 
cell function and how this may influence risk of neurodegenerative diseases such as 
AD.  
 
1.13.1 Mitochondrial theory of aging 
The primary role of mitochondria within the cell is the production of ATP  through 
the transfer of electrons from donors, such as NADH, to a series of electron 
acceptors, such as oxygen, in which electron transfer is coupled to hydrogen ion 
transport across a membrane to create a gradient that drives ATP formation 
(oxidative phosphorylation, OXPHOS) (Figure 1.8). In addition to OXPHOS, the 
mitochondrial compartment is the major site for Krebs cycle reactions, β-oxidation 
of fatty acids, calcium homeostasis, lactate metabolism and the biosynthesis of iron-
sulphur proteins, nucleotides and certain amino acids and phospholipids   
Mitochondria are also a  key component of an apoptotic signalling cascade in which, 
following opening of the permeability transition pore (mPTP), a specific pore in the 
outer mitochondrial membrane, pro-apoptotic signalling proteins  (e.g. cytochrome 
C) are released into the cytoplasm, triggering a cascade of reactions including 
caspase activation, degradation of DNA and ultimately apoptotic cell death. 
Apoptosis can be triggered by a number of factors, among which is damage to 
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proteins, membranes and DNA through interaction with free radicals (reactive 
oxygen species). The main source of reactive oxygen species (ROS) within a cell is 
electron leakage from the electron transport chain (Fig 1.8) [274].  
One way in which the mitochondrial genome could act as a redox sensor is through 
ROS-mediated damage to mitochondrial DNA (mtDNA). The mitochondrial theory 
of aging postulates that mtDNA accumulates mutations with time and that this in 
turn increases mitochondrial ROS production, increasing age-related cellular 
dysfunction and eventually triggering apoptosis [275, 276]. 
 
Figure 1.7 Simple interpretation of 
the mitochondrial theory of aging. 
This represents how the mitochondrial 
genome could act as a redox sensor. A 
feedback loop maintains a vicious 
cycle, resulting in cellular dysfunction 
and eventually triggering apoptosis. 
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1.13.2 The mitochondrial genome 
Each cell contains multiple (103-105) mitochondria and each mitochondrion contains 
several (5-10) copies of the mitochondrial genome. The mitochondrial genome is 
particularly vulnerable to ROS induced DNA damage due to its close proximity to 
the main cellular source of ROS (the electron transport chain), lack of protection by 
associated proteins such as histones, lack of DNA repair pathways (e.g. nucleotide 
excision repair) and the ratio of coding to non-coding DNA [278]. Estimates place 
the mutation rate of mtDNA in the brain up to 10 times as high as for nDNA [279] 
The mitochondrial genome is a closed circular double stranded DNA molecule of 
approx 16kb in size. It contains 37 genes which encode 13 proteins essential for the 
electron transport chain, 2 ribosomal RNA’s and 22 tRNA genes. The mitochondrial 
genome has very little non-coding sequence with the only notable region being the 
D-loop locus which contains the heavy (H) strand origin of replication and both H 
and light (L) strand transcriptional promoters. This region is also often referred to as 
the ‘hypervariable’ region due to the fact that it is highly polymorphic when 
compared with the reference coding sequence of the mitochondrial genome [280].  
There is only one known DNA polymerase that is present in mitochondria, known as 
polymerase gamma (Pol-). This polymerase is responsible for mtDNA replication, 
proof-reading and DNA repair functions. It is encoded by a nuclear polymerase 
gamma (POLG) gene located on chr15q25 and following transcription and 
translation in the cytoplasm, it is transported into the mitochondria. Mouse mutants 
with polymerase gamma (Polg) lacking 3’-5’ exonuclease activity (proof reading 
deficient)  show a two orders of magnitude increase in single nucleotide sequence 
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variants compared with control mice and exhibit premature aging phenotypes [281, 
282] 
In humans and a wide range of other species, the mitochondrial DNA of many post-
mitotic tissues accumulates DNA mutations over the course of a lifetime [278]. 
Increasing the frequency of acquired mtDNA mutations is associated with increased 
evidence of aging and cell death (as in the Polg “mutator” mouse) [282, 283], while 
decreasing their frequency reduces the signs of aging and cell death [284]. In post-
mitotic cells such as neurons, this process may have a  significant impact on cell 
function and survival.  
 
1.13.3 mtDNA damage and mutations  in AD  
Several lines of evidence indicate a role for mitochondrial dysfunction in 
Alzheimer’s disease (for a comprehensive review see de Moura et al [285]). Of 
particular interest is the possibility that mitochondrial mutations can either cause or 
influence risk for AD and other neurodegenerative diseases. This might occur 
through inherited common mutations, acquired somatic mutations that have reached 
a high frequency over time through replication, or by a cumulative burden of 
somatic mutations with individual low frequencies that collectively result in 
impaired mitochondrial function (mitochondrial burden) [286].  
Previously studies have implicated common mitochondrial mutations and 
mitochondrial haplogroups in age related neurodegenerative diseases such as AD 
and PD [287-291]. Additionally some studies report association of mtDNA deletions 
with Parkinson’s disease [288] and others have investigated a common 4997bp 
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deletion (known as the Kearns-Sayre syndrome deletion) with respect to these 
diseases [292-294]. More recently studies have focused on the investigation of 
mitochondrial mutational burden as a possible risk factor for development of 
neurodegenerative diseases [287, 295, 296]. However replication of these reported 
associations has been inconsistent  [297, 298] and the role of mtDNA mutations in 
Alzheimer’s disease remains controversial. 
Another line of inquiry into the possible role of oxidative DNA damage and risk for 
diseases such as AD is the evaluation of mtDNA damage lesions. Several studies 
have identified increased markers for mtDNA damage in the brains of AD subjects 
when compared with age matched controls, [279, 290]. However it is currently 
unclear as to whether this is a feature common to many neurodegenerative diseases 
or a possible disease process specific to AD. 
In this thesis various methods of measuring mitochondrial DNA lesions are explored 
and investigated for association with neurodegenerative diseases. 
 
1.13.4 Complex IV and AD 
In order to produce ATP, the mitochondria transports electrons through a system of 
transmembrane protein complexes creating a proton gradient across the inner-
mitochondrial membrane which drives the production of ATP (Fig 1.8).  All of these 
protein complexes, except for complex II, rely on subunits encoded by both the 
nuclear and mitochondrial genome. Complex II relies entirely on nuclear encoded 
proteins.  
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Several studies have reported deficiencies in energy metabolism associated with AD 
and other neurodegenerative diseases [299-301]. One of the most frequently 
associated changes in energy metabolism associated with AD is that of complex IV 
(cytochromc c oxidase) deficiency [302, 303]. Furthermore, evidence of from cybrid 
studies indicates that altered mitochondrial metabolism is associated with A 
toxicity  [304] indicating a link between mitochondrial dysfunction and AD 
pathogenicity. Additionally, evidence from some studies indicates that APP may be 
partly responsible for the observed complex IV deficiencies in AD [305]. The 
association between APP, A and mitochondrial dysfunction in AD is reviewed 
briefly below. 
 
 1.13.5 APP, A and mitochondria 
As shown in Figure 1.3, data from some studies suggests that APP can be targeted to 
the mitochondrial membranes where it is incompletely translocated across the 
mitochondrial membranes due to a transmembrane arrest sequence. This can result 
in the blocking of the TOM channel (translocase of the outer membrane of 
mitochondria) and thus inhibit the translocation of other proteins and molecules into 
the mitochondria [139, 305] which can disrupt mitochondrial function. Furthermore 
data from mouse studies implicates accumulation of APP at the mitochondrial 
membrane that can result in impaired energy metabolism (the central role of the 
mitochondria) and consequently  mitochondrial dysfunction [139].  
In addition to APP, the A peptide can also be localized to the mitochondria as first 
indicated by Lustbader et al [306]. A found within the mitochondria and can 
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interact with a number of mitochondrial proteins causing downstream mitochondrial 
dysfunction [306]. This indicates an additional mechanism by which A can exert 
toxicity. For example, A can bind to The A-binding alcohol dehydrogenase 
(ABAD) which results in up regulation of cytochrome c release and consequently 
increase apoptosis signalling [306]. More recently cyclophin D (CypD) was also 
found to interact with A within the mitochondria. CypD is located within the 
mitochondrial matrix but can be transported to the inner mitochondria membrane 
where it is thought to participate in the formation of the mitochondrial permeability 
transition pore(mPTP). As mentioned previously  (1.13.1) the formation of the 
mPTP allows the release of pro-apoptotic signalling proteins. The combined 
interaction of A with ABAD and CypD therefore increases pro-apoptotic signalling 
and may represent a relatively novel molecular mechanism by which A exerts 
neuronal toxicity.  
The evidence presented on the previous pages clearly indicate a role for 
mitochondrial dysfunction in AD although the mechanisms by which this can occur 
appear to be multiple and likely heterogeneous. Furthermore it is probable that 
cellular A concentrations and mitochondrial dysfunction are connected possibly in 
a vicious feedback loop whereby increased A causes increased mitochondrial 
dysfunction which in turn may increase A production [285, 304].  
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Fig 1.8 The mitochondrial electron transport chain:  The mitochondrial electron transport chain facilitates the production of ATP by 
transport of electrons through a system of protein complexes (I-IV) to generate a proton gradient that ‘powers’ the ATP synthase (V). 
Here, the solid black arrows illustrate the flow of hydrogen ions trough the protein complexes, whilst the black dashed lines represent the 
normal flow of electrons through the transport chain ending in the production of H2O. The red dashed lines illustrate electron leakage at 
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These studies emphasise the importance of the exploration of multiple aspects of the 
disease in order to elucidate the molecular mechanisms involved in AD. 
 
1.14 Environmental influences on risk for LOAD 
In addition to a genetic component for risk for LOAD, there is also a substantial 
influence of environmental effects on disease risk and/or age at onset of the disease. 
In fact age is the major risk factor for this disease where its influence on risk for the 
disease is greater than any one genetic risk factor, including APOE.  
It has been estimated that the risk for developing AD in the general population can 
almost double every five years after the age of 65 and up 50% of people over the age 
of 85 may have AD although these estimates may be slightly inflated [307].  
In addition to age, a number of other environmental factors have been reported to 
modify risk for the disease; some of these include diet [308, 309], head injury [310], 
gender [307] and years of education [307]. It is believed that a complex interaction 
between environmental and genetic risk factors for the disease exists which modifies 
risk and age of onset for the disease [311].  
Similar to the AlzGene database, the Alzheimer research forum (Alzforum) supports 
an AlzRisk database which  
 “aims to provide a comprehensive, unbiased, centralized, publically available 
and regularly updated collection of epidemiological reports that evaluate 
environmental (ie non-genetic) risk factors for Alzheimer disease (AD) in 
well defined study cohorts” (www.alzrisk.org, Dec 2010) [312]. 
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At the time of writing, the AlzRisk database highlights studies evaluating the 
influence of Diabetes Mellitus, Inflammatory biomarkers, Physical activity and 
Vitamin E on risk for developing AD.  
It is still unclear how much of an influence non-genetic factors have on risk for AD 
but the general consensus is that a healthy lifestyle can likely reduce the risk for 
many diseases associated with old age including AD. 
 
1.15 Outline of the Project 
The aims of the projects in this thesis are to identify novel genetic risk factors for 
LOAD and to develop novel approaches for investigating the genetic risk for 
LOAD. The studies presented here are not limited to the evaluation of nuclear 
genetic risk factors and include the investigation of the mitochondrial genome for 
markers associated with disease.  
Based upon the evidence from previous LOAD GWAS it has become apparent that 
large numbers of cases and controls are needed to identify novel LOAD genes with 
moderate effect size. In this thesis several alternative approaches are combined and 
explored in order to identify novel LOAD loci without the need for infinitely large 
sample size.  An AD related endophenotype, plasma A, was used to identify novel 
loci that influence this trait in isolated populations for which genome wide 
microsatellite (linkage) and/or SNP GWAS data was available. It is hypothesised 
that loci that influence plasma levels of A may be excellent LOAD candidate loci 
because A is a key peptide in AD pathogenesis. The utility of plasma A as a 
LOAD endophenotype in genetic studies has been demonstrated previously. 
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Additionally isolated populations are thought to be a useful tool for studying 
complex genetic diseases where genetic heterogeneity in outbred populations can 
result in reduced power for detecting loci that influence complex traits or diseases.  
The results of the study described above generate a database of p-values that can be 
interrogated in phenotype convergence analysis. It is well established that LOAD is 
likely influenced by multiple genes with individual moderate effects that are 
difficult to detect. However evidence for association of a locus with multiple disease 
related traits can strengthen the plausibility for a role in the targeted disease. This 
approach was explored for a well known LOAD candidate gene IDE, using the data 
from a LOAD GWAS, the plasma A GWAS described in this thesis and measured 
expression levels of IDE in the brain. In the future this approach can be applied to 
additional candidate genes. 
Finally, much of the focus of genetic studies of LOAD is concentrated on 
identifying variation in nuclear chromosomes that influences risk for disease. 
However the variation at the mitochondrial genome is emerging as an important 
factor that can influence neurodegenerative diseases. The study of mitochondrial 
genetics is complicated by the fact that isolation methods must be carefully 
considered to avoid inadvertent in vitro DNA damage. Likewise the presence of 
nuclear mitochondrial pseudogenes can make PCR based methods tedious and can 
introduce confounding into study data. Various approaches that have been 
developed for isolating and studying mitochondrial DNA are evaluated and modified 
in this thesis in order to explore two aspects of mitochondrial genetics that may 
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influence disease (mitochondrial DNA damage and mitochondrial mutational 
burden).   
As outlined in figure 1.9 AD is a complex disease that involves the interaction of 
multiple cellular pathways many of which have been shown to modify risk for 
disease. Identification of novel risk factors and evaluation of known risk factors is 
important to improve the understanding of the disease in order to develop 
therapeutic interventions.   
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 Fig 1.9 Alzheimer’s Disease 
KEGG pathway figure. Figure 
adapted from KEGG website 
[313-315]. Areas of Alzheimer’s 
disease pathophysiology studied 
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Chapter 2. 
2.1 Background 
This chapter describes a study that makes use of isolated populations for both 
performing a genome-wide linkage study and SNP based GWAS of an established 
LOAD endophenotype, plasma A levels. The study design combines three 
established approaches to the study of complex genetic diseases: (i) the use of 
isolated populations (see Section 1.12.2.); (ii) the use of a disease endophenotype (or 
intermediate phenotype (see Section 1.12.1); and (iii) the use of genome-wide 
linkage and association studies, similar to those discussed in Section 1.11.2. 
The aim of this chapter is to identify quantitative trait loci influencing plasma A 
concentrations that provide mechanistic insights into the regulation of plasma A, 
candidate loci for association studies in LOAD and new therapeutic targets for 
future pharmaceutical development.  
The populations in this study are sampled from the islands of Vis and Korcula, 
which are part of a collection of islands off the coast of Croatia in the Adriatic Sea, 
collectively known as the Dalmatian islands (Figure 2.1). Researchers at the 
University of Split, University of Zagreb, Institute for Anthropological Research in 
Zagreb, MRC Human Genetics Unit and University of Edinburgh have been 
studying the populations from the Dalmatian islands for some time and have found 
these populations to exhibit clear evidence of being isolated, both from one another 
and from large, outbred populations [265, 316, 317]. This collaborative effort has 
been referred to as the “10,001 Dalmatians study” [266] which involves the 
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collection of blood and data from subjects on the islands of Dalmatia. The collection 
and study of individuals from the islands of Vis and Korcula is part of this larger 
study. The subjects participating in the Vis and Korcula studies provided blood 
samples for biochemical measurements, provided answers to interview questions 
regarding, for example, smoking and dietary habits, and also allowed measurement 
of anthropometric traits, such as height and weight. Altogether data for over 300 
traits was gathered from the study subjects and blood and plasma was aliquoted for 
additional studies such as this one. The subjects from the island of Vis were initially 
genotyped for 810 microsatellite markers to facilitate genome-wide linkage analysis 
for the traits of interest. The subjects from both Vis and Korcula were then also 
genotyped for over 300,000 SNPs to facilitate genome-wide association studies 
(GWAS), with a much increased marker density, for association with the traits that 





Figure 2.1. A. The location of the Dalmatian islands in the Adriatic sea. B. 
The islands of Vis and Korcula are highlighted in the collection of Dalmatian 
Islands off the coast of Croatia 
1 
(1) Island of Vis  
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To measure plasma A concentrations, we used a well established sandwich 
enzyme-linked immunosorbent assay (ELISA) to specifically measure A40 and 
A42 [94]. The capture/detection antibody pairs used in the ELISA systems varied 
slightly from those used by Suzuki et al [94] and were different in the two studies. 
Details regarding the antibody pairs employed in each study can be found in section 
2.2.5 and are illustrated in Figure 2.2. In both the Vis and Korcula samples the 
BNT77/BC05 capture/detection antibodies were used to detect A42. The BNT77 
capture antibody is always employed by the Younkin laboratory to assay plasma 
A42. This is because the BAN50 capture antibody, when paired with the BCO5 
detection antibody, suffers from non-specific cross-linking by proteins present in 
some plasma samples, which produces a non-specific signal referred to as 
interference. Although it is less problematic, interference can also occur using the 
BAN50/BA27 pair which was used to measure plasma A40 in Vis [Linda Younkin, 
unpublished data]. For this reason the BNT77 capture antibody paired with the 
BA27 detection antibody was used to measure plasma A40 in Korcula samples. 
Additional work conducted by Linda Younkin [data unpublished] indicates that the 
highest extreme values in most plasma A studies, despite the use of antibody pairs 
that minimise this phenomenon, are frequently the result of interference. This 
appears to be unique to a small subset of subjects and does not represent genuinely 
high A values. For this reason, criteria were devised (See Section 2.2.6) for 
defining the extreme values for A40 and A42 in both the Vis and Korcula 
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populations and subsequently a small number of subjects were removed from each 







Figure 2.2 Measurement of plasma Aß A: Antibody pairs for measuring plasma 
A40 and 42 in subjects from the Vis study. B: Antibody pairs for measuring 
plasma A40 and 42 in subjects from the Korcula study C. Interference: i) 
Specific binding is shown where the variable chains specifically bind to the target 
peptide via the Fab region. ii) Non-specific binding is illustrated where cross-
linking substances present in plasma bind to regions of the antibody not usually 
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2.2 Methods 
2.2.1. Study Samples 
Both population studies (Vis and Korcula) received ethical approval from Croatian 
and Scottish ethics boards and all participants gave informed consent. Subjects were 
unselected volunteers, aged 18 years and over, who were invited to participate in the 
studies through various media outlets including mail, posters and radio 
advertisement. For the Vis study, subjects were recruited from two towns on the 
island; Vis and Komiza [272]. Subjects participating in the Korcula study were 
recruited from the town of Korcula and additional villages on the eastern side of the 
island [270]. Subject recruitment was carried out from the year 2002 onwards by 
employees of the School of Public Health at the University of Zagreb Medical 
School, the Institute for Anthropological Research in Zagreb, Croatia, Croatian 
Centre for Global Health, Faculty of Medicine, University of Split, Croatia, the 
MRC Human Genetics Unit, Edinburgh, UK, and the Centre for Population Health 
Sciences, University of Edinburgh, UK. 
 
2.2.2. Sample Collection 
Fasting blood samples were collected between 8am and 9am from the Vis subjects 
and between 8.30am and 9.30am from the Korcula subjects. Serum and plasma were 
separated, aliquoted and stored at -80oC until thawed for analysis or DNA isolation. 
The Vis plasma samples were stored as EDTA-anticoagulated aliquots and thawed 
only once prior to plasma A measurement. The Korcula plasma samples were 
stored as 2ml EDTA aliquots and thawed once prior to the initial plasma A 
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measurement. Repeat measurements of plasma A, when necessary, were subjected 
to an additional thaw cycle in the Korcula subjects.  
In addition to providing fasting blood samples; subjects also completed 
questionnaire interviews and underwent physical examinations in order to collect 
data on health, lifestyle, psychological and anthropometric measures such as BMI 
and height. Sample and anthropometric data collection were carried out from 2003 
onwards by qualified individuals employed by the School of Public Health of the 
University of Zagreb Medical School, the Institute for Anthropological Research in 
Zagreb, Croatia and the MRC Human Genetics Unit, Edinburgh. I was not involved 
in the sample collection. 
 
2.2.3. Plasma sample transfer 
Plasma samples collected from Vis and Korcula study subjects were transferred to 
the MRC Human Genetics Unit in Edinburgh, where they are stored at -80oC. A 
Material Transfer Agreement (MTA) was set-up to facilitate transfer of aliquots of 
plasma from the MRC Unit in Edinburgh to the Mayo Clinic in Jacksonville, 
Florida, where measurement of plasma Alevels was carried out. Plasma samples 
for the Vis study subjects (3x500µl aliquots per sample) were transferred in April 
2006, Korcula plasma samples (1x 2ml aliquot) were transferred in September 2008. 
Samples were shipped on dry ice via Federal Express and the samples all arrived 
intact and still frozen. Samples were immediately placed in a freezer at -80oC, where 
they were stored until thawing for measurement. 
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2.2.4. Genotyping 
DNA isolation: DNA was isolated, by others, from blood samples collected from 
study participants using Nucleon DNA Purification kits (Tepnel). DNA was stored 
at -20oC at the MRC Human Genetics Unit in Edinburgh.  
Microsatellite markers: The Vis study samples were genotyped using an ABI Prism 
Linkage Mapping set for 810 microsatellite markers that define a ~5 centiMorgan 
(cM) resolution map (HD-5). The genotyping panel(s) and reagents were purchased 
from Applied Biosystems and the genotyping was carried out, by others, using an 
ABI Prism 3100 at the MRC Human Genetics Unit. Following implementation of 
quality control of the genotyped markers (by others), 746 markers were included in 
the analysis. 
SNP genotyping: In the Vis study 991 samples were genotyped for over 317,000 
SNPs using the HumanHap300-Duo Genotyping BeadChip (Illumina), of these 
plasma was available for 965 samples. In the Korcula study 953 samples were 
genotyped for over 370,000 markers using the HumanCNV370-Duo DNA Analysis 
Bead Chip (Illumina), although plasma was only available for 941. Genotyping of 
Vis and Korcula samples on Illumina platforms was carried out by the Wellcome 
Trust Clinical Research Facility at the Western General Hospital. Genotypes were 
scored, by others, using the BeadStudio Software v.3 (Illumina). Additional SNPs of 
interest were genotyped, by others, using Applied Biosystems Taqman assays 
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2.2.5. Plasma A measurements 
Plasma A measurements were made using a sandwich ELISA system that has been 
described previously [94]. Prior to assaying the plasma, ELISA plates, buffers, 
antibodies and synthetic and biological standards were prepared as described below. 
Antibodies: All antibodies were provided by Takeda Pharmaceutical Company Ltd. 
Two capture antibodies (BAN50 and BNT77) and two detection antibodies (BA27 
and BC05) were used over the course of these experiments, details of which can be 
found in Table 2.1.  
Name Type Source Isotype Purpose Recognize 
BAN50 Mouse monoclonal Takeda IgG1k Capture A 1-16 
BNT77 Mouse monoclonal Takeda IgAk Capture A 11-28 
BA27 Mouse monoclonal Takeda IgG2ak Detection A 40-COOH 
BC05 Mouse monoclonal Takeda IgG1k Detection A 42 
 
Table 2.1. Antibodies used in the measurement of plasma A levels in the 
populations samples from Vis and Korcula.  
 
The detection antibodies (BA27, BC05) were HRP-conjugated using a kit from 
Pierce (Cat#31489), making use of D-Tube Dialyzers from Novagen (Cat# 71507-
3). For both preparations, the conjugate was dialyzed overnight in 1xPBS at 4oC. All 
detection antibodies were stored at 4oC and used within one month, following HRP 
conjugation. The capture antibodies were diluted in Sodium Carbonate Coating 
buffer (0.1M NaHCO3, 0.1M Na2CO3, pH 9.6) at a concentration of 5ug/ml. ELISA 
plates were provided by Thermo (Immulon 4 HBX 96 well, flat bottom microtiter 
plates with extra high binding, Cat# 3855).  100µl of the diluted capture antibody 
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was immobilized on the centre wells of the plate (60 wells). The plate was then 
covered with an adhesive plate seal and incubated overnight at 4oC. The following 
day, the capture antibody was carefully removed from each of the wells and each 
well was washed twice with 1X PBS using a plate washer (Nunc-ImmunoTM Wash 
8). 300µl of Block Ace solution was then added to each of the centre wells, the plate 
was covered with an adhesive seal and stored at 4oC. All plates were used within 1 
month.  
Capture Antibody HRP-detection antibody
 
Assay BAN50 BNT77 BA27 BC05 
Species Detected
Vis 40 X - X - (1-40) 
Vis 42 - X - X (x-42) 
Korcula 40 - X X - (x-40) 
Korcula 42 - X - X (x-42) 
 
Table 2.2. Pairs of antibodies used in the sandwich ELISAs and the specific 
A species detected.  
 
To measure plasma A40, different pairs of antibodies were used for Vis and 
Korcula, as shown in Table 2.2. The reason for using different pairs of antibodies 
(interference) has been explained in section 2.1. The detection antibody BA27 
specifically detects A species ending at A40 whereas BC05 detects A species 
ending at A42. BAN50 recognizes an epitope near the amino terminus of  so 
the BAN50/BA27 sandwich used for Vis samples detects primarily 1-40. BNT77 
recognizes 11-28 so BNT77 captures  species that are amino-terminally 
truncated (e. g. 3-40 and 3-42) in addition to full length A species. For this 
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reason, the  detected by the BNT77/BA27 pair and the BNT77/BC05 pair is 
designated x-40 and x-42 respectively.   
Buffers: Several buffers are used during the sandwich ELISA protocol; these were 
all prepared prior to experimentation. 
 Coating Buffer: 0.1M NaHCO3, 0.1M Na2CO3  [pH9.6] 
 EC Buffer: 0.02M sodium phosphate buffer [pH 7.0], 2mM EDTA, 0.4M 
NaCl, 0.2% BSA, 0.05% CHAPS, 0.4% BlockAce (Serotec), 0.05% NaN3, 
pH 7.0. 
 Buffer C: 0.02M sodium phosphate buffer [pH 7.0], 2mM EDTA, 0.4M 
NaCl, 1% BSA, 0.002% thimerosal, pH 7.0. 
 10X PBS: KCl 2g, KH2PO4 2g, Na2HPO4 11.4g, NaCl 81.2g, pH7.4, dilute 
in 1L deionised water.  
 PBS + Tween: 0.5ml 0.05% Tween in 1000ml 1X PBS. 
 Block Ace: 1% Blockace (4 g = 1 packet)  in 400 ml  1X PBS, 0.05% Na 
azide, pH 7.4 
 
Plate design: The established plate design for measuring plasma  levels involves 
the use of only the middle 60 wells on the plate for measurement as a fluctuation in 
readings had previously been observed in the outer wells, probably due to spurious 
evaporation. All experimental samples and standards are measured in duplicate. This 
allows for 20 experimental samples, a standard curve generated from 5 known 
concentrations of synthetic standards and a negative standard as well as four 
internal plasma standards to be measured on each plate. Each assay (A40 or A42) 
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is measured on one plate and so two ELISA plates are required to measure both 
peptides for every 20 experimental samples. 
Synthetic standards (standard curve):  Synthetic  peptide for use in the standard 
curve was prepared, by Linda Younkin, from stocks received from rPeptide 
(Recombinant), 1-42 Cat# A-1002-1, 1-40 Cat# A1001-1. The stocks were 
diluted into EC buffer according to the directions from rPeptide and stored as 300µl 
aliquots at a concentration of 5pmol/ml. For the Vis study a standard curve range of 
800 fmol/ml to 3.125 fmol/ml was implemented, using a serial dilution of 0.25 per 
standard (800, 200, 50, 12.5 and 3.125 and 0 fmol/ml). The 800 fmol/ml standard is 
at the top end of the dynamic range of the assay and very few samples fall between 
800 fmol/ and 200 fmol/ml, so in order to increase the specificity of the curve the 
800 fmol/ml standard for the Korcula study was eliminated and replaced with the 
following set of values for the standard curve for Korcula - 200, 50, 12.5, 3.125, 
0.6125 and 0 fmol/ml - where a 0.25 serial dilution was likewise adopted. In both 
studies, EC buffer was used as the diluent. 
Plasma Standards: To correct for plate to plate variation, four plasma samples 
prepared from four anonymous donors prior to each study were measured in 
duplicate on every plate. All experimental values on each plate were normalized to 
the mean value of the four standards on that plate. The aliquots of plasma used for a 
single study are all from a single blood draw but may differ in draw date. Three 
plasma standards were consistent between the Vis and Korcula studies and one 
subject differed between the two studies; this does not impact the interpretation of 
the results because there is no cross-study normalization.  
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Sandwich ELISA protocol: The prepared ELISA plates coated with the relevant 
capture antibody were washed twice with 1X PBS, using a plate washer (Nunc-
ImmunoTM Wash 8). Immediately following the wash step, 50µl of EC buffer was 
added to the centre 60 wells to prevent the wells from drying. 100µl of the relevant 
standard was added to each of the standard curve wells and the plasma was diluted 
1:3 directly into the wells on the plate (33µl plasma, 66µl EC). Following incubation 
overnight at 4oC, the wells were washed twice with 1X PBS and then 100µl of 
prepared HRP-conjugated detection antibody, diluted in buffer C, was added to each 
centre well, followed by a four hour incubation at room temperature. Developer 
solution, at room temperature, was prepared by mixing 1:1 TMB peroxidise 
substrate solution and peroxidase solution at room temperature. Following 
incubation with secondary antibody, the plates were washed twice with 1X PBS and 
then washed a third time with 1X PBS + 0.05% Tween. 100µl developing solution 
was added to all 96 wells on the plate and A40 plates were left to develop for 30 
minutes whilst A42 plates were allowed to develop for 45 mins. The developing 
reaction was terminated by the addition of 100µl 1M phosphoric acid (H3PO4), 
which raises the OD values approximately 3 fold. The plates were then read at 
450nm using the Molecular Devices Emax precision microplate reader. 
Plate reader: The plate design, standard curve concentrations and dilution of 
experimental samples were entered into the Softmax software package, which 
facilitates calculation of plasma Avalues (fmol/ml) for the experimental samples 
and internal plasma controls on each plate. The data was saved and exported from 
this software into text format. 
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Plate normalization: The mean value of the four plasma standards was calculated for 
each plate and the values for the experimental samples on each plate were 
normalized against the average of these mean values in the study. For example, if 
plate A has a mean value for the internal controls of 100 fmol/ml, and the mean for 
all the plates in the study was 120 fmol/ml, then the experimental values on plate A 
would be increased by 20% to fall in line with the overall study values. 
Quality control: Various quality control measures were put in place in order to 
prevent experimental variation or error from unduly influencing the results. As 
mentioned previously, four internal control plasma samples were included on each 
plate to facilitate normalization of each plate due to plate-to-plate variation. When a 
plate failed to successfully measure all four standards in duplicate, the whole plate 
was discarded and repeated. When more than one synthetic standard failed to have 
duplicate measures in the standard curve, the whole plate was again discarded and 
repeated. Finally, when the duplicate measurements of the experimental plasma 
samples had a coefficient of variation (CV) of greater than 0.2, these were also 
repeated. When repeats due to a high CV were necessary and more than 2 
measurements were recorded for an experimental sample, all measurements were 
used but in order to avoid the undue influence of extreme high or low values the 
median rather than the mean of all values was used. 
 
2.2.6. Plasma A analysis 
Descriptive analysis of raw values: The plasma values for A40 and A42 were 
used to create a total of 4 plasma A traits for further analysis, these are A40, 
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A42, the ratio of A42:A40 (from here on out referred to as “ratio”) and the sum 
of A40+A42 (from here on out referred to as “total”). The mean, median, 
standard deviation and distribution of values for each trait are described in the 
results (Table 2.3.). Due to interference, in which falsely extreme high values can 
occur, the highest extreme values for both A40 and A42 were removed.  The 
highest extreme values for plasma A40 and 42 were determined as those with an 
absolute value of greater than 3 times the standard deviation (SD) above the mean 
for all measured values in the population: The values for all four traits were rank 
transformed as the distributions did not fit a Gaussian curve. The rntransform 
function available in the R package GenABEL [318] was used to rank transform 
each of the traits.  
Correlation of plasma A traits: Using Microsoft Excel, Pearson’s test for 
correlation was used to test for the level of correlation between the plasma A40 and 
A42 traits in each of the two populations.  
 
2.2.7. Linkage analysis using SOLAR  
Pedigrees were established from family relationships reported during 
interviews/questionnaires with the subjects. Multipoint identity-by-descent (MIBD) 
estimates were generated by Dr. Veronique Vitart using Markov Chain Monte Carlo 
(MCMC) methods implemented in the program Loki [319, 320]. The files generated 
were used for subsequent polygenic and multipoint linkage analyses in SOLAR 
[321], of A40, A42, the A42/A40 ratio, and the A40+A42 sum. The 
covariates of age, sex, age*sex, age^2, age^2*sex, and APOE 4 alleles 
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(presence/absence) were investigated for association with each of the four plasma 
A traits, using the ‘polygenic –screen’ function in SOLAR. Those variables with a 
p-value of less than 0.1 were retained as covariates in the models analyzed by 
SOLAR. The polygenic analysis provides an estimate of the heritability of the trait 
of interest (H2) and analyzes each covariate for association with the trait. The 
polygenic analysis also creates a null0 model which is used in subsequent linkage 
analyses, where the null hypothesis tested is that the additive genetic variance due to 
the QTL is equal to zero; i.e. no linkage. The null hypothesis is tested using variance 
components linkage analysis where the LOD score represents the difference between 
the log10 likelihood of this null model and a model where the variance due to the 
QTL is estimated. The null hypothesis can be accepted or rejected based on these 
LOD scores, where the well established threshold of a LOD score greater than 3.3 
traditionally reflects rejection of the null hypothesis with a p-value of <0.05. 
Multipoint linkage analysis was run for all 22 autosomal chromosomes implemented 
in SOLAR. Results were plotted using Microsoft excel and loci with a LOD score 
greater than 1 were mapped based on Haldane’s mapping function. The UCSC 
genome browser was used to find the base pair positions of the closest markers to 
marker loci with a maximum LOD >1 and likewise any genes in the proximity 
(within 0.5 LOD support interval or ±10cM, whichever is smaller). The LOAD 
linkage results from the recently published Butler et al. paper [2] were evaluated for 
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2.2.8. Genome-wide association analysis: GenABEL 
Generation of objects gwaa.data-class: The R package GenABEL [318] and its 
functionalities were used for genome-wide association analysis of each of the four 
plasma A traits in each population. Genotype data, following quality control 
carried out using the Illumina Beadstudio software, was formatted into GenABEL 
internal format, by others, using the functionalities within GenABEL that facilitate 
conversion of genotype, SNP and subject data into GenABEL format, using the 
various “convert” functions. Using the converted genotype data provided as a ‘.raw’ 
file and phenotype data (plasma A), a QC script was executed in R. This script 
facilitated creation of the object class gwaa.data.class for the population studied (Vis 
or Korcula) through incorporation of the phenotype and genotype/subject data. This 
script also generates a ‘genomic kinship’ or ‘gkin’ matrix, based upon identity-by-
descent (IBD) estimates using autosomal SNP markers, which serves as a 
replacement for the traditional reported pedigree method. Finally, this script also 
incorporated quality control measures, such that the object created included only 
data that met our quality control criteria. 
Quality Control (QC): A sequential QC procedure was executed for each population. 
SNPs were removed which had a minor allele frequency of less than 2%,  
conservative sample and marker call rate limits of 97% and 95% respectively were 
implemented and a lenient Hardy-Weinburg p-value threshold of 1E-10 was used. 
To avoid inadvertent sample duplication and to control for the presence of any 
twins, we removed subjects who had IBS greater than 95%. The quality control 
sequence was run successively three times to take into account changes in the above 
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statistics following removal of SNPs or subjects. Population outliers were also 
identified and removed when exceeding certain limits using multidimensional 
scaling (mds) methods also implemented in the QC script.  
Trait analysis: As mentioned in Section 2.2.6, the plasma A measurements for each 
of the populations did not fit a Gaussian distribution and so the ‘rntransform’ 
function available in the R package GenABEL was utilized to rank transform the 
data distributions. Heritability estimates and the association of covariates (age, sex 
and APOE 4 allele) with each of the traits were evaluated using the polygenic 
function in GenABEL. Genome-wide association analysis, using an additive model, 
was carried out using the mmscore function in GenABEL, including age and sex in 
the model regardless of significance.  
Polygenic analysis: The polygenic model takes on the form shown below. As an 
example of this model, analysis of the plasma A40 trait in Vis, with the covariates 
of age and sex is shown:- 
 
 AB40 <- polygenic(rnkqt40~age+sex, kin=gkin, df1)  
 
This creates an object ‘AB40’ which is an estimation of the polygenic model for the 
rank transformed plasma A0 trait (rnkqt40) conditional upon the covariates age 
and sex and incorporates the genomic kinship matrix information created previously 
(kin=gkin). 
The maximum likelihood estimates (MLEs) for the (narrow-sense or additive) 
heritability and significance of each covariate are included within the results of the 
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polygenic analysis. The significance of each covariate was evaluated by running the 
model with and without the covariate included in the model. Likewise, to determine 
the significance of the heritability of the trait, the full final model with heritability 
set to 0 (h2=0) was also run. A one-sided p-value can be obtained for the heritability 
estimates since a negative heritability is impossible. To assess population 
stratification, the polygenic model was also used to estimate the genomic control 
parameter, .
GWAS analysis, mmscore: For future meta-analysis purposes the mmscore GWAS 
analysis was incorporated into the ‘formetascore’ function. For example:-
 
metatraitVis40 <- formetascore(AB40, df1, stat=mmscore, transform=“no”, 
build=36, verbosity =2) 
 
The above command will run mmscore GWAS analysis on the AB40 object created 
earlier under the polygenic function, whilst also setting up the output file for future 
meta-analyses within MetABEL [318].  
MetABEL: Meta-analysis of the two populations was executed using the 
functionalities available in the associated R package MetABEL. To perform meta-
analysis of the Vis and Korcula A40 GWAS data, which was stored as two data 
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Meta40 <- metagwa.tables(metatraitVis40, metatraitKor40, name.x=”Vis”, 
name.y=”Kor”) 
 
The resultant data frame containing the meta-analysis results was then written to a 
csv file. 
Quantile-quantile (QQ) plots: QQ plots were generated, representing the distribution 
of observed association p-values from each GWAS locus, against the distribution of 
expected p-values under the null hypothesis of no association, using plotting 
functions in R. 
Haploview: The results of the GWAS were viewed using Haploview 4.1 [322]  by 
importing the GWAS results in “PLINK” format. Haploview recognizes specific 
column headings in the PLINK format that do not match the GenABEL output, so in 
order to view the data a Perl script was used to manipulate the data so that it was in a 
format suitable for uploading into Haploview. The substitute command in Perl was 
used to alter the csv file from a comma delimited to a tab delimited file, and to 
substitute the column header ‘name’ for ‘SNP’ and the column header 
‘chromosome’ for ‘CHR’. The file was converted from .csv to .txt and was then 
ready for import into Haploview. The plot function in Haploview was used to 
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2.2.9 Convergent analysis of LOAD and plasma A GWAS 
The SNP’s identified in this chapter, with a p-value of 1E-05 for association with 
one of the plasma A traits (Tables 2.7, 2.9 and 2.10), were evaluated for 
association with LOAD. Almost all of these SNPs had previously been genotyped in 
a LOAD GWAS [240] and this data was queried for 19 of the 20 SNP’s listed in 
tables 2.7, 2.9 and 2.10. One SNP rs6939603 was not present in the LOAD GWAS 
queried. Analysis was implemented in PLINK as described by Carrasquillo et al. 
Conversely, SNPs that have been identified in recent GWAS [241, 242] proximal to 
the genes CLU, CR1 and PICALM, were evaluated for association with plasma A 
levels in the populations described in this chapter by likewise querying the results 
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2.3 Results 
2.3.1 Plasma A  measurements  
Vis: Plasma A40 was successfully measured for 999 subjects. The analysis of two 
full plates was repeated due to unreliable or outlier internal standard values. 205 
subjects had a CV greater than 0.2 in the initial measurement and so were repeated 
in duplicate and the median value calculated from 3 or 4 measurements. For the 
plasma A42 assays, 998 subjects had successful measurements after 6 full plates 
were repeated, as were 350 subjects that either failed the initial measurement, or had 
a CV greater than 0.2 for the initial duplicate measurements. Eleven subjects had 
A40 values greater than 3 SD above the mean (> 91.21) and 7 subjects had A42 
values greater than 3 SD above the mean (>62.60). There was no overlap between 
these two set of subjects and so 18 subjects were removed from the analysis for Vis. 
Korcula: Plasma A40 was successfully measured for 960 subjects. Two full plates 
were repeated due to unreliable or outlier internal standard values. One hundred and 
eleven samples had a CV greater than 0.2 in the initial measurement and so were 
repeated and the median value calculated from 3 or 4 measurements. For plasma 
A42 assays, 954 subjects had successful measurements after 18 full plates and 22 
subjects with a CV greater than 0.2 were repeated. For Korcula, 9 subjects had A40 
values greater than 3 SD above the mean (>191.16) and 8 subjects with A42 values 
greater than 3 SD above the mean (>112.70). Of these, six were present as extreme 
values for both traits and so a total of 11 subjects were removed from the analysis. 
The discrepancies between the number of subjects with successful measurements for 
A40 and A42, 999 subjects versus 998 respectively for Vis and 960 subjects 
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versus 954 respectively for Korcula, were due to the low plasma volume available 
for some subjects, such that there wasn’t enough plasma to measure both traits 
multiple times.  
Importantly, not all samples that were genotyped had plasma available for A 
measurement; likewise not all samples that were measured for plasma A were also 
genotyped. In total 949 subjects from the Vis study and 945 subjects from the 
Korcula study had both genotype data and plasma A data qualified for GWAS 
analysis.  
The distribution of trait values as shown in figures 2.3.1(A-D) and 2.3.2 (A-D) for 
each trait and both populations does not fit a Gaussian distribution. Following rank 
transformation, each of the traits fit a Gaussian distribution an example of which is 
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Vis               
A 
Dataset Trait Min Max Mean Median SD Ex Valuea
A40 6.24 176.60 47.31 45.53 14.63 91.21 
All 
A42 3.03 231.71 22.14 20.00 13.48 62.60 
A40 6.24 91.20 46.52 45.32 12.36 na 
A42 3.03 59.33 21.34 19.99 8.47 na 
A42:40 Ratio 0.07 2.72 0.48 0.43 0.23 na 
  
ExOutRem# 
A42 + A40 17.13 127.31 67.50 65.52 16.32 na 
          
Korcula        
B 
Dataset Trait Min Max Mean Median SD Ex Valuea
A40 23.21 828.66 82.09 77.39 36.36 191.16 
All 
A42 4.77 836.23 17.17 13.22 31.84 112.70 
A40 23.21 182.34 79.67 77.29 18.23 na 
A42 4.77 110.88 15.09 13.16 8.24 na 
A42:40 Ratio 0.07 1.02 0.19 0.17 0.09 na 
  
ExOutRem# 
A42 + A40 43.35 285.86 94.69 91.36 21.98 na 
 
Table 2.3. Descriptive statistics for plasma A traits from the Vis (A) and 
Korcula (B) populations. * The trait value maximum limit, above which samples 
are deemed as outliers. a. Trait values with extreme outlier values were removed 
from the population. Units are in fmol/ml. Statistics are based upon samples that 
qualified for GWAS analysis. 
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Figure 2.3.1. A-D: Histograms showing the frequency distribution of 
untransformed plasma A traits for the Vis population. Subjects with extreme 














































































































Histogram: Plasma A 40 - Vis Histogram: Plasma A 42 - Vis 
Histogram: Plasma A 42:40 
ratio - Vis 
Histogram: Plasma A 42+40 - 
Vis 
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Figure 2.3.2. A-D: Histograms showing the frequency distribution of 
untransformed plasma A traits (fmol/ml) for the Korcula population. Subjects 































































































































Histogram: Plasma A 40 - 
Korcula 
Histogram: Plasma A 42 - 
Korcula 
Histogram: Plasma A 42:40 
ratio - Korcula 
Histogram: Plasma A 42+40 - 
Korcula 
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Fig 2.3.3. Histogram representing 
the frequency distribution of 
plasma A traits following rank 
transformation. The “rntransform” 
function executed in the R package 
GenABEL was used. Each of the 
traits are rank transformed to a 
value between -3.5 and 3.5. Rank 
transformation to fit a Gaussian 
distribution is necessary to meet the 
assumption of normality to 
facilitate analysis without the need 





Plasma A trait correlation: The correlation between the two measured plasma A 
traits (A40 and A42) was evaluated are using Pearson’s test for correlation (r). 
The results indicate they are highly significantly correlated in both the Vis (r = 
0.245, p < 0.0001) and Korcula (r = 0.313, p < 0.0001) populations. 
 
2.3.2 Linkage Results in the Vis population. 
Following elimination of the extreme outlier values and rank transformation of the 
traits, as described above, multipoint linkage analysis was performed for each of the 
four plasma A traits, using the methodologies available in SOLAR. The polygenic 
analysis did not identify association with the presence or absence of an APOE 4 
allele for any of the traits (p>0.22) and so this covariate was eliminated from further 
analysis. The age covariate demonstrated suggestive (p<0.1) or significant (p<0.05) 























Histogram: Rank transformed 
plasma A.
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models. Sex did not demonstrate any evidence of association with any of the traits 
and was consequently removed from further analysis based upon use of the 
“polygenic –screen” command. The results for the polygenic models are described 
in Table 2.4. 
 
  h









  A40 0.165 0.041 Age, Age^2 0.281   
  A42 0.046 0.317 Age 0   
  A42:40 ratio 0.127 0.078 Age, Age^2 0.124   
  A40+42 0.114 0.132 Age, Age^2 0.088   
 
Table 2.4. Heritability (h2) estimates and results for the 
polygenic model executed using SOLAR. Significant covariates at 
a p-value <0.1 are listed and included in the final model. The 
residual kurtosis is also shown indicating that the trait distributions 
do not violate the assumption of normality. 
 
As shown in Table 2.4, the plasma A40 trait exhibited significant (narrow sense) 
heritability at 16.5% (p=0.041). The “ratio” and “total” A traits had suggestive 
heritability’s of 12.7% and 11.4% respectively, whilst the plasma A42 trait did not 
exhibit any evidence of being a heritable quantitative trait. As might be expected 
given the low heritability’s observed, none of the traits revealed a linkage peak with 
a LOD score greater than 3.3 which is generally considered to be the threshold for 
genome-wide significance. The largest peak observed was on chromosome 6 
(LOD=2.34) at 150cM (Haldane’s mapping function) for the plasma A40 trait. The 
closest genotyped marker was D6S1569. In total, 10 linkage peaks with a LOD 
score greater than 1, which was used as the threshold for suggestive linkage, were 
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observed for three of the traits. All of the peaks had over 10 known genes and one or 
more ‘AlzGene’ genes within the support interval, as reported on the AlzGene 
website [31]. The regions of suggestive linkage are summarised in Table 2.5. There 
were not any regions of suggestive linkage (LOD>1) for the A42 trait and this trait 
also exhibited the lowest heritability, = 0.046, p = 0.317. The linkage results are 














































Fig.2.4.1 Linkage results for plasma A40. 
Multipoint linkage analysis is shown for all 
autosomal chromosomes. The X axis on each 
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Fig.2.4.2 Linkage results for plasma A42. 
Multipoint linkage analysis is shown for all 
autosomal chromosomes. The X axis on each 













































































































































































































































Fig.2.4.3 Linkage results for plasma A42:40 
ratio. Multipoint linkage analysis is shown for all
autosomal chromosomes. The X axis on each plot
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Fig.2.4.4 Linkage results for plasma A40 +Ab42 
(total). Multipoint linkage analysis is shown for all 
autosomal chromosomes. The X axis on each plot is 

















































































































































































































































































































 # Genes 
within support 
interval
Alzgene genes within 
support interval*
Butler et al 
overlap?
1p13.1 A42:A40 Ratio 1.14 150 D1S252 117,358 140 - 160 110,985 - 157,347 >50
NGF, HMGCS2, PRKAB2, 
APH1A, CTSS, FAM63A, 
CHRNB2, LMNA, PMVK, 




1q23.3 A42:A40 Ratio 1.16 175 D1S2878 163,670 165 - 185 157,347 - 172,770 >50
CRP, NCSTN, F11R, 
USF1, FCER1G, RGS4, 




1q31.1 A40 1.05 200 D1S2877 187,611 195 - 215 180,605 - 203,981 >50 CFH, PTGS2, REN No
5q14.3 A40 1.29 115 D5S618 89,802 110 - 120 85,356 - 99,658 44 CAST No
6p23 A40 1.21 35 D6S259 14,843 30 - 40 10,133 - 20,478 11 NEDD9, ATXN1 No
6q24.1 A40 2.34 150 D6S1569 139,095 140 - 160 131,772 - 149,621 >50 ENPP1, LOC645503 No
6q24.1 A42+ A40 1.06 155 D6S308 141,298 140 - 160 131,772 - 149,621 >50 ENPP1, LOC645503 No
6q26 A40 1.21 185 D6S305 162,115 170 - 190 153,855 - 165,989 48 SOD2, ACAT2, LPA, PLG No
6q27 A42:A40 Ratio 1.41 195 D6S1697 167,764 185 - 205 162,115 -  170,394 37 RPS6KA2 No
17q25.1 A40 1.00 120 D17S1807 69,782 110 - 130 65,886- 74,536 >50 GRB2
Yes: 66.6 to 









Table 2.5. Linkage results summary table. Linkage loci identified with a LOD score > 1 are listed here in order of chromosome 
and position on each chromosome. Base pair positions are reported according to NCBI build 36 (March 2006). Linkage peaks 
reported by Butler et al. [2] are listed when there is overlap with the reported linkage peaks identified in this study. *Genes reported 
in the AlzGene database at the time of query (March 2010), bolded genes represent AlzGene “Top hits” genes also at the time of the 
query. An explanation of the AlzGene database and “Top hits” genes can be found in section 1.11.1.   
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AlzGene database: The AlzGene database [31] of AD association studies was used 
to determine if any previously studied genes had been reported within the support 
intervals of our linkage peaks. In total, thirteen AlzGene genes are present within the 
support intervals of the A40 peaks and 26 AlzGene genes are present within the 
support interval of the A ratio and A total peaks. Of these genes, two are found in 
overlapping peaks, so we found 37 LOAD candidate genes within the support 
interval of the suggestive linkage loci in this study, of which three (LOC645503, 
CHRNB2 and NEDD9) are in the AlzGene ‘top genes’ list (March 2010).  
LOC645503 is contained within a pseudogene located in the support interval of the 
linkage peak on chromosome 6 with the highest LOD score in this study (A40, 
LOD = 2.34). According to the AlzGene database (queried on March 25th 2010), 
rs6907175 lies within the same pseudogene and is associated with Alzheimer’s 
disease, based upon meta-analysis of published data and ranks 21st in the Alzgene 
list of “top-hits” [31, 235, 323, 324]. This pseudogene is described on the NCBI 
website as: “similar to SUMO-1 activating enzyme subunit 2”.  
CHRNB2: Cholinergic receptor, nicotinic, beta 2 (neuronal) encodes the beta 
subunit of a neuronal nicotinic acetylcholine receptor.  
NEDD9 maps to chromosome 6 and was cloned and characterized in 1996 by Law 
et al. and Minegishi et al. [325, 326]. It has two major isoforms and has been 
implicated in cancer in several studies [327-329] and in Alzheimer’s disease and 
Parkinson’s disease by genetic association studies [330-332].  
Previously published linkage studies: There have been several published LOAD 
linkage studies [2, 333-346], as well as one study looking at plasma  and linkage 
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to chromosome 10 [62]. In 2009 Butler et al [2] published a meta-analysis of 
independent LOAD linkage studies and our results have been compared with the 
results from this study, indicating overlapping linkage loci in Table 2.5. On 
chromosome 1, two peaks were identified with suggestive linkage to the plasma 
A42:40 ratio that map to two of the top four linkage loci from the Butler paper. In 
addition, overlapping linkage peaks were identified on chromosome 17 indicating 
suggestive linkage to plasma A40 that almost exactly overlaps with the Butler 
finding. Notably, whilst almost all published LOAD GWL (Genome Wide Linkage) 
studies identify linkage to the APOE locus on chromosome 19, none of the plasma 
Aß traits showed linkage to this chromosome. This is not entirely surprising given 
that the APOE 4 allele did not show significant association with any of the plasma 
A traits in Vis. This result indicates that the APOE locus may have an impact on 
the disease that does not greatly influence circulating A concentrations in this 
population and is perhaps independent of A pathogenic pathways. Previous studies 
of plasma Alevels have likewise failed to identify significant association with the 
APOE E4 genotype [204, 347]. 
To summarise, linkage analysis of four non-independent plasma A traits measured 
in over 900 subjects from the island of Vis failed to identify linkage peaks with a 
significant LOD score of >3.3. Although no significant linkage peaks were 
identified, several suggestive peaks were found, the most significant of which was 
on chromosome 6, with a LOD score of 2.34 for plasma A40. Many previously 
reported AD candidate genes fall within the support interval of these suggestive 
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peaks. Of further interest is the overlap of three of these peaks with loci reported by 
Butler et al. [2] in their analysis of published, independent LOAD linkage studies. 
This implies that these LOAD loci might play a role in the disease via an A 
pathway. These loci would be of interest for further investigation into both plasma 
A and LOAD. 
 
2.3.3 Vis GWAS 
Following the Vis linkage study, a GWAS was also conducted on these same 
subjects from Vis.  
Quality control: As mentioned in Materials and Methods (section 2.2.8), quality 
control (QC) procedures were run multiple times in succession. Before QC, there 
were 317,503 SNPs and 991 subjects; after QC procedures, there were 308,998 
SNPs and 925 subjects. The majority of the removed SNPs were due to low call 
rates (7,131 SNPs) with the other major reason being low minor allele frequency 
(1,285 SNPs). The most common reason for removal of subjects from the analysis 
was also low call rates (60 subjects) with a small number being removed due to high 
autosomal heterozygosity or IBS >95% (meaning that the subject is either duplicated 
in the study or has a twin). 
Following QC, 93% of subjects and 91% of SNPs remaining had >99% successful 
genotypes. The mean heterozygosity per SNP was 0.35 and per subject was 0.34. 
Genetic substructure was evaluated in GenABEL, based on multidimensional 
scaling (MDS) and the first two principal components were plotted. Following the 
removal of known outliers [272], no further outliers were detected.  
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Polygenic model 
The heritability of each trait and the trait variance associated with covariates was 
estimated using the polygenic function available in GenABEL. As described in 
Materials and Methods (section 2.2.8) the maximum likelihood estimates (MLE) for 
each of the covariates, the heritability’s and corresponding p-values were obtained. 
The APOE 4 covariate (dichotomous variable, 0 = no APOE 4 alleles and 1= one 
or more APOE 4 alleles) was not nominally significant in any of the analyses 
(p>0.05) and so it was not included as a covariate in the polygenic model. Arbitrary 
inclusion of this covariate resulted in a reduced population sample size due to 
missing APOE genotype data in some subjects, which would lead to reduced power. 
Inclusion of the APOE data was only logical if there was evidence for association 
with A traits. Consequently, only age and sex were included as covariates in the 
final polygenic models. The results for covariate and heritability estimation for each 
trait are shown in Table 2.6. Age was highly significantly associated with plasma 
A40, as were the dependant traits of the A ratio and total A. However, despite 
the high level of correlation between the A40 and 42 traits, there was no evidence 
for a significant influence of age on the plasma A42 trait. Sex was not significantly 
associated with any of the plasma A traits. 
GWAS: mmscore 
As described in Materials and Methods (section 2.2.8), the mmscore (FASTA) 
method in GenABEL was utilized to carry out the GWAS, conditional upon the 
estimated polygenic model. The parameter  which is an estimation of test statistic 
inflation (or deflation) used for genomic control methods can also be estimated 
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using mmscore. For all four traits,  was equal to 1.0 and thus the population sample 
shows no requirement for implementation of genomic control. 
Quantile Quantile plots in Figure 2.5 (a-d) represent the distribution of the observed 
p-values against those that we would be expected under the null hypothesis. 
 
Vis Age Sex Heritability (h2) 
 Trait beta P-value beta P-value beta P-value 
 Plasma A40 0.025 <0.0001 -0.013 0.829 0.028 0.376 
 Plasma A42 0.003 0.221 -0.042 0.558 0.134 0.070 
 Plasma A42:40 ratio -0.023 <0.0001 -0.058 0.426 0.089 0.147 





The GWAS results were imported into Haploview [322] and are displayed as a 
Manhattan plot for each trait (Figure 2.6.a-d). SNPs with a p-value of less than 1E-
05 are plotted above a blue line and are considered to show suggestive association 
with the A trait. SNPs that achieve genome-wide significance with a p-value < 
1.62E-07 are plotted above the red line. None of the SNPs achieved genome-wide 
significance in the study of Vis for any of the four traits evaluated. Eight SNPs 
achieved suggestive association with a p-value of <1E-05. Table 2.7 summarizes the 
“top-hits” for each of the four traits in the Vis GWAS analysis.  
Table 2.6. Maximum Likelihood Estimate’s of effect size (beta) and 
significance (p-value) in the Vis population for covariates and heritability of 
A quantitative traits. The results were estimated using the polygenic function 
in GenABEL. The beta value for age is given with respect to each yearly increase 
and for sex with respect to males. The heritability is reported as a fraction, 
multiplying this number by 100 will generate the heritability as a %. 
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Figure 2.5. Quantile Quantile plots (QQ plots) of the Vis GWAS results on 
A . QQ plots representing the distribution of observed p-values against the 
distribution of p-values as expected under the null hypothesis for the Vis GWAS 
of 308,998  SNPs for each of the plasma A traits studied. 
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Allele MAF N Beta SE beta p-value Geneb Locationc
A40 5 rs1422104 85,483,598 A 0.39 882 0.21 0.044 3.49E-06 NBPF22P 130kb, 5'
A40 13 rs831165 110,590,297 A 0.31 882 0.22 0.049 4.78E-06 ARHGEF7 Intron 1
A40 7 rs10250326 14,970,577 A 0.21 879 -0.25 0.056 6.04E-06 TMEM195 43kb, 5'
A40 13 rs860520 110,584,006 A 0.31 883 0.22 0.049 6.39E-06 ARHGEF7 Intron 1
A42 18 rs9952705 30,017,795 A 0.46 883 -0.23 0.049 1.99E-06 NOL4 Intron 1
A42 18 rs4584903 29,972,523 G 0.42 882 -0.22 0.049 7.01E-06 NOL4 Intron 1
A42 18 rs4239385 29,914,113 C 0.43 881 0.22 0.049 7.55E-06 NOL4 Intron 4
A42+40 5 rs1422104 85,483,598 C 0.39 882 0.21 0.046 6.02E-06 NBPF22P 130kb, 5'





The results shown in Table 2.7 include the closest annotated gene to each of the 
associated SNPs. It is possible that the identified SNPs do not influence the gene to 
which they are physically closest so caution should be taken not to over interpret 
these results. Each of the genes listed in Table 2.7 are however briefly described 
below. 
NBPF22P: neuroblastoma breakpoint family, member 22 (pseudogene). A literature 
search for this gene failed to yield any results, however the name of the gene implies 
a relationship to other cancer-related genes. It is difficult, at this time, to hypothesise 
as to how this locus might relate to plasma A levels. Interestingly this gene does 
fall within the support interval for the Aß40 linkage peak identified on chromosome 
5 in Table 2.5, and it is the only SNP with a suggestive p-value that falls within a 
region of suggestive linkage. 
Table 2.7. Vis GWAS results with a p-value < 1E-05. Results are shown for three 
of the traits studied, the A42:40 ratio did not identify any SNPs with a p-value less 
than 1E-05. a. Base pair positions based upon NCBI build 36 (March 2006), b. 
Gene listed is the closest gene in base pairs within 200kbp of the SNP. c. Location 
of SNP within a gene, or distance from and orientation with respect to the gene 
along the positive strand of the chromosome. 
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ARHGEF7: Also known as COOL-1 or KIAA0142, ARHGEF7 is a Rho guanine 
nucleotide exchange factor. The literature indicates that the enzyme is required for 
interaction between p-21 activated kinases or PAKS and Rho family GTPases such 
as Cdc42 [348, 349]. The possible impact of SNPs at this locus with respect to 
plasma A40 levels are not immediately clear, although the impact may affect 
downstream signalling.  
TMEM195: Variants at the TMEM195 locus have been reported to associate with 
type 2 diabetes mellitus (T2D) and/or glycemic traits in two large studies [316, 350]. 
SNP rs2191349 in the intergenic region between TMEM195 and DGKB is reported 
to show association with both diabetes-related quantitative traits and the 
dichotomous T2D trait in the recent Dupuis et al. study [316]. Several studies have 
implicated a link between T2D and AD, some of which were most recently 
summarised by Han et al. [351]. In this context, the above result is of interest, but 
further study would be needed to elucidate the proposed association with LOAD. 
NOL4: Nucleolar protein four is a 524 residue protein that is expressed in brain and 
contains nuclear and nucleolar localization signal domains. There is little published 
literature on this protein [352, 353] and so it is difficult to build a hypothesis as to 
















Figure 2.6a. Manhattan plot of GWAS results from plasma A40 levels in 
Vis. Chromosomes are plotted on the X axis and –log10 adjusted p-values are 
plotted along the Y axis. The blue horizontal line represents a p-value of   
1E-05. 
Figure 2.6b. Manhattan plot of GWAS results from plasma A42 levels in 
Vis. Chromosomes are plotted on the X axis and –log10 adjusted p-values are 
plotted along the Y axis. The blue horizontal line represents a p-value of   
1E-05. 
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Figure 2.6c. Manhattan plot of GWAS results from plasma A42:40 ratio 
measurements in Vis. Chromosomes are plotted on the X axis and –log10 
adjusted p-values are plotted along the Y axis. The blue horizontal line 
represents a p-value of 1E-05. 
Figure 2.6d. Manhattan plot of GWAS results from plasma A40+42 
measurements in Vis. Chromosomes are plotted on the X axis and –log10 
adjusted p-values are plotted along the Y axis. The blue horizontal line 
represents a p-value of    1E-05. 
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2.3.4 Korcula GWAS 
Quality Control: The quality control procedures for Korcula were run multiple times 
in succession, as previously performed for Vis. Prior to QC, there were 346,027 
SNPs and 953 subjects. After QC procedures, there were 325,224 SNPs and 898 
subjects. The majority of SNPs were removed due to low call rates (11,533 SNPs), 
with the other major reason being a minor allele frequency of less than 2% (10,384 
SNPs). Some SNPs fell under both exclusion categories. The most common reason 
for removal of subjects from the analysis was likewise low call rate (39 subjects), 
with a small number being removed due to high autosomal heterozygosity, or IBS 
>95%, implying that the subject is either duplicated in the study or has a twin. In the 
QC procedure, a lenient p-value threshold of 1E-10 for deviation from Hardy 
Weinberg equilibrium was used for the same reasons as described for Vis. 
Thresholds of 95% and 97% for genotyping success rate for SNPs and subjects 
respectively was used. Following implementation of these QC thresholds, 98% of 
subjects and 97% of SNPs remaining had a proportion of successful genotypes 
greater than 99%; this is somewhat higher that the quality of calls found for Vis and 
may be a reflection on the quality of input DNA or differences in the quality of the 
genotyping chip used. Vis used the HumanHap300 (Ilumina) and Korcula used the 
HumanHap370CNV chip (Illumina). The mean heterozygosity per SNP is 0.35 and 
per subject is 0.34, again similar to Vis.  
Polygenic model: The heritability of each trait, and the trait variance associated with 
covariates was obtained using the polygenic function available in GenABEL [318]. 
As described in Materials and Methods (section 2.2.8) the MLE for each of the 
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covariates and heritability, together with the corresponding p-values was also 
calculated. The APOE 4 covariate (presence/absence) was not nominally significant 
in any of the analyses (p>0.05) and so this covariate was not included in the 
polygenic model. This is a similar result to that observed in Vis for APOE. 
Consequently, only age and sex were included as covariates in the final polygenic 
models. The results for covariate and heritability estimation for each trait are shown 
in Table 2.8.  
The plasma A trait and the dependent traits of the ratio and total Awere highly 
significantly associated with increasing age. When this result is compared with the 
results for the same analysis in Vis, several similarities can be observed. The beta 
coefficient (effect size) for age on plasma A40 in Vis was 0.025 and in Korcula it 
was 0.022. This result is very similar despite the different capture antibodies used in 
the two studies for measuring plasma A40. Likewise the beta coefficients for the 
effect of age on plasma A42 in the two populations was small and non-significant, 
although in Vis we observed a small positive beta coefficient (0.003) and in Korcula 
we observed a small negative beta coefficient (-0.004). Furthermore, the sex 
covariate did not show significant association with any of the plasma traits, similar 
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Korcula Age Sex Heritability (h2)  
Trait beta  P-value beta  P-value beta P-value  
Plasma A40 0.022 <0.0001 -0.024 0.849 0.467 <0.0001 
 
Plasma A42 -0.004 0.071 -0.100 0.159 0.197 0.030 
 
Plasma A42:40 ratio -0.018 <0.0001 -0.075 0.257 0.175 0.030 
 






The mmscore function [you must explain what this is and does – it is the same as the  
 
The mmscore test described and introduced by Chen WM and Abecasis G in 2007 
[354], which implements FASTA (Family Score Test for Association) methods for 
analysis of the data, was used for genome wide association analysis of the 325,224 
SNPs in 898 subjects from Korcula. The parameter  which is an estimation of test 
statistic inflation (or deflation) used for genomic control methods can also be 
estimated using mmscore. In this analysis,  is equal to between 0.96 and 1.00 and 
thus exhibits no requirement for implementation of genomic control. In fact, for 2 
traits,  indicates a deflation factor and implying that the test statistic may be 
underestimated. This can be observed graphically in the QQ plots (Figure 2.7 a-d), 
where the observed distribution falls below the red line which represents the 
distribution of p-values under the null hypothesis. 
The GWAS results were imported into Haploview [322] and are displayed as a 
Manhattan plot for each trait. SNPs with a p-value of less than 1E-05 are plotted 
Table 2.8. MLE of the effect size (beta coefficient) and statistical significance 
(p-value) in the Korcula population for covariates and heritability of 
Aquantitative traits. The estimates were obtained using the polygenic function in 
Gen BEL. The beta coefficient for age is given per yearly increase and for sex the 
beta coefficient is shown with respect to males. The heritability is reported as a 
fraction, multiplying this number by 100 will generate the heritability as a %. 
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above a blue line and are considered to show suggestive association. SNPs that 
achieve genome-wide significance with a p-value of < 1.54E-07 are plotted above 
the red line. None of the SNPs achieved genome-wide significance in the Korcula 
study for any of the four Atraits evaluated. Six SNPs achieved suggestive 
association, with a p-value of < 1E-05. Table 2.9 summarizes the “top-hits” for each 





Allele MAF N Beta SE beta p- value Geneb Locationc
A40 21 rs2832643 30,450,088 G 0.23 875 -0.27 0.056 1.57E-06 CLDN17 10kb, 5'
A40 21 rs2835933 38,045,624 G 0.19 876 0.29 0.060 1.78E-06 KCNJ6 Intron 2
A42 6 rs6939603 5,792,055 G 0.26 872 -0.28 0.057 5.96E-07 FARS2 75kb, 3'
A42 8 rs10505470 127,433,877 G 0.23 875 0.26 0.057 7.28E-06 FAM84B 200kb, 5'
A42:40 Ratio 15 rs1668547 40,130,319 A 0.22 876 -0.28 0.057 1.31E-06 PLA2G4D 17kb, 5'
A42:40 Ratio 1 rs12145722 22,615,572 G 0.27 875 0.27 0.062 9.06E-06 ZBTB40 35kb, 5'
A42+40 21 rs2832643 30,450,088 G 0.23 875 -0.28 0.057 9.47E-07 CLDN17 10kb, 5'
A42+40 6 rs6939603 5,792,055 G 0.26 872 -0.27 0.056 1.42E-06 FARS2 75kb, 3'
A42+40 21 rs2835933 38,045,624 G 0.19 876 0.29 0.061 2.37E-06 KCNJ6 Intron 2  
Table 2.9. Korcula GWAS results with a p-value < 1E-05. Results are shown for 
all four of the Atraits studied, a. Base pair positions based upon NCBI build 36 
(March 2006), b. The genes listed are the closest genes in base pairs, within 200kbp 
of the SNP. c. Location of SNP within a gene or distance from gene and orientation 
with respect to the gene along the positive strand of the chromosome. 
 
 
As mentioned previously in the GWAS analysis of Vis, caution must be taken not to 
over interpret the results with respect to the proximity of the identified SNPs and the 
genes listed in the Table. The genes listed are defined as those closest to the 
associated SNP within a 200kbp window, but they are frequently not the only gene 
within this window. 
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Figure 2.7 a-d. Quantile-Quantile plots (QQ plots). QQ plots representing the 
distribution of observed p-values against the distribution of p-values expected under 
the null hypothesis for the Korcula GWAS of 325,224 SNPs for each of the plasma 
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CLDN17: The SNP at this locus is present 10kb 5’ of the CLDN17 gene with 
reference to build 36 of the human genome. However, the CLDN17 gene is 
transcribed 3’ to 5’ and so this SNP is 3’ of the CLDN17 gene. CLDN17 is one of a 
family of 23 Claudin genes [355]. There is little literature on the CLDN17 gene, 
however the family of Claudin genes are known to be involved in the formation of 
tight cell junctions and have been implicated in cancers [356, 357]. With respect to 
Alzheimer’s disease, the presence of this gene on chromosome 21 is of interest. The 
reasons for the relevance of chromosome 21 in A and LOAD aetiology are 
discussed in chapter 1. 
 KCNJ6: Also known as GIRK2, this gene encodes an inward rectifying ATP 
dependant potassium gated channel expressed in pancreatic beta cells and the brain. 
This gene also maps to chromosome 21. A mouse model, most commonly known as 
the weaver mouse, was generated by mutation of the mouse GIRK2 gene and 
exhibits an ataxic phenotype [358]. Studies have indicated a role for GIRK2 in long 
term potentiation and synaptic plasticity [359, 360], whilst two association studies 
investigating SNP’s at this locus report one positive and one negative association 
with Alzheimer’s disease [361, 362].  
FARS2: This gene encodes a mitochondrial phenylalanyl-tRNA synthetase (PheRS) 
[363]. It is possible that variation at this locus could play a role in mitochondrial 
dysfunction which is a hypothesised pathogenic pathway for LOAD. However, there 
is limited literature on this gene and so a biological role in disease is difficult to 
hypothesise without additional information. 
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FAM84B: This gene maps to chromosome 8, encodes a protein that is a binding 
partner of alpha-1 catenin (CTNNA1) and is found at high levels in cancer cells 
[364]. The SNP on chromosome 8 that is proximal to FAM84B lies within a “gene 
desert” on chromosome 8 that has been linked to multiple cancers and is flanked by 
FAM84B and C-MYC [365]. It is unclear how this locus might relate to plasma A 
or Alzheimer’s disease other than the observation that the protein was found to bind 
CTNNA1. A related gene, CTNNA3 lies within the 1 LOD support interval of the 
plasma A42 linkage peak on chromosome 10 that was described by Ertekin-Taner 
et al. [62] and contains SNPs that have been reported to associate with both plasma 
A and LOAD [206, 366]. 
PLA2G4D: This gene maps to chromosome 15 and is up-regulated in the skin from 
psoriasis patients and other inflammatory skin diseases [367]. Is not known to be 
expressed in the brain although SNPs at this locus have been investigated for 
association with schizophrenia [368]. A biological role for this locus in controlling 
plasma A traits or LOAD susceptibility is not immediately clear. 
ZBTB40: This gene is expressed in bone and two recent studies have implicated 
SNPs at this locus as being associated with bone mineral density, indicating a 
possible role in osteoporosis disease susceptibility [369, 370]. Again, there is no 
obvious biological role for the gene in controlling plasma A traits.  
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Figure 2.8a. Manhattan plot of GWAS results for plasma A40 
concentration in Korcula. Chromosomes are plotted on the X axis and –log10 
adjusted p-values are plotted along the Y axis. The blue horizontal line 
represents a p-value of  1E-05.  
Figure 2.8b. Manhattan plot of GWAS results for plasma A42 
concentration in Korcula: Chromosomes are plotted on the X axis and –log10 
adjusted p-values are plotted along the Y axis. The blue horizontal line 
represents a p-value of    1E-05. 
Chapter 2. 








Figure 2.8c. Manhattan plot of GWAS results for plasma A42:40 ratio 
measurements in Korcula: Chromosomes are plotted on the X axis and –
log10 adjusted p-values are plotted along the Y axis. The blue horizontal line 
represents a p-value of 1E-05. 
Figure 2.8d. Manhattan plot of GWAS results for plasma A40+42 
measurements in Korcula: Chromosomes are plotted on the X axis and –
log10 adjusted p-values are plotted along the Y axis. The Blue horizontal line 
represents a p-value of 1E-05. 
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2.3.5 Meta-analysis 
The R package MetABEL [318] was used to facilitate meta-analysis of the GWAS 
results generated from the Vis and Korcula studies. Meta-analysis was conducted for 
each of the four plasma A traits and the results were reported for all SNPs that 
were present in both studies; in total 297,303 SNPs were present for meta-analysis in 
both studies. The results were imported into Haploview and are displayed as 







MAF N Beta SE beta p- value Geneb Locationc
A40 6 rs11153495 115,108,714 G 0.18 1754 0.19 0.042 5.09E-06 - -
A42 X rs6647514 73,802,014 A 0.23 1732 0.16 0.035 2.47E-06 KIAA2022 68kb, 5'
A42 3 rs883370 133,109,978 G 0.39 1759 0.16 0.035 2.51E-06 CPNE4 Intron 1
A42 14 rs12433867 92,134,836 G 0.18 1754 -0.25 0.055 5.45E-06 RIN3 Intron 3
A42:40 Ratio 1 rs17521587 217,883,729 A 0.14 1758 -0.22 0.047 5.11E-06 - -
A42:40 Ratio 2 rs4848444 117,954,791 A 0.18 1758 0.19 0.043 6.57E-06 - -









KIAA2022: A literature search for this gene reveals that it is both highly expressed 
in brain and has been shown to be associated with mental retardation in males when 
the gene is disrupted [371]. Too little is known however regarding the gene to 
hypothesise a possible biological role in plasma A trait control or LOAD 
association. 
Table 2.10.  Meta-analysis of GWAS results for Atraits with a p-value <1E-
05. Results are shown for all four of the traits studied. a. Base pair positions 
based upon NCBI build 36 (March 2006), b. Gene listed is the closest gene in 
base pairs within 200kbp of the SNP. c. Location of SNP within a gene or 
distance from gene and orientation with respect to the gene along the positive 
strand of the chromosome. 
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CPNE4: The gene is also known as copine IV and enocodes a calcium dependant 
membrane binding protein. Very little has been published on this gene or the protein 
it encodes although more is known about the related protein CPNE1. It is likely that 
the family of copines play a role in signal transduction and there is evidence for the 
expression of some members of this family in the brain [372, 373].  
RIN3: is a widely expressed gene encoding Ras interaction-interference protein 
(Rin). It belongs to a large family of Rin proteins which are known to be binding 
partners to the RAB5 small GTPases. Evidence reported in the literature indicates 
that this protein plays a role in intracellular transport, particularly indicating a role in 
stabilising Rab5 and thus the endocytic transport pathway from the plasma 
membrane to early endosomes [374]. It may be hypothesised that RIN3 could play a 
role in APP processing via the endocytic pathway; however more research would be 

























Figure 2.9a. Manhattan plot of GWAS results from meta-analysis of Vis 
and Korcula plasma A40 concentration: Chromosomes are plotted on the 
X axis and –log10 adjusted p-values are plotted along the Y axis. The blue 
horizontal line represents a p-value of 1E-05. 
Figure 2.9b. Manhattan plot of GWAS results from meta-analysis of Vis 
and Korcula plasma A42 concentrations: Chromosomes are plotted on the 
X axis and –log10 adjusted p-values are plotted along the Y axis. The blue 
horizontal line represents a p-value of 1E-05. 
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Figure 2.9c. Manhattan plot of GWAS results from meta-analysis of Vis 
and Korcula  plasma A42:40 ratio measurements. Chromosomes are 
plotted on the X axis and –log10 adjusted p-values are plotted along the Y axis. 
The blue horizontal line represents a p-value of 1E-05. 
Figure 2.9d. Manhattan plot of GWAS results from meta-analysis of Vis 
and Korcula plasma A40+42 measurements: Chromosomes are plotted on 
the X axis and –log10 adjusted p-values are plotted along the Y axis. The blue 
horizontal line represents a p-value of 1E-05. 
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2.3.6 Association of top plasma A SNPs with LOAD 
The aim of this chapter was to identify candidate LOAD loci through the use of 
GWAS, endophenotypes and isolated population based approaches. Using these 
methods, 20 SNPs were identified to show suggestive association with plasma A 
(tables 2.7, 2.9 and 2.10). Of these, 19 were genotyped as part of a LOAD GWAS 
published in 2009 (Carrasquillo et al). A query of these LOAD GWAS results, for 
the 19 SNPs identified, is presented in Table 2.11.  
One SNP, rs12320234, achieved nominally significant association with LOAD (OR 
= 1.46, p = 0.027), however this would not maintain significance after bonferonni 
correction for multiple tests.  
An evaluation of 19 SNPs would be expected, by chance, to identify 2 SNPs with a 
p-value of less than 0.1. In this study, in addition to rs12320234, a further five SNPs 
achieved a p-value of less than 0.1 (rs12145722, rs17521587, rs12433867, 
rs4239385 and rs2835933), resulting in a far greater number of SNPs with a p-value 
of less than 0.1 than would be expected by chance. Whilst these SNPs do not 
individually achieve significant association with LOAD, it can be argued that these 
SNPs are feasible candidates for follow up with additional genotyping in a greater 




Table 2.11 Association analysis of 19 SNPs with LOAD.  SNPs identified as the 
top candidates in the plasma A GWAS described in this chapter are tested for 
association with LOAD. MAF = Minor Allele Frequency, CHR = chromosome. 
 
2.3.7 Association of LOAD SNPs with plasma A
Recent LOAD GWAS have identified replicable genome-wide significant 
association for SNPs at three loci frequently identified by the proximal candidate 
genes CLU, CR1 and PICALM. Of the reported SNPs at these loci, three were 
present as part of the plasma AGWAS described in this chapter and were 
investigated for association with plasma A levels in both Vis and Korcula using the 
methods described previously. The results are presented in Table 2.12. 
CHR SNP Position (bp) Allele Cases Controls OR 95% CI p-value
1 rs12145722 22,615,572 G 0.19 (733) 0.17 (1103) 1.21 1.00-1.47 0.055
1 rs17521587 217,883,729 A 0.13 (733) 0.15 (1104) 0.83 0.67-1.04 0.099
2 rs4848444 117,954,791 A 0.15 (732) 0.14 (1103) 1.13 0.92-1.40 0.253
3 rs883370 133,109,978 G 0.44 (733) 0.44 (1102) 0.94 0.81-1.09 0.424
5 rs10035841 85,455,353 A 0.34 (729) 0.32 (1096) 1.02 0.87-1.19 0.813
5 rs1422104 85,483,598 A 0.48 (733) 0.47 (1103) 0.98 0.85-1.14 0.834
6 rs11153495 115,108,714 G 0.18 (732) 0.18 (1100) 1.04 0.86-1.27 0.658
8 rs10505470 127,433,877 A 0.22 (733) 0.22 (1103) 1.00 0.84-1.20 0.972
12 rs12320234 76,427,966 A 0.06 (733) 0.04 (1105) 1.46 1.04-2.04 0.027
13 rs860520 110,584,006 A 0.29 (732) 0.30 (1105) 0.92 0.78-1.08 0.289
13 rs831165 110,590,297 A 0.29 (733) 0.30 (1105) 0.91 0.78-1.07 0.268
14 rs12433867 92,134,836 G 0.08 (730) 0.11 (1099) 0.78 0.60-1.01 0.056
15 rs1668547 40,130,319 A 0.27 (733) 0.27 (1102) 1.04 0.88-1.23 0.655
18 rs4239385 29,914,113 C 0.41 (730) 0.45 (1102) 0.87 0.75-1.01 0.074
18 rs4584903 29,972,523 G 0.44 (732) 0.44 (1101) 1.05 0.90-1.22 0.541
18 rs9952705 30,017,795 A 0.48 (733) 0.47 (1104) 1.06 0.91-1.23 0.442
21 rs2832643 30,450,088 G 0.26 (730) 0.23 (1101) 1.08 0.91-1.29 0.385
21 rs2835933 38,045,624 G 0.19 (732) 0.22 (1104) 0.84 0.70-1.01 0.061




This analysis identified nominally significant association with increased plasma 
A42 levels for the SNP at the PICALM locus (rs3851179), in the Korcula 
population (p=0.04) and in the meta analysis of both Vis and Korcula (p=0.027), 
however these p-values would not maintain significance after correction for multiple 
tests.  
Although these results indicate a suggestive association for the PICALM locus with 
plasma A levels, the p-values reported for association with LOAD are much 
smaller and so it is unlikely that the association observed at these loci influences risk 













Table 2.12 Analysis of recently identified LOAD SNPs, for association with plasma A levels. MAF = Minor Allele 
Frequency. 
CHR SNP Position (bp) Gene Allele Vis Korcula Meta Trait beta p-value beta p-value beta p-value
A 40 0.01 0.753 -0.09 0.071 -0.03 0.311
A 42 0.02 0.762 -0.07 0.139 -0.03 0.400
Ab42/40 ratio 0.00 0.995 -0.02 0.631 -0.01 0.735
Ab40+42 0.02 0.653 -0.10 0.053 -0.04 0.306
A 40 0.04 0.453 0.05 0.260 0.04 0.185
A 42 0.05 0.294 0.10 0.040 0.08 0.027
Ab42/40 ratio 0.04 0.465 0.07 0.155 0.05 0.125
Ab40+42 0.05 0.289 0.07 0.166 0.06 0.084
A 40 0.06 0.226 -0.01 0.818 0.03 0.473
A 42 0.03 0.605 -0.04 0.477 -0.01 0.886
Ab42/40 ratio -0.04 0.502 -0.03 0.532 -0.04 0.359
Ab40+42 0.06 0.238 -0.02 0.778 0.03 0.517
205,852,912 CR1 A
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2.4 Summary 
Assessment of the heritability of plasma A concentrations in Vis and Korcula 
revealed surprising differences in these two populations, where Vis showed only 
weak evidence for heritability, conversely, plasma A in Korcula was significantly 
heritable. A genome-wide linkage study of Vis identified several suggestive QTL, 
some of which overlap with known LOAD linkage peaks and provide both 
interesting and relevant candidates for further study as well as supportive evidence 
for functional variation at these loci. GWAS analysis, did not identify any QTL that 
achieved genome-wide significance according to Bonferroni correction standards for 
any of the traits in either study or by meta-analysis. However, several promising loci 
with low p-values that are good candidates for further study were identified. 
Nineteen of these loci were tested for association with LOAD and whilst significant 
association with LOAD, following correction for multiple tests, was not found for 
any of these SNPs there were many more SNPs with a p-value of less than 0.1 than 
would be expected by chance. Conversely, SNPs recently identified for association 
with LOAD did not exhibit significant association with plasma A in these 
populations. 
These studies have also provided data for future use in phenotype convergence 
studies where low p-values recorded for multiple traits such as plasma A, LOAD 
phenotype and gene expression for a given SNP or gene may be informative in a 
situation where individual studies may be under-powered and heterogeneity 
complicates traditional replication studies. One example of this comes from two 
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simultaneously published studies of the insulin degrading enzyme [3, 375]. This will 
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Chapter 3. 
3.1 Background 
In the previous chapter the use of isolated populations, quantitative traits and whole 
genome analyses were used as tools to identify loci that may play a role in LOAD by 
influencing levels of the A peptide. In this chapter, the results of these studies are 
combined with gene expression traits and the LOAD disease trait in order to execute 
phenotypic convergence analysis. The purpose of this approach is to facilitate the 
identification of loci that may not achieve genome-wide significant association ( 
typically less than 1E-07) with any one trait, but nevertheless exhibit nominal 
evidence for multiple relevant traits. Whilst the loci identified using this approach 
likely have weak effects on the disease trait, it is becoming more widely accepted 
that complex traits with a substantial genetic component, such as LOAD, are likely 
caused by variation at multiple loci with individually weak effects. The 
identification of these additional loci, whilst challenging, is pertinent to improving 
our understanding of Alzheimer’s disease. Since the majority of genes implicated in 
AD appear to have some involvement in Aß metabolism it is logical to evaluate the 
effect of SNPs in these genes on plasma Aß levels. In this chapter a phenotype 
convergence approach is used to evaluate the influence of SNPs at the IDE locus on 
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3.1.1 A degrading enzymes 
As discussed in chapter one the amyloid cascade hypothesis postulates that the 
major triggering event in the development of Alzheimer’s disease is likely increased 
levels of the A peptide in the brain [137]. Changes in A levels most likely occur 
through alterations of two main pathways; A generation and A degradation. 
Several enzymes are known to degrade Aß, among the most extensively studied are, 
the Insulin Degrading Enzyme (IDE), which degrades both insulin and Aß, 
Neprylisin (NEP) and the angiotensin converting enzyme (ACE) [205, 376-378]. 
Whilst the A degrading properties of these enzymes are well established, their role 
in LOAD has been difficult to elucidate and genetic studies have produced 
conflicting and inconsistent results [31].  
 
3.1.2 IDE.  
The IDE locus is of particular interest in the study of LOAD since it is not only a 
functional candidate but is also proximal to a linkage peak identified through 
analysis of AD families [379]. For these reasons IDE was explored by the Younkin 
laboratory as a candidate LOAD gene through targeted genotyping of conserved 
variants (>70% sequence identity in human vs rodent) based upon the hypothesis 
that conserved variants have an increased likelihood to impact phenotypes. The 
initial target phenotype (or trait) in this study was expression levels of the IDE gene 
in the cerebellum of AD subjects. In post-mortem AD brains, AD pathology is 
usually observed in many areas of the brain. The cerebellum is unusual in that it is 
virtually unaffected and shows no dense amyloid plaques or NFT’s. Thus the 
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cerebellum provides an opportunity to study gene expression levels in the target 
tissue (brain) whilst controlling for the downstream effects of the disease process as 
much as possible. IDE transcript concentration was chosen as a target trait based 
upon the hypothesis that variants that influence disease might do so by influencing 
the expression of certain genes relevant to the disease. In this chapter two parallel 
studies are highlighted that identified SNP’s in conserved regions of the IDE locus 
that significantly associated with IDE expression levels in the AD cerebellum 
studied and likewise exhibited significant association with LOAD [3, 205, 375].  
The most important of these SNPs was investigated for association with plasma 
levels of A in the Vis and Korcula populations using the data that were described 
in the previous chapter. The association detected for this SNP, for all three traits, 
correlated in a logical manner such that the allele that was associated with increased 
IDE expression was likewise associated with decreased levels of plasma A and 
decreased risk for LOAD [3]. This result is an example of the utility of the 
phenotypic convergence approach, to identify LOAD loci that would otherwise go 
undetected using whole genome analysis approaches for a single trait. 
The results on Aß reported in the previous Chapter greatly strengthened the paper 
reporting these convergent results that was published in 2010 [3]. The author of this 
thesis was an equally contributing author on that paper, and was involved in writing 
and editing the manuscript. For this reason and to present rigorously the entire 
convergent set of results, sections from the text of the published manuscript have 
been liberally incorporated into parts of this chapter. 
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3.2 Methods 
The methods described in this chapter are largely taken from Carrasquillo et al [3]. 
3.2.1 Subjects 
Approval was obtained from the ethics committee or institutional review board of 
each institution responsible for the ascertainment and collection of samples (Mayo 
Clinic College of Medicine, Jacksonville, FL and Mayo Clinic College of Medicine, 
Rochester, MN, USA; MRC Human Genetics Unit, Western General Hospital and 
the University of Edinburgh Medical School, Edinburgh, UK; University of Split 
Medical School and University Hospital “Sestre Milosrdnice”, Croatia; Queen's 
Medical Centre, Nottingham, UK; Queen's University Belfast, Northern Ireland, 
UK; University of Bristol, Frenchay Hospital, UK; University of Manchester, UK; 
University of Oxford, UK; and University of Bonn, Germany. Written informed 
consent was obtained for all individuals that participated in this study. 
The age-at-diagnosis/entry, diagnosis method, and percent female in the LOAD 
cases and controls for each USA and ART series are described in Table 3.1. 
 
3.2.2 DNA Isolation 
For the JS and RS samples, DNA was isolated from whole blood using an AutoGen 
instrument (AutoGen, Inc, Holliston, MA). The DNA from AUT samples was 
extracted from cerebellum using Wizard® Genomic DNA Purification Kits 
(Promega Corp., Madison, WI). DNA from the RS and AUT series was scarce, so 
samples from these two series were subjected to whole genome amplification using 
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the Illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare Bio-Sciences 
Corp., Piscataway, NJ). 
For the ART samples, genomic DNA was extracted from whole blood samples or 
brain tissue using the QIAamp DNA blood mini kit (Qiagen, Crawley, West Sussex, 
UK). 
 




USA      
JS 632 660 1,292  78.1 (6.1) 77.5 (7.7)  62.3 61.4 
RS 576 1,417 1,993  79.7 (7.9) 78.4 (6.0)  63.4 54.6 
AUT 603 374 977  81.1 (8.6) 75.7 (8.3)  59.2 42.8 
NCRAD 702 209 911  75.2 (6.8) 78.3 (8.9)  64.8 61.7 
Total 2,513 2,660 5,173  78.4 (7.7) 77.8 (7.1)  62.5 55.2 
          
ART          
Belfast 237 234 471  78.4 (6.7) 76.2 (7.5)  65.8 65.4 
Bonn 175 199 374  75.9 (7.6) 71.0 (6.9)  76.0 49.2 
Manchester 210 0 210  68.7 (6.3) N/A  50.0 N/A 
Oxford 167 205 372  73.0 (6.8) 77.3 (8.1)  55.7 57.1 
Southampton 227 143 370  80.9 (7.5) 75.8 (6.6)  59.0 49.0 
Total 1,016 781 1,797  75.6 (8.2) 75.1 (7.8)  61.1 56.1 
          




Table 3.1. Subjects. The number of AD patients (AD) and controls (CTRL), mean 
age, and the percentage that are female are given for each individual and pooled 
series. Mean age is given as age at diagnosis/entry. The standard deviation (SD) 
from the mean is given in parenthesis 
 
3.2.3 Variant Discovery 
Conserved segments in the region encompassing all 25 exons of IDE and up to 10 
kb from the 5′ and 3′ ends of the gene, were screened for DNA variation likely to be 
functional in a subset of the JS series (269 cases and 252 controls). This sample size 
provided enough power to detect all polymorphisms that occur at a frequency >1% 
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in this population. The criteria used for conservation was a cut-off of ≥70% identity 
over 100 bp windows between the human and mouse sequence or between the 
human and rat sequence, as determined by the pre-computed alignments in the 
VISTA Genome Browser (http://pipeline.lbl.gov/cgi-bin/gateway2). The human 
genome position screened was chr10:94,335,255-94,475,049 in the Human April 
2003 genome build. The latter build was used as the base genome, and was 
compared to the Mouse Feb. 2003 and Rat Jan. 2003 builds. In each of the 521 
subjects screened, 40 amplicons were evaluated that contained a total of 9,501 bp of 
conserved DNA. Forty PCR primer pairs were designed to screen the targeted 
conserved segments via denaturing high performance liquid chromatography 
(dHPLC). This variant discovery effort yielded 53 variants (42 novel) of which 14 
had minor allele frequencies (MAFs) >1%. Twelve of these were genotyped, 2 could 
not be converted into TaqMan assays (deep intronic, 1 base insertions within simple 
repeats). An additional review of all known IDE variants identified 15 additional 
variants, each located in a 100 bp region that had sequence identity of ≥70% 
between the mouse and human sequence. Of these, 8 had MAFs≥1%. Three of these 
were in perfect LD with variants from the de novo search, thus were eliminated 
leaving 17 common IDE variants in conserved regions to be genotyped.  
Additional details regarding variant discovery is detailed in Carrasquillo et al [3]. 
 
3.2.4 Genotyping of IDE Variants 
All genotyping of USA series samples was performed at the Mayo Clinic in 
Jacksonville using TaqMan® SNP Genotyping Assays in an ABI PRISM® 7900HT 
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Sequence Detection System with 384-Well Block Module from Applied Biosystems, 
California, USA. The genotype data was analyzed using the SDS software version 
2.2.2 (Applied Biosystems, California, USA). 
The ART data, was also generated with TaqMan assays performed at Geneservice 
(Cambridge, UK).  
 
3.2.5 IDE Haplotypes 
Analysis by HaploView [322] (solid spine of LD) showed that the 17 IDE variants 
were in strong linkage disequilibrium.. These variants formed 11 haplotypes with a 
frequency of 1.0% or more that could be identified with 10 tagging variants. 
Analysis by Haplo.Stats identified the same 11 haplotypes, which accounted for 
96% of the IDE genetic variation captured by the 17 variants. Haplotype frequencies 
were estimated using the expectation-maximization approach implemented in the 
haplo.em function of haplo.stats v1.2.2 [380]. Haplo.stats was also used to create 
files showing the inferred haplotypes for each individual, which were used to 
perform logistic regression analyses. 
 
3.2.6 Measurement of IDE mRNA Expression 
Total RNA was extracted from samples of cerebellum from 200 AD brains using an 
ABI PRISM 6100 Nucleic Acid PrepStation and the Total RNA Isolation Chemistry 
kit from Applied Biosystems. RNA was reverse transcribed to single-stranded 
cDNA using the High-Capacity cDNA Archive Kit from Applied Biosystems. Real-
time quantitative PCR was performed in triplicate for each sample using ABI 
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TaqMan Low Density expression Arrays (384-Well Micro Fluidic Cards) with a pre-
validated TaqMan Gene Expression Assay. 18s ribosomal RNA (18s rRNA) was 
used as the endogenous control for the relative quantification of IDE mRNA. Real-
time PCR cycle threshold (CT) raw data was collected and exported using the ABI 
PRISM® SDS software version 2.2. Additional details can be found at Carrasquillo 
et al [3] 
 
3.2.7 Association of IDE Haplotypes and Variants with IDE Transcript 
The fold difference in the expression levels for the minor allele for each variant was 
estimated from the regression coefficient (ß) for the additive model that was fit to 
the ΔCT data, which were expressed on the log2 scale, while also adjusting for APOE 
ε4 dosage, age at diagnosis/entry and sex. Therefore, the associations were 
summarised using 2(−ß) to estimate the fold difference in expression due to a single 
copy of the minor allele, and 2[−(ß±2SEM)] to estimate the corresponding 95% 
confidence interval (CI). The expression differences were further summarised 
graphically by preparing box plots showing the relative amount of IDE transcript in 
any sample in the series as compared to the mean expression level of all of the 
samples that were major homozygotes. This was done by computing the mean of all 
ΔCT values for the samples in the major homozygote category and subtracting it 
from each of the ΔCT values for all samples in all genotype categories (i.e. major 
homozygotes, heterozygotes and minor homozygotes) to obtain ΔΔCT values. Given 
that these ΔΔCT values are the log2 fold changes between two measurements, the 
relative expression levels between any sample and the mean of the major 
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homozygotes is given by 2−ΔΔCT =  (−(ΔCT_Any Sample−mean(ΔCT_Major Homozygotes))). 
These 2−ΔΔCT values are plotted in the box plots. 
The overall association between estimated haplotypes (frequency >0.01 in combined 
dataset) and the level of IDE transcript (ΔCT) was determined by multivariable 
linear regression using a haplotypic dosage model with sex, age at diagnosis/entry, 
and APOE ε4 dosage (0, 1 or 2 copies of the ε4 alelle) as covariates. The association 
between individual haplotypes and IDE transcript (ΔCT) was determined by linear 
regression using an allelic dosage model with sex, age at diagnosis/entry, and APOE 
ε4 dosage as covariates. The haplo.stats package was used to create the files 
containing the inferred haplotypes for each individual that were used to perform 
these analyses. 
IDE variants were analyzed for association with the level of IDE transcript (ΔCT) 
using an additive/allelic dosage (11 = 0, 12 = 1, 22 = 2) linear regression model that 
included sex, age at diagnosis/entry, APOE ε4 dosage and series as covariates. 
 
3.2.8 Association of IDE Haplotypes and Variants with LOAD 
The overall association between haplotypes (frequency >0.01 in combined dataset) 
and LOAD was determined using the global score statistic implemented in the 
haplo.score function incorporated in the haplo.stats package [380] while adjusting 
for sex, age at diagnosis/entry, APOE ε4 dosage, and series effects. The association 
between individual haplotypes and LOAD was determined by entering the estimated 
haplotypes for the cases and controls into univariate logistic regression using a 
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haplotypic dosage model that adjusted for sex, age at diagnosis/entry, APOE e4 
dosage, and series as covariates. 
IDE variants were analyzed for association with LOAD by logistic regression using 
PLINK software [381] with sex, age at diagnosis/entry, and APOE ε4 dosage as 
covariates. For logistic regression using data from the combined series, we also 
included indicator variables for the individual series as covariates. All logistic 
regression analyses were performed using the additive/allelic dosage model as the 
primary test of significance for each variant. To test for evidence of any series-
related effects on these associations, we compared this model to one that also 
incorporated series x genotype interactions in addition to all previously mentioned 
covariates. This analysis showed no evidence for series-related effects on any of the 
associations. 
 
3.2.9 Linkage Disequilibrium between rs6583817 and rs7910977 
A LOAD genome wide association study (GWAS) was previously conducted with 
313,504 SNPs in 844 cases and 1,255 controls that were also analyzed for 
association with the 17 IDE variants in conserved regions [241]. HaploView 3.1 was 
used to calculate the extent of LD between these 17 variants and the GWAS SNPs 
located in IDE or its 100 kb flanking regions. This analysis showed that GWAS SNP 
rs7910977 was in strong linkage disequilibrium with rs6583817 (r2 = 0.996 and D′ = 
1) identified in the current study. The measurements of IDE transcript levels 
described in the “Measurement of IDE mRNA expression” section above included 
174 cerebellar samples obtained at autopsy from subjects that were part of the 
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LOAD GWAS. Consistent with the results reported for rs6583817, rs7910977 
associated strongly with the level of IDE transcript in these 174 samples with a p 
value of 2.7×10−8 that was significant at the genome-wide level [375]. rs7910977 
also showed significant association with LOAD in the 2,099 subjects analyzed in the 
GWAS (p = 0.005). 
 
3.2.10 Association of rs7910977 with Plasma Aβ40 and Aβ42 
rs7910977 was genotyped as part of two genome-wide association studies of the 
Dalmatian island populates of Vis and Korcula, using Illumina genotyping platforms 
[264, 271] Genotypes for this SNP were present (following quality control) for 883 
of the 949 subjects with plasma Aβ measurements in the Vis study and 876 of the 
930 subjects with plasma Aβ measurements in the Korcula study. Study samples 
from Vis and Korcula were collected as described previously (Chapter 2.) and 
plasma levels of the Aß40 and Aß42 peptides were measured, in duplicate, using a 
well established sandwich ELISA system, also described elsewhere (Chapter 2.). 
Antibody pairs BNT77/BC05 were used to measure plasma Aβ42 in both 
populations, the BAN50/BA27 pair was used to measure Aβ40 in the Vis population 
and the BNT77/BA27 pair was used to measure Aβ40 in the Korcula population. 
The ELISA assays were repeated for individuals that had a coefficient of variation 
(CV) of greater than 0.2 for the duplicate measurements; following repetition of 
these measurements the median value was used as the estimate of the plasma Aβ 
value. A third trait was created termed “total Aß” by summing these raw values for 
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Aß40 and Aß42 for each person. This trait was then analysed in the same manner as 
the Aß40 and Aß42 traits individually. 
The R package GenABEL  [318] was used for association analysis as described in 
chapter 2. The results of this analysis for rs7910977 is shown in table 3.3 
 
3.2.11 Functional assessment of IDE variants 
The effect of rs6583817 described in this study was evaluated for functional 
influence on gene expression levels using a dual luciferase reporter assay in Human 
HepG2 hepatocellular carcinoma and Be(2)-C neuroblastoma immortalized cell lines 
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3.3 Results 
3.3.1 Variant Discovery.  
Using the variant discovery approaches outlined in 3.2.3 the Younkin group 
identified 17 common polymorphisms (minor allele frequencies >0.01) likely to 
have functional effects (Figure 3.1). These variants and the haplotypes they form 
were tested for association with IDE mRNA expression using transcript levels 
measured in 194 LOAD cerebella sampled at autopsy from the brain bank at Mayo 
Clinic, Jacksonville. They were also analyzed for genetic association with LOAD in 
a large LOAD case-control series with 3,529 AD cases and 3,441 controls drawn 
from four American and five North European series (data not shown). 
 
3.3.2 Association of IDE SNPs and haplotypes with IDE transcript and LOAD. 
The 17 IDE variants selected in 3.3.1 formed eleven haplotypes with frequencies 
>1% that could be tagged with ten variants. In the combined series, these haplotypes 
were significantly associated with IDE transcript levels (global p = 0.003) and with 
LOAD (global p = 0.02) See Carrasquillo et al [3].  
Assessment of the IDE haplotype tagging SNPs for association with the level of IDE 
transcript identified nominally significant association with four of these SNPs. 
Association was most significant for rs6583817 and rs5786996 with p-values of 
1.5×10−8 and 0.0005 respectively, and linear regression showed that for both of 
these variants the average level of IDE transcript was more than 2-fold higher for 
each minor allele carried (Carrasquillo et al). When these SNPs were later tested for 
association with LOAD, in the combined series, the minor alleles of rs6583817 (p =
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0.03) and v3 (p = 0.02) were also found to be associated with reduced risk of LOAD. 
Notably, neither variant has previously been analyzed for association with LOAD, 
so they are not included in the AlzGene database. The association of these two 
variants with LOAD showed no series-related effects. Results for IDE transcript and 
LOAD association analysis for each of the 10 haplotype tagging SNPs is shown in 
Table 3.2. 
 
3.3.3 Association of IDE variants with plasma Aß concentration 
The involvement of IDE in LOAD pathogenesis was further explored by evaluating 
the effect of IDE on plasma Aß concentrations. This evaluation employed data from 
the studies fully described in Chapter 2. Plasma Aß40, Aß42 and total Aß (Aß40 
+Aß42) were analyzed using 949 individuals from Vis and 930 individuals from 
Korcula (total = 1,879). The analysis took advantage of the strong linkage 
disequilibrium between rs6583817 and rs7910977 (r2 = 0.996 and D′ = 1), since 
rs7910977, but not rs6583817, was included in the genome-wide scan. It showed 
(Table 3.3) that rs7910977 was significantly associated with reduced levels of 
plasma Aß40 in the Vis population (ß ± SE = −0.147±0.06 p = 0.018) and 
suggestively associated with reduced Aβ40 in the Korcula population (ß ± SE =
−0.086±0.08, p = 0.27). Meta-analysis of the two populations showed overall 
significant association with reduced Aß40 (ß ± SE = −0.124±0.05, p = 0.011). 
Analysis of the two populations (Table 3.3) also showed a suggestive association 
between rs7910977 and reduced plasma Aß42 levels (meta-analysis ß ± SE =
−0.07±0.05, p = 0.18). Similarly, analysis of total Aß (Aß40 +Aß42) revealed 
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significant association with reduced levels in the Vis population (ß ± SE =
−0.165±0.06, p = 0.011) and meta-analysis of the two populations showed overall 
significant association with reduced total Aß (ß ± SE = −0.130±0.05, p = 0.009). 
Thus the variant that showed strongest association with elevated IDE expression 
also showed significant association with reduced levels of Aß, a substrate of the 
insulin degrading enzyme that is implicated in LOAD pathogenesis.  
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Figure 3.1 Schematic of the IDE gene. Exons are shown as blue bars, SNPs are shown as red bars, UTR regions are indicated as green 
bars. (A)Ten haplotype tagging SNPs outlined in section 3.3.1 are shown. (B) The location of two variants (rs6583817 & rs7910977) 
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Table 3.2 Association of IDE variants with cerebellar IDE mRNA and LOAD. Variant IDs and rs numbers (dbSNP variant identifier) 
are given for the 10 tagging variants; Chr position indicates relative position to the Human Genome build 36.1. Cons = conservation 
(>70% identity between the human and mouse sequence); MAF =minor allele frequency in controls. Single variant linear analyses vs. IDE 





Association with IDE mRNA   
 
Association with LOAD)  
rs number Position Location Cons MAF 
Minor 
Allele β Fold Δ (95% CI) p AD CTRL OR    (95% CI) p 
V2 (no rs#) 94,202,383 3′ flank 81% 0.02 del −0.03 1.02 (0.60–1.74) 0.94 0 0.02 1.15 (0.88–1.50) 0.3 
rs5786996 94,202,516 3′ flank 74% 0.04 C −1.08 2.12 (1.40–3.21) 0.0005 0 0.04 0.77 (0.62–0.95) 0.02 
rs5786997 94,203,071 3′ flank 88% 0.11 AT ins −0.09 1.07 (0.78–1.45) 0.69 0.1 0.11 0.96 (0.84–1.09) 0.52 
rs4646957 94,219,892 Intron18 71% 0.36 A −0.28 1.22 (1.03–1.43) 0.02 0.4 0.36 0.98 (0.90–1.07) 0.67 
V310 (no rs#) 94,236,972 Exon13 92% 0.08 T −0.22 1.16 (0.68–1.98) 0.58 0 0.02 1.09 (0.80–1.48) 0.6 
rs6583817 94,237,227 Intron12 74% 0.13 A −1.08 2.12 (1.65–2.71) 1.5×10−8 0.1 0.13 0.87 (0.78–0.99) 0.03 
rs17875327 94,264,789 Intron4 85% 0.1 C 0.18 0.88 (0.67–1.15) 0.35 0.1 0.1 0.97 (0.84–1.10) 0.61 
rs4646955 94,284,271 Intron3 76% 0.25 C 0.1 0.93 (0.78–1.12) 0.46 0.3 0.25 1.07 (0.98–1.17) 0.14 
rs17107721 94,288,480 Intron1 71% 0.05 A −0.07 1.05 (0.73–1.50) 0.8 0.1 0.05 0.88 (0.73–1.06) 0.18 
rs11187061 94,295,389 Intron1 70% 0.18 T 0.35 0.78 (0.65–0.94) 0.009 0.2 0.18 1.07 (0.96–1.18) 0.2 
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Table 3.3. Association of rs7910977 with decreased plasma Aβ40 and Aβ42. 




    rs6583817 / rs7910977 
Phenotype N P-value 
Direction of 
association 
      
IDE expression 
(Cerebellum) 
194 1.50E-08 Increase 
In vitro reporter 
assays 
2 cell lines 0.006 Increase 






Table 3.4. Summary of the findings presented in chapter 3 adapted from 
Carrasquillo et al [3]. This result illustrates how a quantitative phenotype, e.g. 
IDE mRNA levels, can show a far stronger association than the disease 
phenotype, e.g. LOAD. Given the evidence presented here we conclude that IDE 
plays a role in LOAD, at least in part through an Aß degradation pathway, 
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3.4 Summary  
In this study, conserved regions of IDE and its 10 kb flanks were examined in 269 
AD cases and 252 were controls, thereby identifying 17 putative functional 
polymorphisms. These variants formed eleven haplotypes that were tagged with ten 
variants. Four of these showed significant association with IDE transcript levels in 
samples from 194 LOAD cerebella. The strongest, rs6583817, which has not 
previously been reported, showed unequivocal association (p = 1.56E-08, fold-
increase = 2.12,); the eleven haplotypes were also significantly associated with 
transcript levels (global p = 0.003, data not shown). Furthermore, using data from 
the genome-wide studies described in Chapter 2, a proxy (rs7910977) for rs6583817 
was found to associate significantly with decreased plasma Aß40 levels (ß =-0.12, p 
= 0.01) and total measured plasma Aß levels ( =0.13, p = 0.01). Finally, rs6583817 
was associated with decreased risk of LOAD in 3,529 AD cases and 3,441 controls. 
(OR = 0.87, p = 0.03), and eleven IDE haplotypes (global p = 0.02) also showed 
significant association. Thus, a previously unreported variant unequivocally 
associated with increased IDE expression was also associated with reduced plasma 
Aß40 and decreased LOAD susceptibility. Genetic association between LOAD and 
IDE has been difficult to replicate. These findings suggest that targeted testing of 
expression SNPs (eSNPs) strongly associated with altered transcript levels in 
autopsy brain samples may be a powerful way to identify genetic associations with 
plasma Aß and with LOAD that would otherwise be difficult to detect. The 
implications of this study are more fully discussed in Chapter 5.
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Increasing age is a major risk factor for development of Alzheimer’s disease. The 
mitochondrial theory of aging highlights the role of mitochondria in the aging 
process [275, 276, 382], making the study of mitochondria and mitochondrial 
dysfunction in age related diseases highly relevant. Furthermore, oxidative stress is 
widely believed to play a role in the aetiology of LOAD which is tightly related to 
mitochondrial function given that oxidative phosphorylation (OXPHOS) is a major 
source of reactive oxygen species (ROS) in the cell. The evidence for a 
mitochondrial role in LOAD was introduced in Chapter 1. As previously mentioned, 
the mitochondrion has its own genome with 37 genes which encode 13 proteins 
essential for the electron transport chain, 2 ribosomal RNA and 22 tRNA genes. The 
remaining proteins essential for the function of the electron transport chain are 
produced by genes in the nuclear genome and are post-translationally transported to 
the mitochondria. Additionally, many genes that produce antioxidant enzymes and 
proteins essential for mitochondrial replication and mtDNA integrity are located in 
the nuclear genome; consequently both the mitochondrial and nuclear genomes play 
an important role in mitochondrial function and mtDNA integrity. Overall there are 
more than 1000 proteins in the human mitochondrial proteome [383]  
The aim of this chapter is to explore approaches for studying mitochondrial genetics 
in Alzheimer’s disease and test these in pilot studies, in order to establish methods 
that can be applied to larger additional studies. This chapter covers three approaches 
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to evaluating the genetics of mitochondria with respect to aging and Alzheimer’s 
disease pathogenesis:  
i) An evaluation of mitochondrial somatic mutational burden as it 
relates to aging; adaptation of a method for measuring this which can 
be applied to DNA isolated from various tissues, such as brain, in 
future studies.  
ii) Investigation of methods for measuring mitochondrial DNA damage 
and development of an adapted method; applying this to the study of 
mitochondrial DNA damage in samples of pathologically confirmed 
normal and diseased brain tissue.  
iii) A candidate gene study is described, using an existing LOAD GWAS 
[3] to evaluate SNPs in known genes that are essential for optimal 
functioning of the mitochondrial electron transport chain.  
Somatic mutational burden: In each cell there exists two copies of each of the 22 
nuclear chromosomes, plus 2 sex chromosomes; however many mitochondria are 
present in each cell and within each there exists many copies of the mitochondrial 
genome, consequently the number of copies of the mitochondrial genome within 
each cell is both variable and greater than the nuclear genome. It has been 
hypothesized that mitochondrial DNA may act as a redox sensor for the cell. 
Accumulation of somatic mutations, over time, due to damage from ROS, that 
individually result in subtle changes to mitochondrial function, may collectively 
constitute a mutational burden, and  result in the triggering of apoptosis [384]. 
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Consequently, the study of somatic mitochondrial mutational burden is of interest to 
the aging and age-related disease fields. Due to the high copy number of the 
mitochondrial genome within each cell, traditional sequencing methods would fail to 
identify rare somatic mutations present in only a small number of individual 
genomes and so to address this issue several groups have made use of variations of a 
PCR-cloning-sequencing method [287, 385-387]. This method involves PCR 
amplification of a target locus in the mitochondrial genome, followed by cloning of 
the PCR products and selection of individual colonies for sequencing, thereby 
allowing the sequencing of PCR products from individual mitochondrial genomes. 
This approach makes it possible to identify variation at the level of a single 
mitochondrial genome from the many in a sample that are isolated from either a 
single cell or tissue.  
The PCR-cloning-sequencing approach was tested using DNA isolated from blood 
samples of 13 control subjects ranging in age from 0 years (umbilical cord blood) to 
97 years to investigate both the need for a high fidelity PCR polymerase and the link 
between mitochondrial mutational burden and aging, in addition to comparing the 
















Mitochondrial DNA damage: In an extension of the somatic mutational burden 
hypothesis for mitochondrial dysfunction in aging and disease, researchers are 
investigating the role of mitochondrial DNA damage. In these studies, molecular 
lesions related to oxidative damage are the primary focus with 8-oxo-G being the 
most commonly measured lesion. However a more general approach to measure 
DNA damage has also been developed that involves the use of quantitative PCR 
(qPCR) where the premise is that molecular lesions, resulting from oxidative 
damage, will reduce the efficiency of the PCR reaction in a way that is measurable. 
This approach has been reported successfully by others previously [386] and has 
been tested and adapted here for measuring mtDNA damage from DNA isolated 
Figure 4.1. An illustration of the PCR-Cloning-Sequencing method for 
evaluating mitochondrial mutational burden. A) Six mitochondrial genomes are 
represented with various somatic mutations illustrated by the letters A,G,C and T. 
B) PCR amplification of this locus generates PCR products with a representative 
proportion of each mutation. C) Ligation of these PCR products into a suitable 
vector generates individual clones with a representative proportion of each 
mutation. D) Transformation and growth of competent cells generates colonies of 
cells with multiple copies of a single PCR product generated from a single 
mitochondrial genome. E) Sequencing of the isolated vectors from individual 
colonies facilitates the identification of mutations isolated from a single 
mitochondrial genome. 
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from brain tissue. Dr. Dennis Dickson at the Mayo clinic in Jacksonville has a large 
collection of Autopsy confirmed AD and non-AD brains. Tissue was collected from 
40 elderly subjects with one of three different disease pathologies (AD, PSP or 
VaD) or no disease pathology. The pathological changes that occur in LOAD are 
more severe in the temporal cortex than in the cerebellum, so DNA was isolated 
from tissue from both regions of the brain to determine if any observations are 
localized to affected tissue in LOAD or are more generalized. The comparison with 
other neurodegenerative diseases, in addition to normal elderly controls, can 
determine if any observations are specific to AD or a more general feature of 
neurodegenerative disease. 
In previous publications, the extent of mtDNA damage has been determined by 
measuring a nuclear locus (nDNA) and one or more mitochondrial loci and 
determining the damage by calculating the ratio of mtDNA to nDNA [386]. This 
approach has been adapted here to allow for differences in the concentration of 
nuclear DNA between samples without this affecting the calculation of mtDNA 
damage. The total [DNA] was measured for each sample using spectrophotometric 
methods and the nuclear contribution to this value was quantified using nuclear 
targeted qPCR assays. An expected concentration of mitochondrial DNA is 
generated by subtracting the quantified nuclear concentration from the concentration 
as determined spectrophotometrically. The damage at each mitochondrial locus of 
interest is then defined as the difference between the expected amount of mtDNA in 
the sample (total minus nDNA) and the observed amount of mtDNA in the sample 
(measured using qPCR). This difference is presented as a proportion of the expected 
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amount of mtDNA and as such represents the proportion of damage. Like the other 
approaches using qPCR methods, this approach does assume that the nuclear locus 
does not exhibit significant DNA damage.  
Additional considerations for mitochondrial genetic studies: When investigating 
mitochondrial DNA there are various considerations that need to be taken into 
account to reduce the effect of experimental artefacts on the results of such studies. 
Primarily, primers targeting mitochondrial loci need to be designed carefully and 
tested where possible to prevent the amplification of nuclear DNA (numts) or 
nuclear pseudogenes. In the studies described in this chapter the oligo’s are tested 
for mitochondrial specificity by including a 0 DNA sample in all experiments. The 
0 sample was isolated from a human osteosarcoma 143b cell line that hade been 
treated to remove all mitochondrial DNA [388]. The generation of PCR product 
from this DNA could only result from nuclear DNA, providing a test for the 
specificity of pairs of primers directed to the mitochondrial genome.  
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Careful consideration of DNA isolation methods is needed to prevent oxidative 
DNA damage during the isolation process. Following tests of various DNA isolation 
methods Helbock et al [389] provide evidence in support of the sodium iodide 
method to prevent in vitro DNA damage. Consequently, for the mitochondrial DNA 
damage study, DNA was isolated from brain tissue using a Kit available from Wako 
Chemicals Inc. This protocol includes the preparation of a crude mitochondrial 
sample, using differential centrifugation, prior to extraction of DNA from the 
sample and the use of sodium iodide for DNA isolation. The advantages of using 
this approach include having a more concentrated mtDNA sample, with expected 
lower levels of nuclear DNA in the sample and reduced in vitro DNA damage.  
The final consideration made in the design of the studies described here was the 
evaluation of the need for a high fidelity PCR polymerase in the initial PCR step of 
Figure 4.2. Mitochondrial 
genome. Figure adapted from 
MITOMAP [1]: mitochondrial 
loci investigated in this chapter 
are highlighted in red boxes. 
The common (Kearns Sayre 
syndrome, KSS) 5kb deletion is 
shown: none of the genes 
selected in this study overlap 
with this deletion reducing the 
risk of the presence of this 
deletion being detected in the 
experimental samples and 
confounding the results. 
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the PCR-cloning-sequencing approach used for studying mitochondrial mutational 
burden. As can be seen from the results of this study described later, the PCR 
polymerases that do not have proof-reading capabilities introduce variation during 
the PCR process that is detected in the sequencing step, so that high fidelity 
polymerases are necessary to improve the reliability of the results for these types of 
studies. 
Nuclear candidate gene association study: A review of the current literature and the 
Alzgene database of Alzheimer’s disease studies, indicates a lack of genetic 
association studies evaluating candidate genes involved in mitochondrial function 
and mtDNA integrity. Since a major focus of this chapter is on mitochondrial DNA 
damage and mutation, a candidate gene study of the nuclear genes that encode the 
mitochondrial DNA polymerase is relevant and SNPs in three genes involved in 
mitochondrial DNA replication (POLG, POLG2 and PEO1) are studied here for 
association with LOAD. Furthermore, there is a wealth of literature reporting 
deficiencies in the mitochondrial electron transport chain in Alzheimer’s patients, 
especially for the cytochrome c oxidase (or complex IV) enzyme [302, 303, 390, 
391]. The three catalytic subunits of this complex are encoded by the mitochondrial 
genome (COX I - COX III), but the remaining 10 structural subunits are encoded by 
genes in the nuclear genome and are excellent candidates for a LOAD association 
study. A literature search did not identify any previously published reports of SNP 
based association studies with these genes and LOAD, so this study would present a 
novel candidate gene study in LOAD. Chandrasekaran.K et al [392] evaluated the 
expression of both mitochondrial and nuclear genes encoding subunits of the 
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OXPHOS pathway and reported changes in expression of COX I, III 
(mitochondrial) and IV (nuclear) in different regions of the brain in AD versus 
control subjects, providing further evidence for a role of both nuclear and 
mitochondrial genes encoding subunits of complex IV of the ETC in LOAD. In this 
chapter, 17 nuclear genes that encode the 10 nuclear subunits of complex IV are 
included in an association study, making use of data from a LOAD GWAS 
published in 2009 [3] that includes 788 AD subjects and 1175 control subjects aged 
between 60 and 80 years of age. The outcome of this study highlights SNPs for 
follow-up analysis in additional LOAD case control series. 
Additional approaches: In addition to the approaches tested in this chapter, there 
have been other methods developed for the study of mitochondrial DNA. It was 
beyond the scope of this chapter to test and evaluate all of these approaches for 
studying mitochondrial genetics but the samples prepared in this study can be used 
for additional studies such as next generation sequencing of the mitochondrial 
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4.2. Methods 
4.2.1. Mutational burden study. 
Study samples: Initially, DNA samples isolated from the white blood cells of three 
control subjects, aged 0 (umbilical cord blood), 59 years and 97 years, that were 
supplied by Dr. Caroline Hayward, were collected for a pilot study of the PCR-
cloning-sequencing method (Figure 4.1.). An additional 10 control subjects were 
later selected to further evaluate the relationship between age and mitochondrial 
mutational burden in blood as a test model. All thirteen subjects and the age groups 
in which they were categorized for analysis are detailed in Table 4.1. The DNA for 
all 13 control subjects described in this study were isolated from blood by others. 
All subjects included in this study gave informed consent. 
Pre-cloning PCR: PCR primers were designed flanking the HVR and ND1 regions 
of the mitochondrial genome; generating PCR products of 999 bps and 1157 bps 
respectively. The primers are detailed in the appendix (Table i). Three polymerases 
were tested for each primer pair: Phusion (Finnzymes, Finland: part# F-540S), 
Platinum (Invitrogen, UK: part# 10966-034) and AmpliTaq Gold (Applied 
biosystems, UK, part# N8080246) According to the manufacturer Phusion has an 
estimated error rate of 4.4 x10-7 nucleotides (nt) in the buffer provided. The 
Platinum and AmpliTaq Gold polymerase manufacturers do not estimate the error 
rates, but published error rates of non-proof reading Taq polymerase enzymes have 
been estimated to be between 2.4 x10-4 and 2.0x10-5 nt [393, 394]. A control DNA 
sample isolated from cells lacking mitochondria (osteosarcoma 143b 0 cell line) 
was also tested with each set of primers in order to evaluate them for mtDNA 
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specificity by checking for the presence of a PCR product on a 2% TBE gel. The 
presence of PCR product using the 0 template would indicate the amplification of 
nuclear pseudogenes. PCR cocktails were prepared using the buffers supplied with 
each of the respective polymerases, and 10mM dNTPs (Qiagen, USA, Cat# 201901) 
was added to the Platinum and Phusion PCR cocktails to a final concentration of 
200µM. The Amplitaq Gold reaction made use of a PCR mastermix which did not 
require the addition of dNTPs. The relevant primers were included in each of the 
three PCR reactions at a concentration of 10µM, with a final concentration of 0.5µM 
in each reaction. Thermocycling conditions for the Phusion polymerase PCR 
reactions were 30 seconds at 98oC, followed by 30 cycles of 10 seconds at 98oC, 30 
seconds at 58oC and 30 seconds at 72oC, with a final extension of 72oC for 8 
minutes. The thermocycling conditions used for the Platinum and Amplitaq Gold 
PCR reactions were 6 minutes at 94oC, followed by 30 cycles of 30 seconds at 94oC, 
30 seconds at 55oC and 60 seconds at 72oC, with a final extension of 72oC for 10 
minutes.  
Cloning: In order to evaluate individual mtDNA molecules for somatic mutations a 
cloning approach was used, similar to that used by others previously [287, 385-387]. 
PCR products generated using Phusion polymerase were incubated with a non-proof 
reading Taq polymerase (Qiagen, USA, part 201203) at 72oC for 10 mins in order to 
add TA ends for cloning into the pGemTeasy vector (Promega, UK, Catalog# 
A1360). PCR products were purified prior to being cloned into the pGemTeasy 
vector using the Qiaquick PCR purification kit spin protocol (Qiagen, USA, 
part#28104), according to the manufacturer’s directions. Ligation of PCR products 
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was carried out according to the manufacturer’s directions with some modifications 
with respect to the PCR product-to-vector ratio which was optimized for each 
reaction. Competent cells (Top10 competent cells, Invitrogen, USA, cat# C4040-03) 
were transformed for each separate sample, according to the manufacturer’s 
instructions, and 200µl, 100µl or 20µl of the transformed cells (with added SOC) 
were plated on three agar plates with 100µg/ml ampicillin (pre-treated with 20µl X-
Gal for blue/white selection), then grown at 37oC overnight in an incubator.  
Post-cloning-PCR: Following bacterial cell growth, 95 individual colonies were 
picked for each of the three DNA samples and types of polymerase (a total of nine 
96 well plates), using sterile techniques, into 15ul sterile water previously aliquoted 
into the wells of a 96 well PCR plate (Greiner bio-one, UK, Cat# 651550). The 
selected colonies were left at room temperature for 1 hour to facilitate cell lysis and 
then used as the template for a PCR using M13 primers, an approach used 
previously by others [387]. The PCR was carried out using a standard PCR reaction 
kit (Qiagen, USA, Cat# 201205) including 10mM dNTPS (Qiagen, USA, Cat# 
201901), after which 5ul of PCR cocktail was added to 15ul of dsH2O into which 
the colonies had been picked. The thermocycling conditions were then as follows: 2 
minutes at 94oC, 35 cycles of 30 seconds at 94oC, 30 seconds at 55oC and 90 
seconds at 72oC, with a final extension of 72oC for 5 minutes. 
Sequencing: PCR products, generated using M13 PCR primers, were purified using 
filter plates, according to the manufacturer’s directions (Millipore, USA, Cat# 
MSNU03010) on a MultiScreen™ Vacuum Manifold 96-well (Millipore, USA, 
Cat# MAVM0960R). The sequencing reaction was prepared using Applied 
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Biosystems BigDye® Terminator v3.1 Cycle Sequencing kits, slightly differently 
from the manufacturer’s directions, based upon data from experiments carried out by 
Stuart McKay at the MRC Human Genetics Unit (data unpublished). The 
sequencing reaction cocktail was prepared as follows; for each reaction, 0.25ul of 
Big Dye Terminator, 1.86ul 5x buffer, 1ul primer (3.2pmol) and 4.89ul dsH2O was 
added to 2ul purified PCR product. Otherwise the protocol was followed as directed 
by the manufacturer. The cycle sequencing was carried out using 96 well PCR plates 
with the following cycle sequencing protocol: 94oC for 10 seconds, 50oC for 5 
seconds, and 60oC for 4 mins, repeated 25 times followed by a 12oC hold. The cycle 
sequencing products were purified using ethanol precipitation, prior to being 
sequenced using a 3100 ABI genetic analyzer in both forward and reverse directions 
using M13 sequencing primers.  The ethanol precipitation was carried out according 
to the directions supplied by Applied Biosystems 3100 genetic analyzer manual 
(chapter 3 page 11). Precipitated PCR products were re-suspended in 10ul Hi-Di 
formamide (Applied Biosystems, Cat# 4311320) and transferred to 384 well plates 
for sequencing (Applied Biosystems, USA, Cat# 4309849). Analysis of sequencing 
data was carried out using the software program Sequencher (Gene Codes, USA). 
Quality control of sequencing analysis: Clones that failed sequencing in one 
direction were removed from analysis in the opposite direction; mutations that were 
detected within the first 25 base pairs of sequence, including the primer sequences of 
HVR and ND1 were not included in the analysis, as frequently the early sequence 
had high background (“noise”) levels. Contigs were constructed within the 
Sequencher program with sequenced samples aligned against the reference mtDNA 
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sequence. The total number of base pairs analyzed was determined by the point at 
which sequence could not be reliably read within a contig; any overlap between 
forward and reverse contigs was subtracted from the total base pair count. All 
mutations were counted once (if they appeared in the overlap of sequence between 
the forward and reverse directions of sequence then it was noted that they were 
confirmed in both directions but only counted once) and the number of clones in 
which they appeared was noted.  
Additional samples: To further investigate the relationship between age and 
mitochondrial mutational burden in lymphocytes, the PCR-cloning-PCR-sequencing 
approach, described in the previous pages, was used for an additional 10 samples to 
investigate the HVR locus only. These samples are described in Table 4.1. The same 
PCR primers were used for the HVR locus as were used previously, and the PCR 
protocol for only the Phusion polymerase (which has proof reading capabilities) was 
used. Since only the Phusion polymerase was used, for the first PCR step, a Zero 
Blunt® PCR cloning kit (Invitrogen, USA, Part# K2700-40) and One Shot®Top10 
competent cells (Invitrogen, USA, cat# C4040-03) were used, instead of adding TA 
ends and cloning in the pGEM-T-easy vector as before. Transformed cells were 
plated onto agar plates with 50ug/ml kanomycin (100ug/ml ampicillin plates were 
used previously). In order to facilitate the sequencing of a larger number of samples, 
47 clones for each locus and subject were selected, (95 clones were selected 
previously). The PCR, cloning and sequencing procedures were identical to those 
described previously except where noted above. 
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Statistical analysis: For each subject, the mitochondrial mutational burden was 
calculated as the number of heteroplasmic mutations identified in 2 or fewer clones 
per subject, divided by the total number of nucleotides evaluated for that subject, 
multiplied by 1.0E06. To evaluate the results of the pilot study, the Kruskal-Wallis 
test was implemented to test the effect of the polymerase across all three samples at 
each of the HVR and ND1 loci; a significant p-value with this test would indicate a 
rejection of the null hypothesis that the polymerase has no effect on the detected 
somatic mutational burden. The Kruskal-Wallis test was also used to evaluate the 
variance of the mutational burden at the HVR locus across the four age groups, in 
the second study.  
 
4.2.2. mtDNA damage study. 
Sample selection: In Alzheimer’s disease, the cerebellum is not usually affected by 
AD pathology, whereas the temporal cortex is frequently affected by AD pathology, 
for this reason, this study focused on brain homogenates generated from frozen brain 
tissue, sampled from the cerebellum and temporal cortex. Tissue was provided by 
Dr. Dennis Dickson, Mayo Clinic, Jacksonville, FL. Subjects were chosen from over 
1,500 subjects for whom frozen brain tissue was available from the temporal cortex 
and cerebellum. Study subjects without mixed pathology were preferred and so 
sample selection was limited: there were 15 elderly normal control subjects and 175 











1  43 Male 
2  46 Female
3 46 Female
A 
 4* 59 Male 
5 60 Male 
6 60 Female
B 
7 80 Male 
8 80 Male 
9 80 Female
C 
10 92 Male 
11 93 Female
 12* 97 Female
D 
 13* 0 Female NA 
 
Table 4.1. Samples and groups used to investigate the role of age on 
mitochondrial mutational burden. # Age indicates the age of the subject at which 
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Among subjects with non-AD pathologies, again without mixed pathology, the most 
frequent were progressive supranuclear palsy (PSP), with 91 elderly subjects and 
vascular dementia (VaD), with 25 elderly subjects. Consequently, PSP and VaD 
subjects were selected as the non-AD dementias in this study. All 40 subjects 
selected for this study are detailed in Table 4.2.  All AD’s had a Braak stage of 6 and 
all other subjects had a Braak stage between 0 and 3 [12]. 
DNA isolation: In a 1998 Helbock et al. [389] described the effects of DNA isolation 
methods on DNA damage, indicating that phenol:chloroform based methods can 
cause in vitro DNA damage and concluding that a DNA isolation method that makes 
use of sodium iodide causes the least in vitro DNA damage during DNA isolation. 
For this reason, the Wako mtDNA Extractor CT Kit (Wako Chemicals Inc., USA, 
Catalog# 291-55301) was chosen to isolate a crude mitochondrial DNA preparation 
from the frozen brain tissue samples. This kit facilitates the isolation of 
mitochondria-enriched DNA samples using the sodium iodide approach so it  should 





















1 AD 76 M   11 Normal 74 M 
2 AD 78 M   12 Normal 76 M 
3 AD 83 M   13 Normal 78 F 
4 AD 86 F   14 Normal 83 M 
5 AD 87 F   15 Normal 86 F 
6 AD 88 F   16 Normal 90 F 
7 AD 88 F   17 Normal 92 M 
8 AD 90 M   18 Normal 93 F 
9 AD 90 F   19 Normal 93 F 
10 AD 97 F   20 Normal 97 F 
Mean   86.3     Mean   86.2   










21 PSP 78 M   31 VaD 74 F 
22 PSP 78 M   32 VaD 76 F 
23 PSP 79 F   33 VaD 83 M 
24 PSP 79 F   34 VaD 84 M 
25 PSP 81 F   35 VaD 87 F 
26 PSP 81 M   36 VaD 87 F 
27 PSP 82 F   37 VaD 89 M 
28 PSP 83 F   38 VaD 90 F 
29 PSP 91 F   39 VaD 90 F 
30 PSP 98 F   40 VaD 91 F 
Mean  83   Mean  85.1  
 
Table 4.2. Subjects chosen for study of mtDNA damage. AD and control subjects 
were matched, based on age at death. Subjects were also matched on ApoE genotype 
within the constraints of the limited number of available subjects. AD: Alzheimer’s 
disease, Normal: No pathology that meets disease phenotype criterion, PSP: 
progressive supranuclear palsy, VaD: vascular dementia. M= Male, F=Female. Age 
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mtDNA was isolated from frozen brain tissue according to the manufacturer’s 
protocol. The concentration of each DNA sample was determined in triplicate 
measurements using the NanoDrop 2000 spectrophotometer (Thermo Scientific, 
USA) in order to get a reliable DNA concentration measurement. 
Selection of loci for qPCR measurement: Applied Biosystems has pre-developed 
assays for quantifying nuclear DNA concentration for two single copy genes: 
RNAseP and -actin. To measure mitochondrial DNA concentration, three loci were 
chosen: 16s, D-loop and COII.  Loci within the common KSS 5kb deletion were not 
selected for this study to avoid confounding arising from the presence of this 
deletion. The 16s locus was a neutral locus with no a priori reason for involvement 
in LOAD. The D-loop locus was of interest due to the fact that it is involved in 
mtDNA replication, while the COII gene was of interest due to the reported 
association between complex IV deficiencies and LOAD. 
Cloning of D-loop, COII and 16s loci for standard curve: In order to perform 
quantitative PCR, a known amount of the target mitochondrial loci (D-loop, COII 
and 16s), was needed as a control for generating a standard curve. This was achieved 
by cloning the target loci from a cord blood DNA sample based upon the 
assumption that the cord blood DNA would exhibit the least baseline DNA damage 
when compared with older samples. 10ng of DNA isolated from cord blood (Table 
4.1) and was PCR amplified using primers for the 16s and D-loop and COII loci 
listed in Table i (appendix). The Phusion proof-reading polymerase and its supplied 
buffer was used for PCR amplification, as described previously. A negative (no 
DNA template) control and 0 DNA sample were also included to check for PCR 
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contamination and amplification of nuclear pseudogenes respectively.  PCR 
products were visualized and separated by running 50µl of PCR product on a 2% 
TBE gel stained with ethidium bromide. The target PCR products were purified 
from the gel using the Qiaquick gel extraction kit (Qiagen, USA, Cat.no 28704) 
according to the manufacturer’s protocols. Purified PCR products were cloned using 
the Zero Blunt® PCR cloning kit (Invitrogen, USA, Part# K2700-40) and One 
Shot®Top10 competent cells (Invitrogen, USA, cat# C4040-03). These cells were 
transformed with the resultant plasmids, plated on agar plates containing kanomycin 
(50ug/ml) and incubated at 37oC overnight. Five colonies were selected and 
transferred into five vials of Luria-Bertani (LB) medium containing 50ug/ml 
kanomycin and grown overnight in a shaking incubator at 37 oC. The plasmids were 
then purified using a QIAprep Spin Miniprep kit (Qiagen, USA, cat.no 27104) 
according to the manufacturer’s instructions. The purified plasmids were sequenced, 
using M13 sequencing primers (Table i), to verify the presence of the correct 
sequence insert. Sequencing was carried out by the sequencing core facility at the 
Mayo Clinic in Rochester Minnesota, USA. 
Quantitative PCR of 16s D-loop and CoxII loci to measure DNA damage: Applied 
Biosystems Taqman assays were designed to quantify each of the three 
mitochondrial loci chosen for investigation of mtDNA damage. The primers and 
probes are listed in Table i. Oligonucleotides for qPCR of the D-loop and COII loci 
were selected from a previous publication by Mambo.E et al. [386], which had 
previously been successful in quantifying these loci. In addition to mitochondrial 
target assays, absolute quantification of the RNAseP nuclear locus (Applied 
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Biosystems cat.no 4316831) and the -actin nuclear locus (cat. no 401846), was 
carried out using pre-designed Taqman assays obtained from Applied Biosystems. 
384 well PCR plates (Applied Biosystems, USA, part# 4309849) were used to 
facilitate the measurement of all samples, standard curve dilutions and negative and 
0 DNA controls, each in triplicate, using one plate per assay. Only the centre wells 
on the plate were used in order to avoid the possibility of evaporation affecting the 
results. PCR cocktails were prepared using 5µl of Taqman Universal PCR master 
mix (Applied Biosystems, USA, cat. no 4364338) in addition to amplification 
primers (forward and reverse, 900nM each), probe (250nM) and dsH2O up to a 
volume of 9µl per reaction, which was added to 1µl of DNA or dsH20 (negative 
controls) plated in each well, so that each reaction had a volume of 10µl. For 
mitochondrial assays, 2ng of DNA was plated in each well and for the RNaseP and 
-actin assays, 10ng of DNA was plated in each well. One µl of standard curve 
dilutions, at the relevant concentrations, were also included on the plate, as 
described below.  
Standard curves: For the RNAseP and -actin assays, a cord blood DNA sample, 
which had been used as the template for cloning of the mitochondrial targets, was 
used to generate a standard curve ranging from 20ng to 0.02ng using a 1:2 serial 
dilution, generating 11 data points on the standard curve, plus an additional point 
with inclusion of the zero template controls. For the mitochondrial assays of 16s, D-
loop and COII loci, the standard curve was based upon the number of target 
molecules generated by the cloned genes in the respective plasmids. The number of 
copies of each target gene can be calculated based upon the ng of DNA purified 
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from the mini-prep for each clone and the known size (in nucleotide base pairs, bps) 
of each plasmid with the target insert. The sample was then diluted to generate a 
standard curve of copy numbers of each gene. Since 2ng of DNA was plated for 
each of the study samples and a maximum contribution of the DNA in the sample is 
100% mitochondrial DNA, assuming each genome is 16kb, the maximum number of 
molecules that can be in 2ng of mtDNA is 1.14E-08 molecules. Consequently the 
upper value of the standard curve was set to 1E-10 molecules and a standard curve 
using a serial dilution of 1:10 was generated, down to an estimated single molecule 
which provided 11 data points on the standard curve. This was done separately for 
each cloned locus (16s, COII and D-loop) and only the relevant clone was present 
on the plate as a standard curve for the target assay. 
Assessment of numts using QPCR: For each of the three mitochondrial absolute 
quantification assays, 0 DNA was included on each plate in triplicate (2ng/well). 
The number of amplified copies of nuclear mitochondrial DNA pseudogenes 
(numts), was measured and quantified using the same approach as for the 
experimental samples. The amplification of numts was compared to the background 
levels, as measured by the negative control, and also in relation to the minimum 
value measured for the experimental samples.  
Data analysis: Applied Biosystems SDS software was used for the initial data 
analysis prior to exporting the data to Microsoft Excel (Seattle, WA) for further 
analysis. The SDS software facilitates the transfer of Ct values (raw data) measured 
for each well on the plate into an estimate of the number of molecules in each well 
using the standard curve. These values are exported to Excel and the median value 
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for each triplicate measure for each sample was determined and subsequently used 
as the estimate of the number of molecules measured (in the case of the 
mitochondrial assays) and of the weight in ng (for the nuclear assays). 
The amount of nuclear DNA (ng) for each sample was determined by the mean of 
the triplicate values (ng) measured by the RNAseP and -actin assays. The 
proportion of DNA for each sample that can be accounted for by nDNA was 
calculated by dividing the average measured value by 20 (20ng of DNA were plated 
in each well for the nuclear assays). This proportion was then used to determine the 
amount of mtDNA that was expected to be measured by the mitochondrial absolute 
quantification assay.  
The amount of measured mtDNA (ng) was determined for each locus individually 
by dividing the number of measured molecules by 5.51E+07: this value is the 
number of full length mtDNA molecules per ng of DNA and was determined as 
follows: 
- The number of base pairs per full length mitochondrial genome molecule is 
16,568, which is equal to a molecular weight of 10.9 million Daltons. 
- A 1E+06 Dalton molecule is equal to 1ug/pmole, so one mtDNA molecule is 
equal to 10.9 ug/pmole. 
- 1 pmole has 6.02E+11 molecules: consequently 10.9ug of mtDNA is equal 
to 6.02E+11 molecules and 1ng of mtDNA is equal to 5.51E+07 molecules. 
The level of damage for each mitochondrial locus and sample was then determined 
as the difference between the expected amount of mtDNA and the observed amount 
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of mtDNA, divided by the expected amount of mtDNA (translated to a percentage 
by multiplying this value by 100). For example: If the average amount of nDNA that 
was measured for sample A containing 20 ng total DNA was 5ng, then it is expected 
that 15ng (or 75%) of the DNA in this sample is mtDNA. Therefore, when 2 ng of 
DNA is plated in a well, it is expected that 1.5ng of this is mtDNA. If the assay at 
the 16s locus measures 0.5ng of mtDNA, then the difference between what was 
expected and what was observed is 1ng, which is equal to a 67% reduction in 
mtDNA compared with the expectation. 
In order to determine if there was variation in the measured damage at each of the 
three mitochondrial loci, Microsoft Excel was used to calculate the correlation co-
efficient (r) between the damage values at each of the three pairs of loci for each set 
of 10 samples categorized by tissue and disease diagnosis. 
To examine if any of the three mitochondrial loci tended to have more DNA damage 
than others, Friedman’s test was implemented, using StatsDirect software 
(StatsDirect Ltd, England) for each set of 10 samples, categorized by tissue and 
disease. 
In order to determine if any of the groups exhibited a significantly different level of 
DNA damage from that of the ‘normal’ samples,  the ratio between the mean DNA 
damage value for each group of 10 samples with a neurodegenerative disease (AD, 
PSP and VaD) and the mean DNA damage value for the 10 samples with no 
neurodegenerative disease (Normal) was calculated and the Mann-Whitney 
(Wilcoxon rank sum) test was implemented in StatsDirect to determine the 
significance of the difference between these mean values.  
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Likewise, to evaluate the relative levels of DNA damage between the cerebellum 
and temporal cortex of each set of 10 samples at each mitochondrial locus, the ratio 
between the mean values were calculated and the Wilcoxon signed rank test was 
implemented in StatsDirect to determine the significance of these differences.  
 
4.2.3. Candidate gene study 
Subjects: The subjects in this study comprise LOAD cases and elderly controls aged 
between 60 and 80 years (at the time of diagnosis, examination or death) that were 
included in stage one of a LOAD GWAS published in 2009 [3].  The subjects are 
sampled from three North American Caucasian case control series comprised of 
clinical subjects from Jacksonville Florida (Mayo-JS series, Neill Graff-Radford 
MD), Rochester Minnesota (Mayo-RS series, Ron Peterson MD) and an autopsy 
series collected at the Mayo Clinic Jacksonville (Mayo-AUT series, Dennis Dickson 
MD). The study was approved by the relevant institutional review board and all 
participants gave informed consent. The subjects from the stage one GWAS 
described by Carrasquillo.M.M et al. that were included in this candidate gene study 
are summarized in Table 4.3. Samples were collected and DNA was isolated as 







  - 180 - 
 









JS 334 307 387 (60%) 73.6 321 (50%) 
RS 234 656 466 (52%) 73.9 340 (38%) 
AUT 220 212 186 (43%) 72.6 187 (43%) 
All 788 1175 1039 (53%) 73.6 888 (45%) 
 
Table 4.3. Demographic data for the case control series used in the 
candidate gene association study using logistic regression analysis. * Age 
at diagnosis. 
 
Genotyping and Quality control: The subjects in this study were genotyped for over 
300,000 SNPs using the HumanHap300-Duo Genotyping BeadChip (Illumina), 
genotypes were scored using Illumina’s bead studio 2.0 software and following 
removal of SNPs with a call rate < 90% additional quality control measures were 
executed using PLINK [381] as described by Carrasquillo.M.M et al.. 
Selection of genes and SNPs: The KEGG website [313-315], which provides 
pathway data, was used to identify the nuclear genes that are responsible for 
encoding subunits of the electron transport chain complexes. Genes known to 
encode subunits of complex IV (cytochrome c oxidase) were selected for this study 
which led to the selection of 17 genes. Pseudogenes were not included in the study, 
however genes that encode variant isoforms of a subunit do exist and were included. 
Genes known to form part of the mitochondrial polymerase complex were also 
selected: POLG, POLG2 and PEO1. In total, 20 genes were selected for the 
candidate gene study: the base pair positions based upon Build 36.1 of the human 
genome were identified using the UCSC genome browser [395] and for each locus 
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the gene and 20kb 5’ and 3’ of the gene was designated as the target area for SNP 
association. Details of each locus and base pair boundaries are detailed in Table 4.4. 
Statistical methods: Carrasquillo M.M et al. previously generated lgen, map and fam 
files using PLINK software (provided by Dr Shaun Purcell at 
http://pngu.mgh.harvard.edu/purcell/plink/), which were used for candidate gene 
analysis in this study. A covariate file was generated with Sex, Age (at 
diagnosis/exam: JS and RS series, or death: AUT series) and a dichotomous variable 
for presence/absence of an APOE 4 allele, to facilitate the inclusion of these 
covariates in the analysis. PLINK was used to execute logistic regression analysis, 
using an additive model with covariates; SNPs were specified using the --from-bp 
and --to-bp PLINK functions to select SNPs for analysis at each of the loci outlined 













  - 182 - 
 















COX4I1 16 84,392,312 84,398,075 5,763 84,372,312 84,418,075 
COX4I2 20 29,689,352 29,696,461 7,109 29,669,352 29,716,461 
COX5A 15 72,999,670 73,017,548 17,878 72,979,670 73,037,548 
COX5B 2 97,628,953 97,631,089 2,136 97,608,953 97,651,089 
COX6A1 12 119,360,287 119,362,912 2,625 119,340,287 119,382,912
COX6A2 16 31,346,556 31,347,222 666 31,326,556 31,367,222 
COX6B1 19 40,830,995 40,841,524 10,529 40,810,995 40,861,524 
COX6B2 19 60,556,777 60,558,275 1,498 60,536,777 60,578,275 
COX6C 8 100,959,548 100,975,071 15,523 100,939,548 100,995,071
COX7A1 19 41,333,664 41,335,611 1,947 41,313,664 41,355,611 
COX7A2 6 76,004,223 76,010,245 6,022 75,984,223 76,030,245 
COX7A2L 2 42,431,148 42,449,654 18,506 42,411,148 42,469,654 
COX7B X 77,041,617 77,047,537 5,920 77,021,617 77,067,537 
COX7B2 4 46,431,721 46,431,966 245 46,411,721 46,451,966 
COX7C 5 85,949,540 85,952,339 2,799 85,929,540 85,972,339 
COX8A 11 63,498,655 63,500,591 1,936 63,478,655 63,520,591 
COX8C 14 92,883,290 92,884,453 1,163 92,863,290 92,904,453 
POLG 15 87,660,540 87,679,030 18,490 87,640,540 87,699,030 
POLG2 17 59,912,173 59,923,631 11,458 59,892,173 59,943,631 
PEO1 10 102,737,302 102,744,148 6,846 102,717,302 102,764,148
 
 
Table 4.4. Twenty candidate genes selected for this study. gene positions and 
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4.3. Results 
4.3.1 Mitochondrial mutational burden. 
Amplification of nuclear pseudogenes: The PCR reactions were all tested for 
amplification of nuclear pseudogenes using a DNA sample from human 
osteosarcoma 143b cell line which contained no mitochondria: 0. Visualization of 
PCR products for this sample on a 2% TBE ethidium bromide (EtBr) gel was 
negative in almost all reactions tested, with the exception of the PCR for the ND1 
locus using the Phusion polymerase; under these PCR conditions a faint visible band 
was occasionally present. However this band had a higher molecular weight than the 
target PCR product and was not visible in the lanes on the gels with PCR product 
generated from the experimental samples. It is likely that this non-specific PCR 
product is not amplified to high levels in the experimental samples as the copy 
number of mitochondrial target is much higher than any nuclear target. Also, if a 
nuclear numt had been amplified this would have been detected in the sequencing 
analysis since any clones containing this product would be longer than the target 
sequence and would not align to the target sequence correctly. Therefore it is 
unlikely that clones of this nuclear pseudogene(s) were included in the sequencing 
analysis. 
Low fidelity PCR polymerases artificially inflate the detected mitochondrial 
mutational burden: For the initial pilot study, testing three PCR polymerases at two 
mitochondrial loci, the average number of clones with good quality sequence 
evaluated using the Phusion polymerase was 81, using Platinum Taq polymerase 
was 76 and using AmpliTaq Gold polymerase was 73. The average number of base 
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pairs that were analysed per clone for Phusion polymerase was 530bps, Platinum 
Taq polymerase was 516 bps and Amplitaq Gold was 449 bps. Investigation of the 
mitochondrial mutational burden at both the HVR and ND1 loci revealed increased 
mutational burden rates when lower fidelity PCR polymerases were used in the 
initial PCR step (Table 4.5) which is probably due to a higher number of PCR errors 
generated when using a lower fidelity enzyme. Analysis of the total mutational 
burden across the three PCR polymerases using the Kruskal-Wallis test resulted in a 
p-value of 0.027 at the HVR locus and 0.051 at the ND1 locus, indicating that the 
measured mutational burden for at least one of the polymerases is significantly 
different from at least one of the others. Together this data implies that the PCR 
products generated by the Phusion polymerase were of the best quality for sequence 
analysis, both in terms of the amount of good quality sequence and low PCR error 
rate. Consequently, the Phusion polymerase was used in the subsequent study for 
evaluating the relationship between mitochondrial mutational burden at the HVR 
locus and age in DNA isolated from blood. 
The HVR locus has a higher mutational burden than the ND1 locus:  Comparison of 
the total mutational burden at the HVR and ND1 loci of the mitochondrial (mt) 
genome using Phusion polymerase (Table 4.5) confirmed that the hyper-variable 
region of the mt genome has a higher frequency of mutation than the ND1 locus. 
The total mutational burden at the HVR locus is 135 variants/1x106 bp, whilst the 
ND1 mean mutational burden is 38 variants/1x106bp, revealing a 3.6 fold difference 
in total mutational burden at these loci. The HVR is the only non-coding region of 
the mitochondrial genome and appears to have a higher tolerance for somatic 
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mutation and hence is called the hyper-variable region. This result is a good positive 
control for the approach used and indicates that this method is able to detect 
expected differences in mutational burden. 
Mitochondrial mutational burden of the HVR and ND1 loci varies with age. Since it 
has been demonstrated that the Phusion polymerase has the lowest PCR error rate, 
the data generated from this polymerase was used for a crude evaluation of the 
relationship between mitochondrial mutational burden and age in these samples. The 
results summarized in Table 4.5 show that the mutational burden at both loci is 
greatest in the 59 yr old sample: 203 variants/1x106 bp at the HVR locus and 79.6 
variants/1x106 bp at the ND1 locus. The lowest mutational burden at the HVR locus 
was observed in the cord blood sample with 44.1 variants/1x106 bp, whilst the 97 yr 
old sample exhibited the lowest mutational burden at the ND1 locus with 
11.7variants /1x106 bp. The data imply that mutational burden may vary with aging 
or from one subject to another; the analysis of additional samples is needed to make 
more reliable conclusions about any association between aging and mitochondrial 
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burden   
x 106 
Phusion 4 90,618 44.10 15 73,942 203.00 15 87,113 172.00 34 251,673 135.00 
Platinum 30 66,930 448.00 25 74,045 338.00 23 54,120 425.00 78 195,095 400.00 HVR 
Gold 29 60,390 480.00 32 47,310 676.00 33 60,701 544.00 94 168,401 558.00 
Phusion 2 89,724 22.30 7 87,989 79.60 1 85,756 11.70 10 263,469 38.00 
Platinum 33 91,437 361.00 26 98,430 264.00 35 86,062 407.00 94 275,929 341.00 ND1 
Gold 41 93,889 437.00 28 74,189 377.00 23 57,117 403.00 92 225,195 409.00 
 
Table 4.5. Mitochondrial mutational burden of ND1 and HVR loci for three subjects measured using three DNA polymerases. The 
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The relationship between age and mitochondrial mutational burden at the HVR 
locus is unclear: To further evaluate the affect of age on mt mutational burden at the 
HVR locus, 10 additional control samples were selected and grouped with the 59yr 
old and 97 yr old samples used previously, to generate 4 age groups with 3 samples 
in each group (Table 4.1). Using the PCR-Cloning method used for the previous 
analysis, the HVR locus was investigated for mt mutational burden in these 12 
samples. Table 4.6 shows that the highest mutational burden was observed in the 80-
year-old age group: median 88.23 variants/1x106 bp and the lowest mutational 
burden was observed in the 60 year-old age group with a median of 22.41 
variants/1x106 bp. There is a lot of within group variability of mutational burden 
where the range of the 3 values is greater than the median value in all groups except 
for the most elderly group of subjects aged over 90 years. The results do not indicate 
a direct relationship between age and mutational burden at the HVR locus and 
analysis of variability in mutational burden across the four groups yielded a Kruskal-
Wallis p-value of 0.092, indicating a trend for at least one of the groups to yield a 
larger number of somatic mutations than at least one other group, however this 
observation does not achieve significance at p <0.05. 
The number of clones analysed per sample may not have a linear correlation with 
the number of somatic mutations identified: Two study samples were included in 
both the pilot study and the follow-up study (Sample 4, aged 59 years and sample 
12, aged 97 years: Table. 4.1). The number of clones selected in the first study was 
95, of which 48 were randomly selected for inclusion in the second study. The 
number of somatic variants identified in the first study was 15 for each of the 
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samples. However, in the second study, only 1 and 2 somatic variants were 
identified for the 59 and 97 year old samples respectively. If there was a linear 
relationship between the number of clones analysed and the number of variants 
identified then it would be expected that between 7 and 8 somatic variants would 
have been identified in the analysis of 48 clones. It is therefore possible that this 
study is underpowered to detect differences between age groups based upon picking 
only 48 colonies per sample: many more colonies may need to be selected for the 
study.  
 











1 43 2 29,293 68.28   
2 46 4 39,207 102.02 68.28 72.27 A 
3 46 1 33,614 29.75   
4 59 1 44,619 22.41   
5 60 0 39,369 0.00 22.41 49.0 B 
6 60 2 40,817 49.00   
7 80 7 43,714 160.13   
8 80 4 45,335 88.23 88.23 109.98 C 
9 80 2 39,878 50.15   
10 92 1 35,326 28.31   
11 93 2 41,076 48.69 47.46 20.38 D 
12 97 2 42,143 47.46   
 
Table 4.6. Mitochondrial mutational burden for 12 control samples Samples 
have a range of ages, organized into 4 age groups.  
 
 
Overall, these data indicate that the mutational burden at the HVR locus in 
leukocytes is highly variable and may not be influenced by age. Further analysis 
with a much larger number of samples, colonies and age groups is likely to be 
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necessary to establish reliable estimates of the mean mutational burden for each age 
category. This type of study would likely be cost prohibitive using the approach 
described here due to the large numbers of colonies that would need to be 
sequenced, so alternative sequencing methods would need to be explored. For these 
reasons, the measurement of mitochondrial mutational burden was not explored 
further in DNA isolated from the target tissue: the human brain.  
An alternative to measuring mutational burden is to measure DNA damage: various 
published approaches were considered and a method using absolute quantification 
by qPCR was selected for evaluation in mtDNA isolated from brain tissue, the 
results of this study are described over the next pages.  
 
4.3.2 Mitochondrial DNA damage. 
The nDNA (RNaseP and -actin) measurements are highly correlated: Two nuclear 
loci were measured in each sample to improve the reliability of nuclear 
quantification. The measured values were highly correlated: cerebellum:  r = 0.986, 
p <0.001, temporal cortex: r = 0.991, p <0.001, indicating that the two sets of values 
are very similar. The mean of the nuclear quantification estimates for each of the 
two nuclear loci was used to determine the proportion of nDNA in each sample. 
The mtDNA measures are highly correlated: Three mitochondrial loci were 
measured using qPCR and pair wise comparisons were made to determine if there 
was any correlation between the measured values in the two sets of tissues studied. 
Remarkably, there was a high level of correlation between each pair of measures 
taken for each set of 10 samples based upon diagnosis and tissue (cerebellum and 
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temporal cortex), the correlation coefficients are detailed in Table 4.7. This result 
indicates that, in these subjects, there is not a large difference in the relative levels of 
measurable mtDNA at different areas of the mt genome.  
  
Assay: mean mtDNA damage 
(rank)^ 
 Correlation coefficient* 












































































0.067  0.95 0.98 0.99 
 
Table 4.7 Absolute levels of mtDNA damage measured for 4 pathological 
categories and regions of the brain for three mitochondrial loci.^ Friedmans test, 
the average rank for each assay is presented in parenthesis.  *Correlation in Excel 
 
An evaluation of the DNA damage data indicates that, overall, the 16s locus 
consistently exhibited the greatest levels of damage across all disease groups. The 
average mtDNA damage at the 16s locus is estimated at 92.82%, whereas the 
corresponding values for COII and D-loop assays are 83.32% and 80.92% 
respectively. The results of Friedman’s test indicate that the absolute levels of 
damage at one or more of the loci is significantly different from at least one other 
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locus in all except the VaD subjects, where the p-value was >0.05 in both 
cerebellum and temporal cortex (Table 4.7). This is probably due to the fact that the 
levels of damage in the VaD tissue are very high at all three mitochondrial loci and 
so the difference between the damage values at the different loci is much smaller. So 
despite the levels of mtDNA at each locus being significantly correlated in pair wise 
comparisons, the assessment of mtDNA damage at each of these loci indicates a 
significant difference overall between the different mitochondrial loci. 
 
There are significant, tissue-specific, differences between the extent of mtDNA 
damage in diseased versus normal tissue: To determine the difference between the 
extent of mtDNA damage in each of the disease groups against the damage 
occurring as a part of “normal” aging, the ratio of the mean mtDNA damage values 
between each disease group and the normal group was calculated for each locus and 
tissue type. The results are summarized in Table 4.8. The significance of the 
observed  differences was determined using the Wilcoxon rank sum test (a.k.a. 
Mann-Whitney test) where a p-value of less than 0.05 led to the rejection of the null 
hypothesis that there is no difference between the mtDNA damage values in 
diseased versus normal tissue.  
VaD: The data presented in Table 4.8 indicates that VaD subjects have significantly 
higher levels of mtDNA damage than normal subjects; this difference is more 
pronounced in the cerebellum (ratio 1.12-1.40) than in the temporal cortex (ratio 
1.02-1.05) at all three loci examined. 
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PSP: The data in Table 4.8 indicates that subjects with PSP have lower levels of 
mtDNA damage than that found in normal aging. This difference is significant in the 
temporal cortex but not in the cerebellum indicating some tissue selectivity of 
mtDNA damage in PSP subjects. 
AD: The data in Table 4.8 shows that whilst the ratio of mtDNA damage in AD vs 
normals indicates a trend for an increase in damage in AD’s, this difference is not 
significant in either the cerebellum or temporal cortex tissues (p-value 0.211 to 
0.968). This result is consistent across all three mitochondrial loci and implies that 
mitochondrial DNA damage, at the loci examined, may not play a significant role in 
LOAD disease aetiology. This is in contrasts to the data for the PSP and VaD 
subjects and implies that mitochondrial DNA damage is complicit in other 
neurodegenerative pathologies. 
 
The temporal cortex exhibits greater levels of mtDNA damage than the cerebellum 
in normal aging and disease: To determine the difference between the levels of 
mtDNA damage measured in the temporal cortex vs the cerebellum, the ratio of 
mean mtDNA damage values between the two tissues was determined for each 
phenotype and mtDNA locus. The Wilcoxan signed-rank test was used to determine 
if differences observed were significant, where a p-value of < 0.05 led to the 
rejection of the null hypothesis that there is no difference between the mDNA 
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  mtDNA damage (%)*  Vs Normal$ Vs Cer#  Tissue 
/ 





Normal 80.13 93.68 87.13 0.05  - - - -  
AD 81.09 99.90 90.20 0.08  1.04 0.430 - -  




VaD 91.06 99.95 97.78 0.03  1.12 3E-04 - -  
Normal 91.34 99.73 95.21 0.03  - - 1.09 0.002  
AD 93.40 99.76 96.09 0.03  1.01 0.675 1.07 0.084  
PSP 86.50 96.38 91.72 0.04  0.96 0.038 1.06 0.010  
Tx    
 
16s 
VaD 92.38 99.77 97.53 0.02  1.02 0.038 1.00 0.695  
Normal 53.10 87.42 70.25 0.16  - - - -  
AD 56.69 99.95 78.95 0.20  1.12 0.211 - -  




VaD 78.84 99.97 95.49 0.07  1.36 4E-04 - -  
Normal 85.51 99.69 91.14 0.05  - - 1.30 0.002  
AD 84.92 99.80 92.30 0.06  1.01 0.968 1.17 0.037  




VaD 85.35 99.84 95.81 0.04  1.05 0.017 1.00 0.922  
Normal 54.58 82.99 67.82 0.14  - - - -  
AD 47.88 99.95 74.86 0.26  1.10 0.569 - -  
PSP 31.06 77.57 57.90 0.28  0.85 0.211 - -  
Cer     
 
D-loop 
VaD 74.66 99.93 94.65 0.09  1.40 3E-04 - -  
Normal 75.72 99.76 88.55 0.08  - - 1.31 0.002  
AD 83.06 99.84 90.89 0.07  1.03 0.624 1.21 0.084  
PSP 57.42 93.02 77.54 0.16  0.88 0.038 1.34 0.006  
Tx      
 
D-loop 
VaD 78.95 99.82 95.16 0.06  1.07 0.017 1.01 1.000  
 
Table 4.8. Evaluation of mtDNA damage measured at three loci for samples 
obtained from two regions of the brain and 4 pathological groups.  * damage 
determined as described in section 4.2.22. $ Ratio of damage between the target 
group and the normal group within the same tissue for each assay, p-value 
determined using the Wilcoxon rank sum test (a.k.a. Mann-Whitney test), # Ratio of 
damage between the temporal cortex and the cerebellum for each sat of 10 paired 
values, p-value calculated using Wilcoxon signed-ranks test. 
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VaD: The analysis did not identify significant differences between the levels of 
mtDNA damage in the temporal cortex and cerebellum at any of the three 
mitochondrial loci. The ratio of damage in temporal cortex versus cerebllum tissue 
was 1.00 – 1.01 for VaD subjects. This indicates that the difference in the magnitude 
of the ratio when VaD were compared to normal subjects in the previous analysis is 
likely due to differences between the cerebellum and temporal cortex in the normals 
and not in the VaD subjects. 
Normal: The results presented in Table 4.8 indicate that at all three mitochondrial 
loci there is selective mtDNA damage in the temporal cortex, when compared with 
the cerebellum, during normal aging. The ratio of DNA damage was smallest at the 
16s locus (1.09) but was highly significant across all three loci (p-value = 0.002 at 
all loci). 
PSP: The ratios presented in Table 4.8 indicate that the levels of mtDNA damage 
are significantly greater in the temporal cortex than in the cerebellum at all three 
mitochondrial loci for PSP subjects (p-values 0.010 to 0.006). Similar to the normal 
subjects, this difference was least at the 16s locus, but still remained significant 
(ratio 1.06, p-value = 0.010) 
AD: The AD subjects exhibited a positive ratio (>1.00) of mtDNA damage between 
the temporal cortex and the cerebellum at all three mitochondrial loci, that was 
significant at the COII locus (p-value=0.037) but did not achieve statistical 
significance at the 16s or D-loop loci (p-value=0.084). This finding was unique to 
the AD subjects, as the other three disease groups investigated exhibited either 
significant or no significant difference, between the temporal cortex and cerebellum 
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at all three mitochondrial loci. This indicates that for AD subjects, the COII locus 
might be more sensitive to DNA damage in affected tissues than other mitochondrial 
loci, when compared to a baseline level of damage in unaffected LOAD tissue. This 
finding is of relevance to the study of LOAD, given the associations reported 
between cytochrome c oxidase activity and LOAD. 
Sensitive quantification of numts using Rho0 DNA:  The amplification of nuclear 
mtDNA pseudogenes, also referred to as numts, may be a potential confounder to 
any study of mitochondrial DNA that involves PCR amplification. Throughout this 
chapter the use of 0 DNA, isolated from cells with no mitochondria, has been 
described as a way to assess the tendency of any PCR reaction to amplify numts. 
Previously, this has been assessed by running PCR products on an ethidium bromide 
gel and visualizing the presence or absence of visible bands from the 0 sample. 
However, the use of qPCR is a more sensitive method for identifying amplification 
of numts. For each of the three qPCR mitochondrial assays, a 0 DNA sample was 
also measured, in triplicate, on the same plate as the experimental samples, to 
determine if the assays were measuring mtDNA specifically or if there was a 
contribution from nDNA pseudogenes or numts. The 0 DNA was plated at a 
spectrophotometrically measured concentration of 2ng/ul on the plates used to assay 
the mitochondrial loci. For all three of the mitochondrial assays, the 0 sample had 
increased levels of product amplification when compared with the no template 
control; however this varied depending on the assay.  
The ratio between the number of copies of amplified “genes” measured in the 0 
sample when compared with the no template control (background) is a good 
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measure of how specific the qPCR assay is to mitochondrial DNA sequence. For the 
D-loop assay this ratio was small, at 1.08, however the 16s and CoxII assays had 
much higher ratios of 117 and 10 respectively. Given this data, it is highly unlikely 
that the D-loop assay targets any nuclear locus; however both the 16s and CoxII 
assays do show evidence of amplification of numts.  
For the CoxII assay, the measured amount of [mtDNA] for the 0 sample was greater 
than 1 of the experimental samples, but was 255 times smaller than the average 
measured value for all of the experimental samples. For the 16s assay, the measured 
amount of [mtDNA] for the 0 sample was greater than 2 of the experimental 
samples. The data at the 16s and CoII loci may therefore be confounded by 
amplification of numts. Consequently the results from the D-loop may be the only 
mitochondrial assay that can be reliably interpreted. However, it is important to 
consider the fact that the 0 sample is 100% nuclear DNA and so the data from this 
sample is an extreme test of the tendency for PCR primers to amplify nuclear DNA. 
In an experimental sample the majority of the DNA is mitochondrial DNA and there 
are many more copies of the mitochondrial genome per ng of DNA than copies of 
the nuclear genome per ng of DNA, resulting in the number of mitochondrial targets 
far outweighing the number of nuclear targets. This likely reduces the impact of 
amplification of numts on the data obtained from the experimental samples. 
Furthermore the CoII and 16s data are highly correlated with the D-loop data; this 
would be unlikely to occur if the CoII and 16s assays were significantly influenced 
by the amplification of numts. Consequently, whilst the results obtained from the 
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CoII and 16s assays need to be interpreted with caution; it is likely that the reduced 
specificity of these assays may not have a significant impact on the data. 
For the analyses described on the previous pages, the p-values have not been 
corrected for multiple tests; however given the small sample size and the small 
number of tests for each hypothesis tested, a p-value of <0.05 was used to reject the 
null hypothesis. This may lead to a small number of false-positive findings, however 
the goal of this study is to function as a pilot study and any conclusions drawn from 
the study would need to be confirmed in additional studies with a larger number of 
samples. 
 
4.3.3 Candidate gene study. 
Previously in the chapter, the effect of damage to the mitochondrial genome was 
specifically investigated using techniques to measure both mutational burden and 
DNA damage. The mitochondria however, rely on both nuclear and mitochondrial 
genes to function and so the study of nuclear genes that encode key proteins 
necessary for mitochondrial function is also of relevance in the study of 
mitochondrial genetics in dementia aetiology. To this end, the mitochondrial 
polymerase (polymerase ) which functions in mitochondrial DNA replication and 
integrity is an excellent candidate gene, as it is encoded by nuclear genes and is the 
only know DNA polymerase to function in the mitochondria. Three genes: POLG, 
POLG2 and PEO1 form some of the necessary components for mitochondrial DNA 
replication and so were investigated for association with LOAD using data from a 
published LOAD GWAS [3]. 
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The results of this study (Table 4.9) identify two SNPs which show nominally 
significant association with LOAD: rs2351000 at the POLG locus which shows 
significantly increased risk for LOAD associated with the minor allele (OR: 1.36, p-
value=0.006) and rs1991401 at the POLG2 locus which shows significantly 
decreased risk for LOAD associated with the minor allele (OR=0.84, p-
value=0.025). Neither of these SNPs maintain significance after a Bonferroni 
correction for multiple tests, however an association study of 18 SNPs would be 
expected to yield less than 1 SNP with a p-value < 0.05 by chance and so both of 
these SNPs warrant further study in additional LOAD case control series. This is 
considered stage 1 of a candidate gene study where follow-up in additional samples 
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Gene Chr SNP Position N OR L95 U95 
P-
value 
POLG 15 rs1138465 87,659,606 1940 0.91 0.79 1.05 0.181 
  rs976072 87,660,381 1959 0.91 0.79 1.05 0.203 
  rs3087374 87,660,998 1960 1.07 0.84 1.36 0.576 
  rs2351000 87,670,737 1922 1.36 1.09 1.69 0.006 
  rs2247233 87,676,941 1957 1.01 0.88 1.16 0.905 
  rs7495044 87,685,173 1956 1.05 0.91 1.21 0.503 
    rs176641 87,691,186 1947 1.12 0.96 1.29 0.146 
POLG2 17 rs1427463 59,923,044 1962 1.15 0.91 1.45 0.253 
  rs1140409 59,927,132 1956 0.89 0.67 1.17 0.395 
  rs2075552 59,931,215 1947 1.21 0.92 1.58 0.179 
    rs1991401 59,932,897 1952 0.84 0.73 0.98 0.025 
 10 rs2863095 102,736,493 1935 0.92 0.78 1.09 0.341 
PEO1  rs3740484 102,737,353 1931 0.96 0.83 1.11 0.575 
  rs3740487 102,740,773 1938 0.91 0.77 1.08 0.301 
  rs701836 102,757,107 1894 0.97 0.83 1.15 0.742 
  rs807023 102,760,072 1907 1.15 0.94 1.40 0.175 
  rs11190790 102,762,273 1949 1.01 0.87 1.16 0.939 
    rs807019 102,762,830 1948 1.06 0.88 1.28 0.558 
 
 
Table 4.9. Single SNP association at three loci. rs2351000 is located in intron 
nine of the PolG gene, 110bp 3’ of exon nine. rs1991401 is located in the 5’UTR 
of the gene DDX5 and is 9 kb 3’ of the POLG2 gene. 
 
 
Decreased activity of cytochrome c oxidase (complex IV of the mitochondrial 
electron transport chain) has been frequently associated with Alzheimer’s disease.  
The catalytic subunits of this multi-subunit enzyme are encoded by three genes in 
the mitochondrial genome (COXI-III), with the remainder of the subunits being 
encoded by the nuclear genome. Whilst the nuclear encoded subunits do not have 
catalytic functions, they undoubtedly play an important role in the function of this 
enzyme. Consequently, the investigation of SNPs at the nuclear genes that encode 
COX subunits is of relevance to the study of this enzyme in LOAD aetiology. The 
human cyctochrome c oxidase enzyme is composed of 13 subunits, 10 of which are 
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nuclear encoded; however tissue specific isoforms exist for several of the subunits. 
In this study, genes for all 10 subunits and 7 non-pseudogene isoforms were 
included in the analysis. SNPs in these genes were evaluated using data available 
from the Carrasquillo et al. LOAD GWAS [3]. 
The result of this study identified four SNPs with nominally significant association 
with LOAD in two of the seventeen genes investigated. None of the SNPs would 
maintain significance after a Bonferroni correction for multiple tests, however like 
the previous study there are a greater number of SNPs with a p-value of less than 
0.05 than would be expected by chance (3.5 by chance, 4 observed), consequently 
all four SNPs warrant further investigation in additional LOAD case control series.  
One of the genes, COX7B did not have any SNPs within the defined locus and is 
therefore not included in the results tables. 
Two genes: COX6B1 and COX6B2, which encode two isoforms of the COX6B 
subunit, harbor SNPs at their respective loci that show nominally significant 
associations with LOAD, whereas none of the other loci harbor SNPs with 
significant association (Table 4.10).  Both of the COX6B genes are found to be 
expressed in brain and both are also located on chromosome 19, approximately 10 
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Gene Chr SNP  Position  N OR L95 U95 P-value
COX4I1 16 rs6120890 29,671,320 1958 1.03 0.86 1.24 0.752 
    rs6060403 29,684,765 1939 1.07 0.91 1.25 0.418 
    rs11907253 29,696,334 1959 1.09 0.85 1.4 0.493 
    rs6060454 29,696,565 1954 1.11 0.87 1.42 0.415 
    rs6058259 29,698,963 1947 1 0.86 1.16 0.981 
    rs6060531 29,707,019 1952 1.11 0.86 1.42 0.436 
    rs6060563 29,712,464 1961 0.9 0.77 1.05 0.164 
COX4I2 20 rs11860152 84,374,825 1961 0.78 0.57 1.06 0.115 
    rs896253 84,377,703 1961 0.76 0.56 1.05 0.096 
    rs10514609 84,381,574 1957 0.91 0.77 1.07 0.245 
    rs2291658 84,384,374 1908 1.02 0.85 1.24 0.81 
    rs2733954 84,393,757 1959 0.92 0.77 1.1 0.376 
    rs11117407 84,411,812 1959 0.95 0.8 1.14 0.591 
COX5A 15 rs4886636 72,983,229 1913 1.06 0.92 1.22 0.408 
    rs11856413 72,986,945 1956 1.07 0.93 1.23 0.341 
    rs11072518 73,021,663 1954 1.05 0.91 1.22 0.489 
COX5B 2 rs1800649 97,631,289 1957 1.05 0.91 1.21 0.512 
    rs11692435 97,641,786 1946 1.09 0.85 1.39 0.498 
COX6A1 12 rs206965 119,340,715 1958 1.06 0.89 1.26 0.505 
    rs4766961 119,346,915 1950 0.98 0.84 1.13 0.74 
    rs2235218 119,373,002 1945 0.97 0.84 1.13 0.721 
    rs7137953 119,379,068 1958 1.15 0.96 1.37 0.14 
COX6A2 16 rs8056122 31,335,179 1957 0.96 0.83 1.1 0.536 
    rs4889657 31,344,433 1955 0.84 0.62 1.13 0.238 
    rs8045738 31,357,499 1957 1.03 0.89 1.19 0.703 
COX6B1 19 rs2285415 40,814,281 1943 0.97 0.85 1.12 0.697 
    rs2285419 40,826,048 1948 0.78 0.61 1 0.046 
    rs3761093 40,828,289 1928 1.14 0.99 1.32 0.078 
    rs7254601 40,839,155 1953 1.12 0.95 1.31 0.176 
    rs4806187 40,841,601 1948 0.99 0.86 1.14 0.894 
    rs2267584 40,848,428 1944 0.98 0.84 1.14 0.786 
    rs2267586 40,851,208 1958 0.72 0.57 0.91 0.006 
COX6B2 19 rs7253685 60,537,198 1952 0.9 0.78 1.04 0.141 
    rs1870073 60,542,081 1957 0.97 0.83 1.13 0.662 
    rs2384685 60,546,125 1880 0.93 0.81 1.07 0.306 
    rs1058511 60,551,251 1930 1.04 0.91 1.2 0.545 
    rs11084396 60,557,339 1949 1.07 0.93 1.22 0.346 
    rs12976922 60,562,163 1954 1.06 0.87 1.3 0.567 
    rs897799 60,564,003 1937 1.15 0.97 1.37 0.119 
    rs1126757 60,571,684 1947 0.83 0.73 0.96 0.01 









Gene Chr SNP  Position  N OR L95 U95 P-value 
COX6C 8 rs4626565 100,959,718 1953 1.14 0.95 1.37 0.154 
    rs4518636 100,973,453 1961 1.13 0.94 1.36 0.182 
    rs13277184 100,986,128 1945 1.12 0.92 1.36 0.249 
    rs10098852 100,990,479 1948 0.98 0.84 1.13 0.735 
    rs7837596 100,993,447 1958 1.13 0.91 1.4 0.264 
COX7A1 19 rs10410162 41,319,630 1958 1.11 0.96 1.28 0.162 
    rs7255180 41,332,159 1948 1 0.74 1.35 0.992 
    rs753420 41,335,535 1931 0.87 0.75 1.02 0.09 
    rs11665903 41,344,025 1939 1 0.86 1.17 1 
COX7A2L 2 rs6716767 42,412,760 1960 0.91 0.73 1.13 0.38 
    rs1981664 42,430,674 1942 0.97 0.84 1.12 0.675 
    rs10206058 42,437,171 1952 1.03 0.89 1.19 0.693 
    rs1992258 42,453,421 1870 1.08 0.94 1.25 0.28 
    rs7592036 42,457,613 1949 1.1 0.95 1.28 0.189 
    rs12615383 42,464,055 1961 0.99 0.81 1.2 0.909 
    rs7560797 42,469,000 1959 0.98 0.84 1.14 0.751 
COX7A2 6 rs431116 76,003,142 1961 1.16 0.89 1.52 0.27 
    rs654428 76,020,471 1953 1.12 0.81 1.54 0.506 
COX7B2 4 rs9790574 46,429,658 1962 0.98 0.82 1.17 0.799 
    rs4395475 46,437,406 1944 1 0.81 1.24 0.999 
COX7C 5 rs4605828 85,942,414 1938 1.11 0.97 1.27 0.136 
    rs10805837 85,947,410 1959 1.05 0.91 1.21 0.497 
    rs17476583 85,958,923 1957 0.98 0.84 1.14 0.803 
COX8A 11 rs11231657 63,482,185 1953 0.99 0.7 1.4 0.942 
    rs481835 63,482,358 1945 0.95 0.83 1.1 0.513 
    rs480211 63,496,015 1955 0.98 0.86 1.13 0.823 
    rs483340 63,511,562 1936 1 0.87 1.15 0.968 
COX8C 14 rs7155081 92,869,929 1957 1.15 0.91 1.46 0.229 
    rs6575325 92,898,942 1962 1.04 0.89 1.21 0.631 
 
Table 4.10. Single SNP association for 16 genes that encode components of the 
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COX6B1: Two SNPs at the COX6B1 locus showed nominally significant 
association with LOAD in the case control series tested. rs2285419 (OR 0.78, p-
value 0.046) is a coding SNP (Asp to Asn substitution) in exon 5 of the gene ETV2 
and is 19kb 5’ of the COX6B1 gene. The second SNP, rs2267586 (OR 0.72, p-value 
0.006) is also a coding SNP (Ser to Thr substitution) in exon 2 of the gene UPK1A 
and is 10kb 3’ of the COX6B1 gene. 
COX6B2: Two SNPs at the COX6B2 locus showed nominally significant 
association with LOAD in the case control series tested. rs1126757 (OR 0.83, p-
value 0.010) is a synonymous SNP (Ala to Ala) in exon 3 of the gene IL11 and is 
14kb 3’ of the COX6B2 gene. The second SNP, rs6509940 is 18kb 3’ of the 
COX6B2 gene. 
It is worth noting that the SNP’s identified at the two COX6B loci do not lie within 
either gene but are greater than 10kb away and in some cases within the exons of 
flanking genes. It is therefore unlikely that the SNPs identified in this study have a 
functional influence on the COX6B genes, but are rather in LD with functional 
variants. It is also possible that these findings are influenced by APOE or are in LD 
with each other, however given the physical distance in bps between the two loci 
(~2 million bps) and with APOE (~1 million bps), this is unlikely.  
The data presented here implies a possible role for the COX6B subunit of complex 
IV of the ETC in LOAD aetiology, further investigation of these loci with additional 
SNPs and case control series is needed to both confirm the detected association and 
to fine map the loci. 
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4.4. Summary 
The role of mitochondrial genetics in the aetiology of LOAD has yet to be 
elucidated. In this chapter, various approaches for evaluating the role of 
mitochondrial genetics are tested and preliminary data highlights the need for 
additional studies in this area of research. 
It is beyond the scope of this chapter to explore all possible hypotheses for the role 
of mitochondrial genetics in LOAD and so two aspects of mitochondrial genetics 
were focused on: i. Methods for evaluating mitochondrial mutational burden and 
DNA damage and ii. A candidate gene study of nuclear genes selected for their 
importance in mitochondrial function. 
Initially a pilot test was designed to study mitochondrial mutational burden using a 
previously reported method (based upon PCR, cloning and sequencing), using DNA 
isolated from blood leukocytes in order to evaluate: (A) the effectiveness of the 
method for detecting differences in mitochondrial mutational burden and (B) the 
validity of using DNA isolated from circulating cells, which are readily available 
and can be collected from live subjects, to detect changes in mitochondrial burden 
with age. If age related changes can be detected in DNA isolated from blood then it 
may be possible to explore the use of mitochondrial mutational burden as a clinical 
diagnostic tool for evaluating risk for age related diseases.  
The pilot study confirmed the need for a high fidelity polymerase when employing 
PCR based methods for studying mitochondrial mutational burden. The PCR error 
rate of the highest fidelity polymerase used in this study, Phusion, is reported to be 
4.4E-07 errors/bp (or 0.44 errors per million base pairs), much lower than the 
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detected mutational burden for the samples investigated using this polymerase 
(average 57 mutations per million base pairs). This indicates that, after correction for 
PCR errors, the loci investigated in this study have a detectable level of mutational 
burden. The analysis of mitochondrial mutational burden in additional samples, 
representing an expanded range of ages was unable to establish a clear relationship 
between age and mitochondrial mutational burden. Whilst the approach tested here 
for measuring mitochondrial mutational burden was validated in the tissue tested 
(white blood cells), the approach appears to require a large number of clones to be 
sequenced and is therefore financially prohibitive for the study of many samples.  
In addition to evaluating methods for detecting changes to mitochondrial DNA in 
blood, this chapter also explored mitochondrial DNA changes in the brain. Given 
that the previous mutational burden approach identified the need for a large number 
of samples and clones to be sequenced, an alternative method was employed for 
exploring mtDNA isolated from brain tissue. Here the use of qPCR was tested as a 
means of measuring mtDNA damage by adapting an approach used previously by 
others [386]. The results of the DNA damage study indicate that mtDNA damage 
may be a major player in VaD aetiology, but the data is far less convincing for 
Alzheimer’s disease. In AD samples, the most interesting result was a significant 
increase in mtDNA damage at the COII locus in the temporal cortex compared with 
the cerebellum. This comparison was not significant for the other two loci tested, 
although the trend was in the same direction. This might indicate that COII is more 
damaged in the temporal cortex in particular compared with other mitochondrial 
loci.  
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The final study described in this chapter was a candidate gene study for association 
between Alzheimer disease and genetic variants in nuclear genes that encode 
proteins essential for optimal functioning of the mitochondria. Genes were selected 
that are involved in mitochondrial DNA replication since defects in this process may 
lead to increased incorporation of somatic mutations and decreased mtDNA 
integrity. Additionally, nuclear genes that encode subunits of the terminal enzyme 
complex of the electron transport chain, complex IV, were also investigated, since 
deficiencies in this enzyme have previously been linked to LOAD.  
Nominally significant association was identified for six SNPs included in the study, 
which is more than would be expected by chance alone; indicating that at least one 
of these SNPs is a true positive association. However the p-values for these six 
SNPs would not survive a bonferonni correction for multiple tests. This data 
cautiously indicates a possible role for genes involved in mtDNA replication and in 
particular subunit COX6B of the cytochrome c oxidase, with LOAD. Genotyping of 
the SNPs identified in the study reported here warrant further analysis in additional 
samples to better characterise these associations. 
Overall this chapter outlines a novel approach for evaluating the mtDNA damage 
and provides insight into the extent of mtDNA damage that can be measured from 
frozen brain tissue samples of different neurodegenerative diseases. This study also 
identifies two novel candidate LOAD loci proximal to the genes COX6B1 and 
COX6B2 that could possibly impact risk for LOAD through alterations in 
cytochrome c oxidase function. 
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Chapter 5. Discussion 
The majority of Alzheimer’s disease occurs in subjects older than age 65. The 
importance of research into the molecular mechanisms and causes underlying AD is 
of increasing significance given the reality of an aging society.  
This thesis presents novel approaches for studying the genetic and biological risk 
factors that can influence AD and provides a useful resource for future studies. The 
key findings for each of the studies presented in this thesis were summarised at the 
end of the results chapters (2, 3 and 4). These findings are briefly reviewed over the 
next pages and discussed in the context of their impact on AD research.  
 
5.1 AD facts and figures.  
As a means to following and documenting the impact of AD on society, Alzheimer’s 
disease international (ADI) publishes an annual report summarising the global costs 
of this disease and the number of people it affects. The most recent numbers indicate 
that AD costs $604 billion globally and there are over 30 million people in the world 
currently suffering from AD, with approximately 4.6 million new cases every year 
[396]. These numbers are expected to increase dramatically over the next 50 years 
due to improvements in health care and aging populations [397, 398].  
Currently the only medications available to AD sufferers treat only the symptoms 
and have very little impact on delaying the disease course significantly. There is no 
cure for AD and there are also no tests (beyond genetic tests for EOFAD) that can 
predict who will develop the disease prior to the emergence of symptoms. Strategies 
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are needed for both identifying who is at risk of developing this disease and for 
producing advances in preventative or curative therapies.  
 
5.2 Overview of AD therapeutics 
Current drug therapies: Currently there are five drugs approved in the U.S. for 
treating the symptoms associated with AD. All of these therapies have been shown 
in clinical studies to improve the cognitive function of AD patients receiving the 
drug compared with placebo. The molecular pathways targeted by these drug 
therapies are: (i) inhibition of acetylcholine breakdown via the administration of 
acetylcholinesterase inhibitors (Donepezil, ENA-713, Galantamine and Tacrine) or 
(ii) attenuation of NMDA receptor function (Memantine). Acetylcholine (ACh) is a 
neurotransmitter that is directly involved in learning and memory functions in the 
brain. Inhibition of the metabolism of ACh as a treatment for memory dysfunction 
was explored largely based on the cholinergic hypothesis for neurodegenerative 
diseases such as AD [399]. In the case of memantine the evidence suggests that 
therapeutic activity is largely due to the protection of vulnerable cholinergic neurons 
that may be susceptible to glutamate induced excitotoxicty [400, 401]. 
Whilst these treatments are fairly well tolerated and provide some relief to AD 
patients and carers, none of these drugs delay the progression of the disease and the 
number of patients that respond positively is relatively low [402-405]. 
Consequently, alternative therapies are critical for preventing an AD epidemic. 
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Drug trials and future prospects: An improved understanding of the molecular 
mechanisms that contribute towards the development of AD is critical for the 
development of therapeutic strategies.  
With the identification of A as a major pathological peptide in AD and the 
subsequent advent of the ‘amyloid hypothesis’, a large effort was made towards 
targeting A production and removal for therapeutic purposes. Among the targets 
explored were inhibition of  and -secretase, responsible for the generation of A 
through APP cleavage, and A immunization therapy was also investigated [406-
408]. Unfortunately, many of the drug targets explored have experienced specificity 
and toxicity problems. More recent approaches aim to avoid these problems, for 
example multiple A immunization therapies are in clinical trials using a shorter 
epitope of the A peptide [409, 410]. An updated account of current drug trials is 
maintained on the Alzforum website (www.alzforum.org).  
 
In this thesis, several approaches for identifying novel drug targets through 
improved understanding of the genetics of AD were explored. The results of these 
studies are discussed below. 
 
5.3 Genome-wide screen for novel genes that influence plasma A
The aim of this project was to identify loci that influence plasma concentrations of 
Aa key peptide in AD pathogenesis.. The rationale behind this was that genes that 
influence plasma A are also likely to influence risk for LOAD. The loci identified 
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in this study represent excellent candidate genes for study in LOAD that may have 
otherwise gone undetected using a LOAD case-control association study approach. 
This rationale has previously been validated in extended LOAD pedigrees with 
extreme plasma A concentrations [62]. In the present study, the populations 
investigated did not have extreme plasma A levels and were not selected based 
upon probands with LOAD, but were instead sampled from two isolated 
populations.  
Isolated populations provide several advantages for identifying genetic loci that 
contribute to phenotypes of interest. For example, extended linkage disequilibrium 
in these populations can decrease the number of marker genotypes required to 
adequately “tag” the common haplotypes and can increase the power of the study for 
detecting association. Furthermore, genetic and environmental heterogeneity is far 
better controlled in studies of population isolates. However, the study of isolated 
populations can introduce added complexity requiring the use of statistical 
approaches that take into account the higher degree of relatedness in the population 
[411-413]. This was addressed in this study by using the statistical tools available in 
the R package GenABEL. Most significantly, the tools in this package (mmscore) 
allow the user to account for the relatedness of study subjects based upon genetic 
data (IBD) rather than relying on reported relationships. Reported genealogical data 
can be a potential confounder in these types of studies where inaccuracies in the 
reporting can occur. Also, when studying a population isolate there may be a higher 
degree of unknown relatedness (2nd cousins etc) than in outbred populations.  
Chapter 5 . 
- 211 - 
The tendency of a set of samples in an analysis to have inflated test statistics due to 
confounders such as population substructure is represented by a scaling factor 
termed lambda (). The populations studied in Chapter 2 consist of subjects many of 
whom are distantly related and a smaller proportion of who are either closely related 
or unrelated. Consequently the mmscore test (FASTA) was used to execute the 
GWAS analysis, since it can incorporate the estimated genetic relationships between 
all pairs of subjects in the study (gkin). The model estimate of  was generated for 
each analysis and did not indicate any inflation in the test statistic. On the contrary, 
for some of the A traits, the value of  indicated deflation of the test statistic. This 
effect can similarly be viewed by looking at quantile-quantile (Q-Q) plots that 
represent the distribution of p-values obtained in the analysis against the null 
hypothesis of no association beyond what would be expected by chance (Chapter2).  
 
Linkage analysis:  Initially, plasma A levels were assessed in the population of Vis 
using a linkage analysis approach. In order to implement this analysis, a subset of 
the population was divided into pedigrees of varying size and complexity and IBD 
estimates were generated using MCMC methods implemented in the program Loki. 
Linkage analysis was then implemented in Linux using the software package 
SOLAR [321] which makes use of a variance component approach for quantitative 
trait analysis. This approach may result in reduced power to detect loci that 
influence the trait variance since many sampled individuals were not members of 
known pedigrees, whereas all individuals are used with the genomic relationships 
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approach implemented in GenABEL, where pedigrees are not defined [414] and the 
many unknown relationships in the population are accounted for.  
The analysis implemented in SOLAR did identify plasma A40 as a significantly 
heritable trait in the Vis population with an estimated heritability of 16.5%. This is 
substantially lower than the estimated heritability observed for this trait by Ertekin-
Taner et al. in extended LOAD pedigrees (~41%) [62, 204]. It is not surprising 
however that the heritability of this trait is lower in this population when compared 
with the findings of Ertekin-Taner et al. In that study, the authors selected pedigrees 
in which LOAD was known to segregate and which were identified via a proband 
with A levels in the highest extreme. The study samples were therefore preselected 
for an increased probability of plasma A heritability. Furthermore, in the Ertekin-
Taner et al. study, plasma A42 exhibited even higher heritability (~56%) [62, 204] 
than A40. This is in contrast with the findings in the Vis study where significant 
heritability was not found for the plasma A42 trait using the analysis methods 
implemented in SOLAR (h2 = 4.6%). The A42 peptide is generally considered to 
be more pathogenic than its shorter sibling; consequently in a study of LOAD 
pedigrees it is more likely to show significant heritability. However, in the context 
of the Vis population, the absence of significant heritability for this trait may 
indicate that plasma A42 is not under significant genetic control. The implications 
of this are apparent in the genome-wide linkage analysis where analysis of A42 did 
not identify any suggestive or significant linkage peaks. In contrast, analysis of the 
plasma A40 trait did identify some interesting loci with suggestive linkage in the 
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Vis population. Encouragingly, three of these overlapped almost perfectly with three 
of eleven (27%) significant or suggestive linkage peaks reported in a meta-analysis 
of LOAD linkage studies [2]. This convergence, whilst not statistically significant, is 
noteworthy nonetheless and indicates that there may be one or more LOAD genes 
within these three linkage peaks that may function through an A pathogenic 
pathway. 
Overall the study did not identify any linkage peaks with a LOD score of greater 
than 3.3 (the generally accepted threshold for significance in a genome-wide linkage 
scan) for any of the four traits evaluated (A40, A42, A40:42 ratio and 
A40+42). The study had been designed to make use of techniques that increase 
power and reduce the effects of genetic heterogeneity, so the lack of significant 
linkage was disappointing. However the results of this study did confirm that plasma 
A is a heritable quantitative trait even in populations that are not enriched for 
samples with cognitive deficits.  
Given the convergent evidence for some of the suggestive linkage peaks reported in 
this study with LOAD linkage peaks, the question of which genes lay within the 
support interval of these peaks was investigated and these genes were then checked 
to see if any had been reported as candidate genes in LOAD association studies. To 
this end, a web resource within the Alzforum website called ‘AlzGene’ was used 
[31], which is reviewed in Chapter 1. Table 2.5 summarises, as others have done 
previously [2], the AlzGene genes within the support interval of the suggestive 
linkage peaks and it was encouraging to note that three AlzGene ‘top genes’ 
Chapter 5 . 
- 214 - 
(queried in March 2010) lay within the support intervals for three of the peaks. 
These are described in more detail below: 
LOC645503 is a pseudogene which is described on the NCBI website as “similar to 
SUMO-1 activating enzyme subunit 2”. SUMO is an acronym for ‘Small Ubiquitin-
like Modifier’, SUMO proteins bind to other proteins, as a form of post-translational 
modification, in a process commonly referred to as SUMOylation. There are many 
published studies reporting the effects of SUMOylation on different peptides. In 
2007 Scheschonka et al. reviewed the role SUMOylation in relation to neuronal 
processes [415]. In 2003, Li et al. [416] published a report on the effect of 
SUMOylation on the production of A and this has since been confirmed by others 
[417], implicating a role for SUMOylation in Alzheimer’s disease pathogenesis. 
However, since LOC645503 is a pseudogene, the convergent identification of 
association of this locus with AD and suggestive linkage with plasma Amay be 
indicative of a false positive. 
CHRNB2: Variants in this gene have frequently been linked to epilepsy disorders 
and nicotine addiction [418-420] and there have also been several reports of 
association (both negative and positive) with Alzheimer’s disease [232, 237, 324, 
421-423]. For many years, the loss of cholinergic neurons has been studied in 
Alzheimer’s disease and many of the drugs currently used to help manage the 
symptoms of AD function by inhibiting acetylcholinesterase (AChE) and thus 
increasing cholinergic activity (see above). The identification of a suggestive 
linkage peak to plasma A located proximal to the CHRNB2 locus is of interest 
given the possible functional interactions, which warrants additional investigation. 
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NEDD9: The NEDD9 protein has a SH3 domain and two SH2 domains and is 
believed play a role in focal adhesions, cell signalling and possibly apoptosis [424]. 
NEDD9 is expressed in brain, as its name ‘neural precursor cell expressed, 
developmentally down-regulated 9’ suggests, and several studies implicate a role for 
NEDD9 in development and differentiation of neuronal progenitor cells [425, 426]. 
A literature search did not reveal any evidence to suggest a direct role for NEDD9 in 
modulating A or related proteins and so it is likely that if variation at the NEDD9 
locus is responsible for linkage to A its effect may be via an indirect or as yet 
undiscovered pathway or interaction. 
Given that most genes reported in the AlzGene database have either been 
investigated for association with AD because of some a priori reason for candidacy, 
or have been identified through reports of a positive association with AD, these 
genes must represent interesting candidates and so their presence under a linkage 
peak for plasma A40, albeit suggestive, will be of interest to the field. As 
illustrated in Table 2.5, the greatest abundance of ‘AlzGene genes’ was found within 
the linkage peaks on chromosome 1 that overlap with the LOAD linkage peaks 
reported by Butler et al. [2]. This may be due to the fact that many candidate gene 
studies have focused on reported LOAD linkage regions, so there is an over-
representation of Alzgene genes at these loci.  
  
GWAS analyses: Following on from the linkage analysis of plasma A in subjects 
from Vis, a GWAS involving over 300,000 SNPs was carried out. An additional 
population from the neighbouring island of Korcula was also studied. The study 
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subjects recruited from the island of Korcula were likewise genotyped for over 
300,000 SNPs and plasma concentrations of A40 (Ax-40) and A42 (Ax-42) in 
these subjects was also measured. The measurement of plasma A40 in this second 
population differed from the measurement of this peptide in Vis due to a change in 
the capture antibody used and this should be considered when interpreting the 
results, in particular the meta-analysis of the A40 trait. Encouragingly however, 
there was consistency between the two populations in the relationship between age 
and the plasma A40 trait, indicating that the use of the different capture antibodies 
may not have affected the results significantly. The relationship between age and the 
A40 trait has previously been reported by others [427]. Replication of this 
observation indicates that plasma A40 has similar properties in these populations to 
those observed in outbred populations. This increases the possibility that the 
findings in this study will be of relevance to large urban populations.  
The results of GWAS analysis of the four plasma A traits in each population, both 
independently and using meta-analysis, whilst interesting and worthy of further 
investigation, was disappointing since it did not identify any SNPs that achieved 
genome-wide significant association following traditional Bonferroni correction for 
multiple tests. Several interesting loci were identified that met the criteria for 
suggestive association and these will be good candidates for follow-up in LOAD 
case control studies. This data will also be useful in helping to identify LOAD genes 
by careful and thoughtful use of the database of results in convergent analysis with 
other disease related traits, as illustrated in Chapter 3. It should also be noted that the 
use of the Bonferroni correction for multiple tests is likely to be over-conservative 
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for GWAS studies where the assumption of independent tests is violated by the 
presence of LD between SNPs. This is especially true for GWAS studies of isolated 
populations where larger regions of LD exist [269] within the genome and the 
probability of one or more markers being in LD is increased. For these reasons, the 
SNPs identified with the lowest p-values for each study are highlighted in Tables 
2.7, 2.9 and 2.10. The SNPs and loci listed in these Tables should therefore be 
considered as providing strong evidence that they influence circulating A 
concentrations and should be further evaluated  in LOAD.  
Finally, association was not observed with the APOE locus in either the Vis or 
Korcula studies and suggestive linkage to chromosome 19 was also not observed for 
Vis. This is not surprising given that previous studies evaluating plasma A levels 
have also not identified significant association of this trait with the APOE E4 
genotype [204, 427]. This is in contrast to the highly significant association of this 
locus in AD samples. These observations collectively suggest that the molecular 
mechanisms by which the ApoE protein influences risk for AD do not act by 
influencing circulating levels of A.  
 
Trait heritability: When a polygenic model for the Vis traits was applied in SOLAR, 
significant heritability for the plasma A40 trait was identified in this population 
(p=0.041) (Table 2.4). However, when a polygenic model was applied for the Vis 
traits in GenABEL, significant heritability was not found for any of the traits in this 
population, although the plasma A42 trait revealed the strongest (but non-
significant) evidence for heritability (Table 2.6). There are multiple possible 
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explanations for the differences observed in estimating heritability of these traits 
using the two methods. Primarily, it should be noted that the evidence for 
heritability of these traits in the Vis population is marginally significant using both 
SOLAR and GenABEL analyses. The sample subset used in each of the analyses 
was also slightly different, due to genotyping and quality control measures 
eliminating different subjects from each analysis. Furthermore, the kinship estimates 
used in the two methods are considerably different. In the SOLAR method, kinships 
reported by questionnaire and interviews were used to determine pedigrees. While 
this method is widely used, it is known to have problems, such as incorrect or 
incomplete reporting of familial relationships. The method used in the GenABEL 
analysis was not based on reported relationships but instead on a genomic kinship 
matrix which uses IBD values calculated between each pair of individuals based 
upon the genotypes gathered in the GWAS [318]. This method does have the 
problem of being subject to genotyping errors, but provided that careful and 
thorough genotype quality control is undertaken it is likely to produce an accurate 
portrayal of relationships in the population.  
The analysis of plasma A in subjects from the Korcula population revealed that, in 
this population, plasma A concentrations are a heritable quantitative trait. All four 
plasma A traits were significantly heritable, with plasma A40 having a heritability 
of 46.7%, similar to the heritability values identified by Ertekin-Taner et al. in 
LOAD pedigrees [204]. [204]. In the Korcula study, plasma Aß40 was studied using 
BNT-77 as the capture antibody instead of BAN-50, which was used for capture in 
the Vis study. As discussed in Chapter 2, this change was made to improve the 
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accuracy of measurement by reducing non-specific signals (interference). The 
improved accuracy of measurement may well account for the increased heritability 
observed in the Korcula population, but the possibility that the two populations have 
a true difference in the heritability of plasma Aß40 cannot be eliminated. In this 
regard, it is important to emphasize that plasma Aß42, which showed significant 
heritability in the Korcula but not in the Vis population, was measured identically in 
the two populations. 
Given the relatively high heritability of the plasma A traits in the Korcula 
populations, it was surprising that none of the SNPs achieved genome-wide 
significant association in this population. This may indicate that the study was 
underpowered or that the trait is under the influence of multiple genetic factors with 
individually small effect sizes. A similar result has been observed with other traits 
such as height [428] and Alzheimer’s disease [242, 243] where, despite high 
heritability (up to 80%), very large numbers of samples are needed to identify SNPs 
that achieve genome-wide significant association.  
One of the aims of conducting a meta-analysis of the results from these two studies 
was to increase the sample size and thus increase the power to detect association. 
Unfortunately, the meta-analysis also failed to identify SNPs that achieved genome-
wide significance and, with the exception of the plasma A42 trait, all of the top hits 
for this analysis were in intergenic regions. The identification of SNPs with low p-
values in intergenic regions for GWAS is a not an uncommon finding [429, 430]. 
Although these regions do not harbour genes there are many other alternative 
explanations for a true association at these loci. These include but are not limited to 
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the possibility that the SNP may lie within or be proximal to a microRNA sequence 
or may influence a long range enhancer or suppressor. It may also be possible that 
the meta-analysis was affected by the fact that Vis showed weak evidence of 
heritability, that the A40 species measured in the two studies was slightly different, 
or that the study was still underpowered and needed additional samples or 
populations. Alternatively, it is possible that multiple SNPs in each population 
influence levels of plasma A and that there is little similarity in the SNPs that play 
such a role between the populations. The study of these traits in additional 
populations will be important to both increase the power to detect association 
through meta-analysis and to provide replication of SNPs identified in this study. 
Furthermore, the results of this study can provide a useful tool for phenotype 
convergence analysis. To this effect, the top 19 SNPs identified in chapter two were 
evaluated for association with LOAD using the results from a published LOAD 
GWAS. This analysis did not identify any SNPs with a p-value less than 0.0026 
which is the threshold for significance after correction for 19 tests. However there 
were 6 SNPs with an uncorrected p-value of less than 0.1, where by chance we 
would expect to see only 2.  
These results in one respect indicate that the approach used in chapter 2 to identify 
likely LOAD candidate loci through identification of plasma A loci may not have 
been successful. However it is known from various studies in the literature and is 
exampled in chapter 3 of this thesis, that a larger sample size is often required for 
identification of significant association with LOAD than for LOAD 
endophenotypes. Consequently the results presented in table 2.11 are inconclusive 
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given the relatively small sample size of the LOAD series (~730 cases and 1100 
controls) and the SNP’s will likely need to be genotyped in additional case-control 
samples. This is especially pertinent for the 6 SNPs identified in table 2.11 with a p-
value of less than 0.1, as this over representation of SNPs with smaller p-values may 
be indicative of a true, but modest, association with LOAD for one or more of these 
SNPs that warrants further investigation.  
In addition, three recently identified LOAD loci (CLU, CR1 and PICALM), were 
investigated for association with plasma A levels in the Vis and Korcula 
populations. The results did not indicate strong evidence for a role of these loci in 
influencing plasma A levels in these populations where only the SNP proximal to 
the PICALM gene (rs3851179) showed nominally significant association with 
plasma A. This finding is similar to that which has been observed for APOE where 
both this study and others have failed to identify association for this established 
LOAD risk locus with plasma A levels. This result indicates that there may be 
molecular pathways that can influence risk for LOAD that do not have a direct 
impact on A measured in plasma, the implications of which are open to 
interpretation and should be the subjects of further study. 
 
5.4 Phenotypic convergence analysis identifies significant association of a 
functional IDE SNP.  
As mentioned previously (Chapter 1), A degrading enzymes are of particular 
importance in the study of Alzheimer’s disease. Improved knowledge of enzymes 
that actively degrade A has substantial implications for development of therapeutic 
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targeting strategies. The findings presented in Chapter 3 provide compelling 
evidence that variants at the IDE locus can influence AD through altered IDE 
expression and subsequently altered A levels.  
The approach implemented here was to first identify SNPs that are likely to be 
functional by selecting SNPs located in conserved regions. These SNPs were then 
evaluated for association with the expression levels of the target candidate gene 
IDE. Since the SNPs were selected based upon conservation, it is likely that SNPs 
that then show association with altered expression levels may directly represent a 
functional SNP. In this case, the target gene was a known A degrading enzyme 
(IDE).  Consequently the effect of the identified eSNP(s) could be directly tested for 
association with altered levels of A in vivo by evaluating a proxy (rs7910977) for 
the eSNP (rs6583817) that was genotyped in the isolated populations of Vis and 
Korcula. A SNP that influences expression of IDE may also have the potential to 
influence plasma A concentration.  
The result indicated that plasma A did indeed associate with the eSNP proxy and in 
such a way that the allele that correlated with increased IDE expression likewise 
correlated with decreased plasma A in both populations. The third stage of the 
convergence analysis was to determine if this SNP(s) could also influence AD risk. 
Indeed, analysis of rs6583817 indicated association of the minor allele with 
decreased risk for LOAD which is consistent with the previous findings. 
Furthermore, evaluation of rs6583817 in functional test models supports the belief 
that this is in fact a functional SNP that has a direct effect on IDE expression. 
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The results presented here strongly support a role for IDE in LOAD pathogenesis, 
however the data indicate that the effect of altered IDE expression on risk for LOAD 
is small (OR = 0.87). It is unlikely that the potentially functional variant identified in 
this study would have been identified using GWAS methods that predominantly 
identify common variants with larger effect sizes than the SNP identified here. Thus 
this phenotype convergence approach represents a relevant avenue of research for 
future studies. 
As discussed in Chapter 1, the effect size of identified LOAD genes, with the 
exception of APOE, is consistently weak. The implications of this for future use of 
identified genetic risk loci as tools for predicting risk of disease in individuals thus 
becomes challenging and at this time is unlikely to be feasible. Furthermore, 
therapeutic targeting of biological candidates that do not show a substantial 
influence on disease risk is also less appealing than when there is little evidence for 
a substantial influence on disease. The data presented here however evaluate the 
effect of a human IDE SNP that influences expression of the associated gene on AD 
risk. If IDE or other A degrading enzymes were to be targeted for therapeutic 
intervention, alteration of the expression or activity of the targeted enzyme would 
probably have a far greater affect than the SNP effect and over the normal range; so 
potentially providing a useful therapeutically effect. Thus, the identification of 
genetic variants that influence risk for LOAD, even with small effect sizes is, of 
potential importance for future research into this disease. 
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5.5 Evaluation of approaches for studying mitochondrial DNA damage in 
disease. 
The emergence of a role for mitochondrial dysfunction in Alzheimer’s disease and 
subsequent work indicating that A can interact with mitochondrial proteins 
represents a relatively novel molecular mechanism influencing AD. This has led to a 
renewed interest in understanding the role that this organelle plays in AD and other 
neurodegenerative diseases. This avenue of research has also led to the development 
of multiple hypotheses to account for the involvement of mitochondria in AD.  
There are many possibilities for testing mitochondrial hypotheses in LOAD, some of 
which include: 
1. Investigation of mitochondrial haplogroups or homoplasmic variants which 
can be tested for association with disease. Like most nuclear-encoded SNPs 
tested in candidate genes, the reports of this type of association are mixed. 
Similarly, the common 4997bp mtDNA deletion can be tested for association 
with disease. Published association studies of common mitochondrial 
variants in AD have recently been added to the AlzGene database[31] 
2. Study of mitochondrial mutational burden. Measurement of the cumulative 
number of rare, heteroplasmic variants in the mitochondrial genome as a 
whole or in individual genes or groups of genes in order to test the 
hypothesis that AD patients have a higher mutational burden than control 
subjects. 
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3. Measurement of mtDNA damage and its association with disease. Here, a 
general measure of deletions, cross-links, adducts and other mtDNA 
modifications that are detectable by the qPCR assay  which have the 
common property of inhibiting processivity of the polymerase and hence 
PCR efficiency.  
4. Candidate nuclear genes can be tested for association with disease or 
possibly for association with a marker for oxidative stress or mitochondrial 
dysfunction (mitochondrial quantitative trait). 
In this thesis, mitochondrial mutational burden and mtDNA damage were explored 
for association with age and neurodegenerative disease. Additionally a candidate 
gene study was conducted evaluating SNPs for association with LOAD in nuclear 
genes that encode essential components of the mitochondrial polymeraseand 
electron transport chain complex IV. 
Mitochondrial mutational burden: Others have previously reported an increase in 
mutational burden with age. In 2002 Lin et al [295] reported an evaluation of 
mitochondrial mutational burden using mtDNA isolated from brain tissue. The 
authors identified a mutational burden of 2.89E-04 mutations/bp (or 289/million bp) 
in elderly control subjects and 1.21E-04 (or 121 per million bp) in young subjects 
[431]. However, this age related analysis compared the mitochondrial mutational 
burden of only two data sets, young (<31 yrs old) and elderly (>53 yrs old) with a 
sample size of 14 and 10 respectively. The data described in Chapter 4, in contrast, 
investigated four age groups (sample size of 3 per group) and suggests a more 
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complex relationship between age and mitochondrial mutational burden, at least 
with respect to mtDNA isolated from blood. The mutational burden estimates 
reported by Lin et al. [295] also indicate a higher mutational burden in mtDNA 
isolated from brain tissue than that from blood. This is highlighted by the fact that in 
the study described in chapter 4, the HVR locus, which is expected to have a higher 
mutational burden than other loci in the mt genome [280], has a lower mutational 
burden than the COI locus studied by Lin et al. Despite the higher mutational burden 
reported in the brain, the values are generally remarkably similar in magnitude (22-
160/million bp vs 121-289/million bp). Furthermore the cell turnover of leukocytes 
is much higher than brain cells since leukocytes are derived from erythropoietic 
stem cells, which may be under strong selection pressure to eliminate cells that have 
accumulated substantial mtDNA damage or mutation. The opportunity for 
leukocytes to survive in the presence of acquired somatic mutations is therefore 
probably substantially less than that for brain cells, so it is not surprising that the 
mitochondrial burden is higher in the brain.  
The mitochondrial mutational burden estimates in chapter 4 were obtained by using 
a PCR-cloning-sequencing approach the utility of which has been previously 
demonstrated by others [287, 385-387, 432]. However since these experiments were 
completed, alternative sequencing methods have been developed that are capable of 
evaluating the entire mitochondrial genome instead of 1kb targets by use of new 
technology collectively referred to as ‘next-generation’ (next-gen) sequencing. At 
the time of the experiments presented in chapter 4, next-gen sequencing was in its 
infancy and was not a viable technology for most studies due to economic 
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constraints. Furthermore the ability of this technology to detect extremely rare 
somatic mutations (heteroplasmy) in a sample comprised of many mitochondrial 
genomes was controversial. Improvements have been made to this technology which 
may improve the efficacy of this approach in the future, however current error rates 
[433] and the reduced capacity for detecting very rare variants maintains the 
relevance of the PCR-cloning-sequencing approach, used here, at this time. It may 
be beneficial in the future to combine the next-gen sequencing approaches to 
identify common mutations and to estimate heteroplasmy [434], followed by the 
targeted PCR-cloning-sequencing approach to confirm mutational burden estimates 
for very rare variants, 
 
A recent paper that evaluated the relationship between oxidative stress and 
mitochondrial DNA damage or mutation, concluded that despite extensive ROS 
damage to mtDNA, acquired mutations in mtDNA are kept at low levels [432]. It 
was suggested by the authors that this might result from a mechanism by which 
damaged DNA molecules are either repaired by base excision repair or, DNA 
molecules are linearised and degraded by unknown exonucleases. Unrepaired pre-
mutagenic base lesions, such as 8-hydroxyguanosine (8-oxo-G), lead to mutations 
(mostly transversions). Surprisingly, oxidative damage (by hydrogen peroxide) 
caused ten times as many single strand breaks (SSB) and apurinic sites compared 
with oxidized pre-mutagenic base changes. The degradation mechanism was found 
to be unique to mtDNA, presumably because there are multiple copies of mtDNA 
but not nDNA. It suggests that while mtDNA mutations may not increase 
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dramatically with age (because they are either repaired or degraded) degradation of 
oxidatively damaged mtDNA may increase with age, leading to low copy number.  
Evaluating the extent of DNA damage by qPCR or copy number assay, rather than 
mutational burden, may therefore be more reflective of the overall level of ROS 
induced damage or functional impairment of mtDNA. This was explored in this 
thesis for mtDNA isolated from the frozen brain tissue of patients diagnosed with 
various neurodegenerative diseases and controls.  
 
Mitochondrial DNA damage: DNA damage can be assessed using qPCR methods 
based upon the hypothesis that molecular DNA lesions such as adducts, base 
modifications (e.g. 8oxoG) and strand breaks will result in stalling of the PCR 
polymerase in a way that is measurable [435, 436]. Previously, others have used 
qPCR to measure DNA damage by estimating mitochondrial copy number using 
short qPCR assays and then measuring damage by long qPCR, with the difference in 
copies detected by both methods serving as an indicator of the damage. This is 
reviewed by Senyene Hunter et al. 2010 [437]. The study presented in this thesis 
however has demonstrated that DNA damage can be detected even in short PCR 
amplicons. Consequently it is possible that estimating the mitochondrial copy 
number using short amplicons may result in confounding copy number change with 
DNA damage. Both the study presented in Chapter 4 and the Mambo et al. study 
[386] support this observation.  
An alternative way to use qPCR to evaluate DNA damage is to use Sybr green. The 
advantage of this is that larger target regions can be investigated as the technique 
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does not rely on annealing of a probe to the target DNA sequence. However Sybr 
green is known to cause some inhibition of the PCR reaction which may also be a 
potential confounder [438]. Additionally biochemical assays are available that allow 
for the measurement of 8-oxoguanine (8oxoG), a molecular lesion that is both 
highly mutagenic and believed to be the most frequent lesion associated with 
oxidative DNA damage. However these approaches limit the study to evaluation of 
just one oxidative DNA lesion and as such do not provide the same breadth of 
analysis as the qPCR approach. In summary there are many ways of measuring 
mitochondrial DNA damage; all methods have caveats and potential confounders 
that must be controlled. Consequently, whilst the method employed here relies on 
certain assumptions and also has possible confounders, the alternatives do not 
provide an obviously better solution.  
The data presented in this thesis evaluated mitochondrial DNA damage in samples 
of frozen brain tissue isolated from the temporal cortex (frequently affected by 
LOAD pathology) and the cerebellum (rarely affected by LOAD pathology). The 
level of mtDNA damage was investigated in these two brain regions for four groups 
of elderly subjects defined by pathological criteria into three disease categories and a 
normal control group. mtDNA damage was measured using qPCR techniques and 
the analysis approach outlined in Chapter 4 allowed for evaluation of mtDNA 
damage independent of estimation of mitochondrial DNA copy number.  
The results of this study imply an association between neurodegenerative diseases 
and mitochondrial DNA damage which is especially high for samples isolated from 
the brains of subjects diagnosed with VaD.  Interestingly in the case of the vascular 
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dementia (VaD) samples, there was no significant difference in the levels of DNA 
damage between the two areas of the brain sampled: Cerebellum and temporal 
cortex (Table 4.8). This result indicates that the brain tissue of VaD patients may 
undergo high levels of non-selective oxidative DNA damage either during the 
course of the disease process or possibly upon the death of the patient as a result of a 
fatal stroke. The results observed for the VaD subjects warrants further investigation 
in additional samples and may present informative novel data for VaD research. 
The results from the analysis of the PSP and normal subjects (Table 4.8) both 
indicated a significant increase in mtDNA damage in the DNA isolated from the 
temporal cortex when compared with the cerebellum at all three mitochondrial loci 
investigated. The results also indicate that whilst the temporal cortex exhibited more 
damage than the cerebellum for PSP subjects, there was reduced damage at the 
temporal cortex when compared with controls. This indicates that increased DNA 
damage at the temporal cortex may occur as a function of normal aging without 
associated cognitive deficits or pathology. Furthermore the decreased levels of 
damage observed in the temporal cortex for PSP subjects could represent either a 
protective effect against oxidative damage in these subjects or it is possible that 
damaged mtDNA molecules in these subjects has been selectively degraded.  
When mtDNA damage observed for AD subjects was compared with that of controls 
(Table 4.8) it was surprising to note that there were no significant differences 
between these two sets of subjects for any of the mitochondrial loci examined or the 
two tissues sampled. It may be possible that the results presented here indicate that 
indeed mtDNA damage is not a significant factor in AD pathogenesis or, as 
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proposed above for the PSP subjects, damaged molecules are selectively degraded. 
This would indicate that the majority of DNA molecules that are intact are as yet not 
damaged beyond that observed in normal aging. However, the data presented in 
Table 4.8 did identify a significant increase in the levels of mtDNA damage at the 
COII locus for mtDNA isolated from the temporal cortex of AD subjects, when 
compared with that isolated from the cerebellum. This finding is of interest since 
there have been multiple reports of cytochrome oxidase deficiency in LOAD 
samples [303, 439, 440] and the COII gene encodes one of the three catalytic 
subunits of this OXPHOS enzyme.  
Overall the 16s locus was the most damaged locus in normal control subjects and 
could indicate a higher tolerance for DNA damage at this locus when compared with 
the D-loop and COII loci. As suggested by Shokolenko et al, the mitochondria may 
degrade damaged and mutated mitochondrial DNA molecules. It is not beyong the 
realm of possibility that mtDNA molecules with damage detected at certain loci of 
the mitochondrial genome are more preferentially degraded and consequently 
mtDNA molecules with damage at the COII and D-loop loci have been degraded 
more actively than those molecules with damage at the 16s locus. This effect was 
noted by Mambo et al [386] where the ‘repair time’ following damage of mtDNA 
with chemical agents varied across the different loci evaluated.  
The interpretation of the data presented here has to be considered in the context of a 
tissue homogenate which means that the proportion of neuronal cells in each 
homogenate is unknown and likely to be variable across different subjects, diseases 
and locations in the brains from which the samples were isolated. It would be 
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pertinent to follow this study up in a larger number of samples with mtDNA isolated 
from neuronal cells only (e.g. by laser capture microdissection) to determine if this 
data is reflective of neuronal cells or perhaps other brain cells such as glial cells. 
Furthermore, the sample size used in this study is relatively small (10 subjects per 
group), so additional studies would benefit from a larger sample size, although this 
may be limited by the availability of the appropriate tissue. Exploration of additional 
loci or optimisation of long-range PCR techniques may improve the investigation of 
mtDNA damage in future studies. 
 
Candidate gene association study: The mitochondrial genome encodes essential 
proteins involved in mitochondrial function and as such can have important 
implications in disease, especially when mitochondrial dysfunction is implicated. 
However the majority of the proteins that are present within the mitochondria and 
are likewise important to its function are encoded by the nuclear genome [383]. One 
example of a mitochondrial disease that can be caused by mutations in the nuclear 
genome is progressive external opththalmoplegia (PEO). In this disease mutations in 
the genes that form the components of the mitochondrial DNA polymerase (POLG, 
POLG2, PEO1) cause impaired mitochondrial replication and repair resulting in 
reduced mtDNA copy number and the accumulation of mtDNA deletions and 
mutations[441-443]. The onset of symptoms of this disease can range from 18 to 40 
years [444] indicating that the effect of impaired mitochondrial replication and proof 
reading activities requires a significant amount of time to progress prior to the onset 
of symptoms. It could therefore be possible that late-onset disease such as AD and 
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PD might also be caused by defects in the mitochondrial polymerase where longer 
periods of time are needed before the effects of loss of mitochondrial DNA becomes 
apparent. Consequently the three genes that form the principle components of the 
mitochondrial polymerase gamma were investigated for SNPs that show association 
with LOAD. Interestingly two SNPs included in this study showed nominal 
significant association with LOAD (Table 4.9) although neither maintained 
significance following bonferonni correction for multiple tests. However given the 
logical rationale behind the pursuit of SNPs at these loci for association with LOAD, 
genotyping of additional samples to increase power for detection of SNPs with small 
effect size might confirm the association detected here.  
In addition to the three genes described previously, a candidate gene study was also 
carried out to investigate SNPs in 17 nuclear genes that encode components of 
cytochrome oxidase (complex IV) of the mitochondrial electron transport chain. The 
rationale behind the selection of these genes was that several studies have reported 
decreased activity of complex IV in brain and platelet samples for AD patients [302, 
303, 390, 439]. One cause of this observed decreased activity could be impaired 
function or expression of the structural components of this complex, all of which are 
encoded by nuclear genes. Association analysis of SNPs at these 17 loci identified 
70 SNPs within each of the genes and their 20kb flanks, of which four exhibited 
nominally significant association with LOAD, localized to two genes. Interestingly 
the two genes identified in this study encode two isoforms of the same subunit of 
complex IV, namely the COX6B subunit. Both of these genes are located on 
chromosome 19, however they are located approximately 20 million base pairs apart 
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and 10 million bps from the APOE locus indicating independent effects. Whilst none 
of the four SNPs identified at the locus for these 2 genes maintain significance 
following bonferonni correction for multiple tests, they do represent a novel finding 
and warrant further evaluation in additional samples.  
The limitations of the candidate gene study are firstly the narrow age range of the 
subjects studied - aged 60-80 years. If there are SNPs that interact with age such that 
risk for AD is only realized in older samples then these would be missed. Secondly, 
the size of the study (788 AD and 1165 control samples) may be too small to 
identify SNPs with small effect sizes. This possibility was evident in the recent 
LOAD GWAS studies, which contained sample sizes of many thousands of subjects 
to reliably identify LOAD risk SNPs. On the other hand, this study provides insight 
into complex IV genes that may play a role in LOAD aetiology and follow-up 
studies using a subset of the SNPs identified here would permit a more extensive 
evaluation of these genes. 
 
5.6 Conclusions 
The aim of the projects presented in this thesis was to identify novel genetic risk 
factors for LOAD.  
Evaluation of plasma A concentrations in two isolated populations identified 
significant heritability of plasma A40, however the evidence for A42 was much 
less convincing. This result indicates that genetic factors may not explain as much of 
the variation in plasma A concentrations (especially A42) in populations that are 
not selected for cognitive deficits than those that are. Although these studies did not 
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identify significant linkage or association of genetic variation with the plasma A 
traits tested, several promising candidate genes were identified. Furthermore the data 
generated from these studies is a valuable resource for phenotype convergence 
analysis as exampled for the IDE locus in chapter 3. 
Finally, exploration of mitochondrial genetic risk factors for LOAD surprisingly 
identified high levels of mtDNA damage in VaD patients; however the evidence for 
AD was less compelling. These studies also highlighted the need for careful 
consideration of methods and controls to prevent amplification of numts or in vitro 
DNA damage that can confound the interpretation of the results. Furthermore the 
evaluation of nuclear encoded proteins essential for mitochondrial function may be 
an overlooked area of research into the genetics of LOAD. The identification of 
novel candidate LOAD genes in this study that play a role in mitochondrial function 
warrant further evaluation. 
 
 
5.7 Future directions 
In an extension of the plasma A GWAS analysis, the R package ProbABEL, can be 
used to facilitate imputation of additional genotypes in the two populations studies 
in this thesis. Analysis of imputed SNP data will enable the evaluation of additional 
SNPs in each population that may not have been ‘tagged’ by the more common 
variants genotyped in each study. Any SNP association identified using imputed 
data will need to be validated by genotyping the samples for the SNPS in question 
using traditional genotyping techniques such as Taqman. 
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The evaluation of additional populations for GWAS with plasma A is another 
plausible approach for both evaluating replication of SNPs of interest identified in 
the first two studies and for increasing power in subsequent meta-analysis.  
Additionally measurement of plasma A40 levels in Vis using the BNT77 capture 
antibody as used for the Korcula study might also improve the meta analysis for this 
trait. 
Studies of nuclear genetics in LOAD have, until recently, failed to unequivocally 
identify variation that is associated with the disease beyond the well known APOE 
E4 association. It was only the use of GWAS in very larger numbers of cases and 
controls that advanced the field to the point of being able to identify SNPs that 
replicate reliably. This could likewise be the case with common mtDNA variations 
and perhaps one avenue of research that should be pursued is the evaluation of 
common mtDNA variants and haplogroups in very large case control series. The 
latter can be achieved most easily by high throughput sequencing of the relatively 
small mitochondrial genome in many thousands of cases and controls.  
Finally the possibility that damaged mtDNA molecules, that cannot be repaired, are 
degraded opens up a new avenue of research into the complexities of the 
relationship between mitochondrial DNA damage and disease. To this end the 
expression levels of mtDNA degrading enzymes could be evaluated to see if they 
are upregulated in AD. Exploration of the mechanisms that lead to identification and 
degradation of damaged mtDNA molecules may implicate additional molecular 
pathways that can be manipulated therapeutically. 
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Table i. Primers and probes used in the studies described in chapter 4. 
 
